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ABSTRACT
EFFECT OF TOTAL BODY IRON ON METABOLIC DYSFUNCTION AMONG U.S.
FEMALES IN THE NHANES 2003-2010 SURVEY, AGED 12-49
Joseph M. Carhart
December 05, 2017
Experimental and epidemiological studies have reported positive associations
between iron parameters and metabolic dysfunction including: Type 2 diabetes mellitus
(T2DM) (1-6), metabolic syndrome (7-15), non-alcoholic fatty liver disease (NAFLD)
(16-22) and insulin resistance (23,24) with a number of studies showing that reductions in
total body iron via dietary modification (e.g., reducing red meat intake) or phlebotomy
lead to increases in insulin sensitivity (25), decreases in insulin resistance (26), and
reductions in the prevalence of complications associated with T2DM (5, 27), metabolic
syndrome (28) and NAFLD (22, 29). Moreover, the risk associated with these outcomes
and total body iron differ between males and females and it has been hypothesized that
the divergence in risk of disease due to total body iron is related to the female
reproductive lifespan (e.g., age at menarche, parity, oral contraceptive use and age at
menopause). Regardless of study design, serum ferritin and transferrin saturation have
consistently been used in these investigations to estimate total iron stores, which are
affected by inflammation and demonstrate diurnal variation.
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The aim of the current study was to examine the clinical utility of an index of iron
repletion developed by JD Cook et al. in 1993 (i.e. FeCOOK), which is unaltered by
inflammation or liver function in a nationally-representative, community-dwelling, noninstitutionalized group of females participating in continuous NHANES from 2003 to
2010 and to examine the association between the index and metabolic dysfunction.
The current results highlight the clinical utility of FeCOOK in assessing the iron
status in females of reproductive age. I did not observe a statistically significant
association between metabolic dysfunction and continuously-scaled FeCOOK. However,
when FeCOOK was modeled in accordance with common reporting patterns (i.e.,
categorically), significant, positive associations between increasing FeCOOK and metabolic
dysfunction were observed among all females, and this pattern persisted after
stratification by ethnicity and menopausal status. Further research is warranted to
examine the clinical utility of FeCOOK among other cohorts. Moreover, additional research
using FeCOOK is recommended in order to replicate these findings among a larger sample
comprised of both males and older females.

.
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CHAPTER 1: INTRODUCTION

Experimental and epidemiological studies report positive associations between
iron parameters and metabolic dysfunction including: Type 2 diabetes mellitus (T2DM)
(1-6), metabolic syndrome (7-15), non-alcoholic fatty liver disease (NAFLD) (16-22) and
insulin resistance (23, 24). While much consensus in the research community has been
reached regarding the ascertainment of T2DM, metabolic syndrome and insulin
resistance in population-based studies using World Health Organization (WHO) criteria,
National Cholesterol Education Program-Adult Treatment Panel III (ATP III) criteria and
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), respectively, no
gold-standard method exists for the detection of hepatic steatosis that is both noninvasive and cost-effective. Therefore, several algorithms which utilize markers found in
serum have been developed to estimate the presence of fatty liver in large cohorts (Table
7). Among these algorithms, the fatty liver index (FLI) has received the most attention in
the epidemiological literature (30) and is the only algorithm that has been externally
validated in four independent studies (31-34, Table 7) since its inception in 2006 (30).
More recently, an index referred to as the U.S.-FLI has been developed to determine the
presence of NAFLD among multi-ethnic cohorts. Unlike the FLI, the U.S.-FLI accounts
for age and ethnicity and has been shown to outperform its predecessor (i.e., the FLI) (35)
However, the U.S.-FLI has not been employed thus far to estimate the prevalence of
NAFLD in U.S. females as a subgroup.
1

The magnitude of risk in the above reported associations between iron stores and
metabolic dysfunction differ between males and females and it is thought that the
divergence in risk of disease due to body iron status is related to the female reproductive
lifespan. In his 1981 article entitled “Iron and the sex difference in heart disease risk”
Jerome Sullivan was the first to hypothesize that blood loss during menstruation is the
primary factor that protects premenopausal females from ischemic heart disease (36). In
the years that followed, several publications have reported that parameters related to
ovulation and menstruation (e.g., decreasing age at menarche, increasing parity,
decreasing length of oral contraceptive use and increasing age at menopause) confer
protection against chronic disease (37-40) and that this protection appears to be lost
following the onset of menopause (38). Supporting these observations are clinical trials,
cohort studies and case-control studies whose results consistently demonstrate that
participants who reduce total body iron via dietary modification (e.g., reducing red meat
intake) or blood donation/phlebotomy experience increases in insulin sensitivity (25),
decreases in insulin resistance (26), and reductions in the prevalence of complications
associated with T2DM (27), metabolic syndrome (42) and NAFLD (43). Regardless of
study design, however, serum ferritin and transferrin saturation have consistently been
used in these investigations to estimate iron stores. Despite its clinical utility, ferritin is
adversely affected by inflammation, with levels of serum ferritin rising under
inflammatory conditions (44). In addition, transferrin saturation (TSAT), which is the
ratio of serum iron to total iron binding capacity (TIBC), demonstrates diurnal variation
(45) and increases in the presence of health conditions such as inflammation, cirrhosis,
hepatitis and microbial infection (46-49).
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Predictive, non-invasive, and inexpensive analytes unaltered by inflammation or
liver function would be of value in monitoring the iron status of females across the
reproductive lifespan to distinguish the effects of iron stores on metabolic dysfunction.
Moreover, reproductive parameters vary between females and this offers a natural setting
in which to examine the effect of these parameters on iron stores and their association
with metabolic dysfunction while controlling for the effect of covariates such as age,
ethnicity, education, body mass index (BMI) and lifestyle factors (e.g., diet composition
(i.e., foodstuffs and supplements which enhance and/or inhibit iron absorption), alcohol
intake and smoking status (i.e., exposures which increase iron loading) and physical
activity (i.e., an exposure which decreases iron loading).
In this secondary analysis, my aim was to test the effect of reproductive
parameters on iron stores and to evaluate body iron as a predictor of metabolic
dysfunction in female participants of childbearing age (i.e., 12-49 years) participating in
the continuous National Health and Nutrition Examination Survey (NHANES) from
2003-2010. To estimate iron stores in the current sample, I employed a well-validated
algorithm developed by JD Cook et al. in 2003 (50) which is a mathematically-derived
ratio of soluble transferrin receptor and ferritin found in serum and appears to be a more
stable index of iron stores than either analyte used independently (51-52).

Aim 1: To estimate iron stores in a nationally-representative, community-dwelling,
non-institutionalized group of females participating in continuous NHANES from
2003 to 2010 using an index of iron repletion developed by JD Cook et al. in 2003.
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Aim 2: To describe the relationships between age, ethnicity, education, BMI, alcohol
consumption, smoking history, physical activity, dietary iron, foodstuffs which
enhance/inhibit dietary iron absorption, reproductive parameters, and FeCOOK in the
female cohort. Specifically, it was hypothesized that:
A. FeCOOK would be positively associated with
1. Hispanic and Non-Hispanic Caucasian ethnicity
2. Education
3. BMI
4. Alcohol consumption
5. Smoking history
6. Dietary iron intake
7. Length of oral contraceptive use
8. Decreasing age at menopause
B. FeCOOK would be negatively associated with
1. Non-Hispanic African American ethnicity
2. Physical activity
3. Decreasing age at menarche
4. Parity
Aim 3: To estimate the prevalence of non-alcoholic fatty liver disease in the current
sample using a validated algorithm developed by Ruhl et al. in 2015 (35), the U.S.
fatty liver index (U.S.-FLI).
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Aim 4: To describe the relationship between FeCOOK and risk of metabolic
dysfunction in the female cohort. It is hypothesized that:
A. FeCOOK would be positively associated with:
1. Type 2 diabetes mellitus after controlling for age, BMI, alcohol
consumption, smoking status physical activity and micronutrient
status.
2. Metabolic syndrome after controlling for age, BMI, alcohol
consumption, smoking status physical activity and micronutrient
status.
3. Non-alcoholic fatty liver disease after controlling for age, BMI,
alcohol consumption, smoking status physical activity and
micronutrient status.
4. Hepatic fibrosis, developed by Angulo et al. and defined by the Nonalcoholic fatty liver disease Fibrosis Score (NFS) after controlling for
age, BMI, alcohol consumption, smoking status physical activity and
micronutrient status.
5. Insulin resistance after controlling for age, BMI, alcohol consumption,
smoking status physical activity and micronutrient status.
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CHAPTER 2: OVERVIEW OF IRON METABOLISM AND IRON STATUS IN
HUMAN POPULATIONS

As an essential micronutrient, humans require iron for cellular respiration, DNA
synthesis, DNA repair, as a cofactor in biochemical reactions, oxygen transport,
endocrine regulation, immunological regulation and bone health. Thus, iron is a major
contributor to subcellular, intracellular, and systemic homeostasis due to the transition
metal’s capacity for redox cycling (53), where labile iron can be oxidized from ferrous
iron (Fe2+) to ferric iron (Fe3+) and reduced from ferric iron (Fe3+) to ferrous iron (Fe2+).
Homeostasis of human iron metabolism is achieved at two levels: 1) systemic and 2)
cellular. Each will be taken in turn, followed by a summary describing their interaction.
Systemic iron metabolism The regulation of systemic body iron occurs at the
level of iron absorption (54). Humans acquire iron in two distinct forms: 1) heme iron
contained in meats, poultry, seafood and fish and 2) non-heme iron contained in plantbased foods such as vegetables, fruits, grains, nuts, beans and seeds. The heme iron
content of meat varies considerably depending upon the source. Red meat contains 50% 80% heme iron while the heme iron content of chicken, pork or turkey varies between
25% - 40% (55). Compared to non-heme iron, heme iron is absorbed with five to ten
times greater efficiency (56) and its absorption is unaffected by current body iron stores
(57). Moreover, absorption of heme iron is independent of duodenal pH (58) and is
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relatively unaffected by common inhibitors of iron absorption such as phytate and
polyphenols (59 Abbaspour et al.). In contrast, the bioavailability of non-heme iron is
much less than that of heme iron (5-12%) (60) and its absorption is affected by current
body iron stores (61) as well as dietary factors which can either promote or inhibit its
absorption (62-64). Despite its lower bioavailability, however, non-heme iron appears to
contribute more to human iron nutrition than does heme iron in developed nations (65).
Heme iron is absorbed from the duodenum in the proximal intestine by hemecarrier protein-1 (HCP1); also known as solute carrier family 48 member 1 (SLC48A1))
(66), whereupon it enters the cytosol of the enterocyte and is degraded by hemoxygenase
1 (HOX1) to abstract the central ferrous iron ion from the heme group contained within
the porphyrin moiety. In addition to heme iron intake, factors such as hypoxia and ironregulatory proteins (IRPs) serve to upregulate HCP1 mRNA expression (67). Cytosolic
(soluble) ferrous iron in the enterocyte is oxidized to (insoluble) ferric iron by hephaestin,
a multicopper oxidase localized mainly within the basolateral membrane of enterocytes
(68) which loads oxidized iron onto transferrin, which serves as a siderophore. Briefly, a
siderophore (e.g., Greek for “iron carrier”) is any small iron-chelating protein or
compound which exhibits high-affinity for binding iron (69). Transferrin can bind up to
two atoms of ferric iron (70) Hephaestin then works in concert with ferroportin to export
transferrin into circulation (68,70) for utilization in the above mentioned physiological
processes. The relationship between hepahestin and ferroportin is noteworthy in iron
metabolism because under normal physiological conditions, hephaestin is down regulated
when body iron is replete and if hepaestin activity is abolished, ferroportin is degraded
(71).
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In contrast to heme iron metabolism, non-heme iron metabolism is subject to
tighter systemic regulation (e.g., non-heme iron metabolism requires an acidic duodenal
pH for optimal absorption) (72). Following intake of non-heme iron, duodenal
cytochrome B (DcytB), also known as cytochrome b reductase 1 (Cybrd1), a
ferrireductase localized within the enterocyte apical membrane, reduces ferric iron to
ferrous iron. Divalent metal transporter 1 (DMT1, also known as Nramp2) then transports
ferrous iron into cell. DMT1 is expressed at the brush border of duodenal enterocytes and
within intracellular endosomes of erythroid precursors (72) and is activated only in an
acidic environment. In iron deficiency, DMT1 is upregulated and localizes at both the
microvilli and cytoplasm. When body iron is replete, DMT1 is downregulated and
localized to the cytoplasm. Similar to the above-mentioned step during heme iron
metabolism, hephaestin then oxidizes ferrous iron to ferric iron and works in concert with
ferroportin to regulate the efficiency of cellular iron efflux and loads oxidized (i.e., ferric)
iron onto transferrin. In cells apart from enterocytes, ceruloplasmin (another multicopper
oxidase enzyme synthesized and secreted by the liver with 50% homology to hephaestin)
(73) regulates cellular iron export though the mechanism is not yet completely
understood (74). Normally, transferrin in circulation is 25-35% saturated with ferric iron
ions at a pH of 7.4 (75). Each transferrin siderophore then competitively binds transferrin
receptors on target cells with HFE protein, which has been shown to function as an iron
switch/sensor. In conditions such as hereditary hemochromatosis (HH), a mutation in the
HFE gene (i.e., rs1800562: C282Y) leads to misfolded HFE proteins which aggregate in
the Golgi complex and are thus not available to competitively bind transferrin receptors.
Carriers of this mutation experience increased iron absorption due to a lack of this protein
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sensor coupled with chronically suppressed hepcidin expression (discussed subsequently)
(76). Under normal physiologic conditions, however, transferrin siderophores compete
with HFE proteins and upon binding with transferrin receptor 1 (TFR1) or transferrin
receptor 2 (TFR2) (and to a lesser extent glyceraldehyde-3-phosphate dehydrogenase
(GAPDH)) (77-79), transferrin is endocytosed. It should be noted here that studies have
reported that TFR1 has ~ 30-fold higher binding affinity for transferrin-bound iron and
thus plays a larger role in receptor-mediated iron uptake into the cell (80, 81). Within the
low pH of the endosomal compartment iron dissociates from transferrin and both the
siderophore and receptor are recycled. However, if pH of arterial blood becomes acidic
(i.e., pH < 6.5) transferrin loses it iron loading capacity (82).
As labile (i.e., ferrous) iron accumulates within the cell or within systemic
circulation, a soluble protein called ferritin is synthesized by nearly all cell types for iron
storage. Each ferritin molecule is a nanocage that stores up to 4,500 atoms of iron and is
composed of two heteropolymers, a heavy chain and light chain (83). Labile iron is
imported through channels that are created between the bonds of the heavy and light
chains (84). Ferritin heavy chain conducts ferroxidase activity that is necessary for iron
deposition into the nanocage by converting ferrous iron to ferric iron (85). In addition to
labile iron, expression of ferritin heavy chain is induced by NF-kB in response to TNF-α
and is higher in tissues that require rapid/high utilization of iron (e.g., heart) (86). In
contrast, ferritin light chain facilitates iron incorporation onto ferrihydrite (87), which
binds iron to the inner wall of the nanocage and has been observed to participate in
ferridoxase turnover. Ferritin light chain expression is higher in tissues that require long
term storage (e.g., spleen, liver) (88). As ferritin becomes increasingly saturated, excess
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iron precipitates around the protein and causes ferritin cages to aggregate. (89) The
resulting insoluble protein is called hemosiderin. Once hemosiderin is formed, the
protection provided by ferritin is lost and redox cycling begins (90). As such, some
authors define iron deficiency and overload on the basis of the hemosiderin to ferritin
ratio, where values less than 1 denote increasing iron deficiency and values greater than 1
denote increasing iron overload (91). While appealing as an index of body iron burden,
the quantification of hemosiderin is currently not cost-effective, as the only techniques
available as of this writing for measuring hemosiderin are liver biopsy or MRI (92, 93).
Regulating the above-mentioned mechanism is a recently discovered acute-phase
protein called hepcidin. Hepcidin is expressed primarily in the liver, though some reports
indicate that the protein is also expressed by macrophages and adipose tissue (94) and can
be detected in urine, bile, ascitic, pleural, or cerebrospinal fluid (95). Hepcidin regulates
body iron homeostasis at the level of duodenal cell absorption of dietary iron and
macrophage release of iron from recycled erythrocytes, where the latter leukocytes
increase ferritin synthesis with increasing hepcidin expression to sequester iron from
invading pathogens. Hepcidin’s primary role in iron metabolism is in binding ferroportin,
the only known cellular iron exporter. Increasing expression of hepcidin protein in serum
results in the degradation, internalization, and eventual recycling of the ferroportin
receptor on the cell membrane (96). In turn, this results in decreased export of iron from
the cell into circulation.
Several studies have demonstrated that hepcidin expression is regulated by
systemic iron availability (i.e., transferrin saturation) (97), hepatic iron stores (i.e.,
feedback loops between iron sensing proteins such as hemojuvelin (HJV), HFE and
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transferrin receptor) (98), erythropoietic activity (i.e., which increases in response to
hepcidin suppression) (99), hypoxia (i.e., hepcidin expression is suppressed by hypoxia)
and inflammatory/infectious states and induced by IL6, IL1β, bone morphogenic protein2 (BMP-2) and LPS) (100, 101).
Given that less than 10% of daily iron needs are met by intestinal absorption, the
remaining iron requirements are fulfilled by macrophages that recycle intracellular iron
(102). Macrophages phagocytose senescent or damaged erythrocytes and catabolize them
via HOX1 which abstracts the central ferrous iron ion from the heme group contained
within the porphyrin moiety after heme is broken down into biliverdin (103) Natural
resistance-associated macrophage protein 1 (NRAMP1), a divalent metal transporter
homologous to DMT1, is expressed within the phagolysosomal membrane of the
macrophage and participates in iron export from phagocytic vesicles (104). Export of
ferrous iron from macrophages then occurs via ferroportin, where it is oxidized to ferric
iron by ceruloplasmin and bound to transferrin (105). Reflecting its crucial role in
systemic iron balance, ferroportin expression in macrophages is regulated at the level of
1) ferroportin transcription induced by erythophagocytosis and heme iron, 2) translation
by the IRE/IRP system and 3) protein stability via hepcidin (106).
Cellular iron metabolism Iron homeostasis at this level of regulation is
maintained by specific DNA binding proteins and sequence motifs called iron-regulatory
proteins (IRPs) and iron-responsive elements (IREs), respectively. IREs are located in
untranslated regions of genes which encode mRNAs that produce proteins involved in
iron uptake, storage, utilization and export (70). The binding of IRPs to IREs suppresses
the assembly and translation complex involved in ferritin and ferroportin mRNA
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synthesis and increases transferrin receptor and DMT1 mRNA expression (70). When
iron concentrations are high IRPs are degraded or inactivated causing a downregulation
of serum transferrin receptor. IRP1 (also known as ACO1) is activated by iron deficiency
(70) and loses affinity for IREs during iron replete status. IRP1 also exhibits aconitase
activity. IRP2 (also known as IREB2) is activated by iron deficiency and degraded in
conditions of iron excess and does not demonstrate aconitase activity (107, 108).
Iron status in human populations The following sections are an overview of the
distribution of iron in the human body, the observed iron status and intake in human
populations and a summary of trends and exposures (i.e., dietary and otherwise) which
contribute to body iron stores. When data permits, iron status in males and females (i.e.,
pre-menopausal (nonpregnant), pre-menopausal (pregnant), post-menopausal) are
presented separately and summaries are stratified by age and ethnicity.
The total amount of body iron in free-living apparently healthy adults is
maintained at a level of about four grams which is distributed in proteins and serum (109,
110). One-to-two mg of iron per day is absorbed from the diet and is balanced by the
excretion of 1-2 mg of iron per day via sloughing of intestinal epithelial cells,
desquamation of skin and urinary cells, perspiration and fecal transit (109, 110). Total
body iron in males typically ranges from 3.5 to 5 grams (109, 110) (~55 mg/kg) and in
females ranges from 2 to 3.5 grams (109, 110) (~45 mg/kg). The distribution of body iron
in both males and females is quite similar, where most of the metal is contained within
hemoglobin (60%), myoglobin and enzymes (10%), ferritin and hemosiderin (20%), bone
marrow (10%) and transferrin (~1%) (109, 110). In line with the reported distribution of
hemoglobin, the average adult has 4 pints of blood and each pint (i.e., 1/2 liter) of blood
12

contains 250 mg of iron (109, 110). At ten pints (i.e., 5 liters), the human body therefore
contains ~ 2.5 grams of iron in circulation (i.e., 62.5%).
Several studies have shown that indices of iron status vary with gender, age,
ethnicity and education (51, 111-114). Surveys of body iron status in populations have
consistently demonstrated that males, regardless of ethnicity, begin to accumulate iron in
their early 20s and by age 40 have approximately four-fold as much body iron as agematched females who have not yet proceeded through natural or surgical menopause
(112). Thus, compared to males, iron status in females can be affected by factors such as
age at menarche, parity, oral contraceptive use and/or age at menopause (115). However,
once females reach menopause body iron stores tend to increase and eventually converge
with those of males by the 7th decade of life (112). Table 5 contains common iron
parameters with reference ranges.
It is hypothesized that blood loss due to regular menstruation should decrease iron
stores in females with each menstrual cycle and that an earlier age at menarche should
equate to lower iron stores over time. Using data obtained from NHANES 1999-2006,
however, Miller reported that self-reported age at menarche was not statistically
associated with iron stores at the time of study participation (P = 0.31) (115). To my
knowledge, this was the only survey to directly examine this hypothesis and replication is
warranted before inferences can be made.
Though the number of studies which have examined the association between
parity and iron stores is small, two separate population-based studies have nonetheless
thus far confirmed the hypothesis that increasing parity is associated with decreased body
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iron (116, 117). Thus, these results need to be confirmed by more independent
investigators.
The effect of oral contraceptive (OC) use on body iron appears to be related to the
formulation. Most OC formulations are composed of synthetic estrogen and progestin,
hormones which inhibit the synthesis of follicle-stimulating hormone and leutinizing
hormone. These hormones facilitate menstruation and ovum release from the ovaries.
Thus, blocking their production via OC use should result in decreased iron loss (118).
Frassinelli et al. assessed the effect of an oral formulation on iron parameters in a group
of females (n = 46) over the course of two years and observed increased serum iron,
transferrin, mean corpuscular volume (MCV), ferritin and decreased TIBC compared to
another group of females (n = 71) who never self-administered oral contraceptives (119).
The results suggest that OC use does indeed increase body iron. These observations were
replicated in a separate investigation conducted by Milman et al. (117) and in a large,
population-based study using data from NHANES 1999-2006 (115).
In the U.S., pregnant females often develop transient anemia during the second
and third trimesters due to hemodilution and iron loss to the developing fetus. Thus, the
prevalence of iron-deficiency anemia in U.S. pregnant females during the second and
third trimester has been estimated at 18% (120). Disparities in this estimate are evident,
however, when stratifying by ethnicity. Hispanic and African American pregnant females
are consistently observed to develop iron-deficiency anemia at higher rates than
Caucasian females. Moreover, the disparity persists among nonpregnant African
American and Caucasian females, where hemoglobin values among females in the latter
ethnic group are higher compared to those of the former (112).
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Compared to the adult reference ranges established by the CDC, both Caucasian
and African American nonpregnant females have low mean hemoglobin values.
According to Cook et al., however, “an estimated 2.6% of premenopausal and 1.9% of
postmenopausal females (and 0.2% of males) are iron deficient in the U.S.” (121, p.729)
If one extrapolates these data to the population-level, this estimate is quantitatively
different than that reported by the CDC, where about 3 million rather than 5 million
females would be considered iron-deficient (109). Results published by Cogswell et al.
using females participating in NHANES 2003-2004 are congruent with these
extrapolations. Cogswell and company estimated the prevalence of iron-deficiency
among a sample of 3,742 nonpregnant females using an algorithm developed by Cook et
al. for the quantification of body iron and compared these prevalence rates to those
generated using a standard model for estimating iron-deficiency (51). Similar to the
discrepancy in the prevalence estimates above, the equation developed by Cook et al.
“produced lower estimates of iron-deficiency, better predicted anemia and was less
affected by inflammation” than the standard model (51, p.1,334). Thus, the discrepancy
between CDC estimates and those produced by the algorithm developed by Cook et al.
most likely arise due to the difference in hemoglobin reference ranges utilized during the
times when incidence was calculated and the fact that national surveys did not take into
account the symptoms of iron-deficiency apart from hemoglobin values. In other words,
the CDC appears to have used hemoglobin values alone in the determination of iron
deficiency anemia. According to Moon, the presence of iron-deficiency anemia is not that
common in developed nations (109). For instance, iron-deficiency due to menstruation is
not the antecedent of iron deficiency anemia in most females (109). Although
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hemoglobin levels and transferrin saturation may temporarily decrease during
menstruation, dedicated compensatory mechanisms in the human body insure the
absorption of more iron from the diet (109). Therefore, if iron-deficiency anemia does
temporarily manifest during the menstrual cycle, it appears to be efficiently counteracted
by increased iron absorption (109). This leads one to hypothesize that the iron status
among females in developed nations has perhaps been estimated incorrectly.
Using data obtained from participants in the Framingham Heart study and sexspecific cutoffs for defining high iron stores (i.e., ferritin > 300 µ/L in males and > 200
µ/L in females), Fleming et al. observed a high prevalence (12.9%) of elevated iron stores
and a low prevalence of iron deficiency (122). Milman et al. observed a similar
prevalence (i.e., 13%) of high iron stores in a small sample of 85-year old healthy Danes
(123). In another healthy, free-living population of 1,332 Danish men aged 4-70 years,
Milman et al. (124) observed a high prevalence of elevated iron stores in males
comprising two of the oldest age groups (i.e., 20.8% in males in the 60-year old age
group and 15.2% in males in the 70-year old age group). The results published by Garry
et al. are congruent with these findings, where the authors report that the prevalence of
elevated iron stores in free-living elderly males and females in Mexico were 35% and
15%, respectively when defining elevated body iron stores on the basis of ferritin > 200
µ/L (125). In a separate study conducted by Milman et al. which examined iron status
among the Danes from 1994 to those who participated in the Dan-Monica survey ten
years earlier the authors concluded that the prevalence of all-cause iron deficiency did not
change, whereas the prevalence of iron overload increased (126). Moreover, the authors
hypothesized that “the 1987 abolition of mandatory iron fortification of flour apparently
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had no negative affect on iron status,” (126, p.612) stating that members of the
population are ultimately accountable for their own primary prevention. Taken together
these studies also appear to support the hypothesis that iron stores increase with age and
that the prevalence of high iron stores is relatively common among both males and
females in developed nations.
As mentioned previously, body iron stores vary as a function of ethnicity. Using
data obtained from NHANES III (1988-1994), Zacharski et al. reported that African
American males have a higher body iron burden across the lifespan compared to
Caucasian and Hispanic American males and that this disparity is amplified with
increasing age (112). Gillum observed a similar trend for Hispanic American males using
NHANES III data (113). Unfortunately, the latter author did not compare indices of body
iron in these participants to those of other ethnic groups.
Zacharski et al. also observed a similar trend among females following
menopause. In other words, no difference in body iron stores among females of
childbearing age was observed until after the 4th decade of life when body iron in black
females rose more rapidly and exceeded those of Caucasian and Hispanic American
females. However, as with most studies assessing body iron, the authors employed
ferritin as a proxy for iron stores and did not control for inflammation. Thus, the observed
differences in body iron burden across ethnicities by these authors could have been due to
the anemia of chronic disease. The results from a more recent study using NHANES data
from 2003-2006 are discordant with those of Zacharski et al. among females aged 20-49
years. While the latter authors did not observe disparities in body iron burden among
females of childbearing age, the results of Pfeiffer et al. demonstrate higher body iron
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stores among Caucasian females followed by Hispanic American and African American
females (114). The group used the algorithm developed by Cook et al. in the estimation
of iron stores. More research is needed before inferences can be made on these results.
In a follow-up study examining dietary factors associated with high iron stores in
the Framingham cohort, Fleming et al. concluded that intakes of highly bioavailable
forms of iron (e.g., supplemental iron and heme iron from red meat) and of fruit with
vitamin C (i.e., an enhancer of iron absorption) promote high iron stores, whereas foods
containing phytates (e.g., whole grains) decrease these stores (127). The results from
another population-based study are congruent with these findings. In a study published
using participants in NHANES III, the proportion of iron supplement users whose intake
was at or below the recommended dietary allowance (RDA) was 18.1% in males aged
19-30 years (n = 773), 21.7% in males aged > 31 years (n = 2,235), 59.3% in
premenopausal females (n = 1,553) and 22.5% in postmenopausal females (n = 1,387).
From these data, one can infer that over 81% of males aged 18-30 years, 78% of males
aged 31 years and older, 40% of premenopausal females and 77% of postmenopausal
females consume iron supplements in quantities greater than those recommended by the
RDA. Among users with very high supplemental iron intakes, the authors report that
males aged 19-30 years who consumed > 4 times the RDA was 12% and 12.7% in males
> 31 years. The proportion of premenopausal and postmenopausal females who
consumed > 4 times the RDA was 4.2% and 8.2%, respectively (128). The results
published by Garry et al. are in alignment with these findings. In their study of free-living
elderly males and females living in Mexico the authors reported that participants
consuming > 18mg (i.e., roughly twice the RDA) had iron stores that were 65 mg higher
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than participants who did not consume iron supplements (125). The current RDA for
dietary iron and supplements combined in females of childbearing age is 18 mg/day. For
pregnant females, the RDA is 27 mg/day and during lactation it is 10 mg/day. For all
other adults, the RDA is 8 mg/day (129). Thus, it is not surprising that much of the
population in developed nations is iron-replete, where the reported median dietary iron
intake for men is 16-18 mg/day and 12 mg/day for postmenopausal females (109, 128).
As mentioned previously, the rate of iron absorption depends on a variety of
factors, such as body iron stores, rate of erythropoiesis, hemoglobin concentration and
oxygen concentration. Several studies have demonstrated that the average rates of iron
absorption in males and nonpregnant females is 15% of total dietary iron while pregnant
females absorb approximately 17% of ingested iron. According to the Food and Nutrition
Board, roughly half of the total amount of dietary iron ingested by the human population
originates in fortified foods (i.e., flour, pastas, bread, cereals) (109). This is not
surprising, given the mandatory fortification of the U.S. food supply with iron beginning
in 1941 (109). It has been reported that some cereals contain up to 24 mg of iron per onecup serving (109) and Abbaspour et al. have demonstrated that the iron content in
different varieties of wheat can vary from 25 mg to 56 mg/kg and iron in various strains
of rice grains can vary from 7 mg to 23 mg/kg (59).
In addition to fortified foods, body iron can be increased by means of other
dietary exposures which increase its absorption. For instance, consumption of sugar has
been shown to increase non-heme iron absorption by four-fold (62). Other dietary
exposures which increase intestinal iron absorption are beta carotene, cauliflower,
tomatoes, kiwifruit and oranges (130). Ascorbic acid (i.e., vitamin C) induces a change in
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the redox potential of non-heme iron, shifting the valence from ferric iron to ferrous iron
(109, 131). As mentioned earlier in the current chapter, the latter form is more soluble
and 40-50% of iron ingested concomitantly with ascorbic acid is readily absorbed in the
duodenum compared to the average rate of absorption of 15% or less (131). Moreover,
concomitant consumption of red meat with non-heme iron can result in a significant
increase in iron absorption and it has been reported that one gram of red meat intake has
an enhancing effect on non-heme absorption equivalent to that of one milligram of
ascorbic acid (110). Given that the heme iron content of the typical Western diet averages
~10-15% (i.e., from red meats, processed meats, poultry and fish), it doesn’t appear as
though heme iron is an independent contributor to total body iron stores. In other words,
both heme iron as well as nonheme iron, in addition to exposures which increase and/or
decrease iron absorption are all factors which must be accounted for when estimating
total body iron stores.
Exposures not typically found in the diet which nonetheless increase iron
absorption include alcohol and smoking. Approximately 20-30% of heavy drinkers
acquire up to twice the amount of dietary iron as do abstainers and light drinkers (132,
133) because alcohol inhibits delta-amino-levulinic acid dehydratase, a key synthetase in
porphyrin biogenesis and, ultimately, hemoglobin levels (134). Alcohol also increases
non-heme iron absorption due to increasing gastric acid production, where the increased
acidity precipitates iron ions in solution as they reach the duodenum where absorption
into bloodstream occurs (134). In addition, alcohol decreases hepcidin synthesis and
increases expression of DMT1 in the intestine, resulting in increased iron absorption
(135). A typical cigarette contains approximately 84 micrograms of iron per gram of
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tobacco (110, 136) Given that a cigarette contains approximately one gram of tobacco, a
one-pack-a-day smoker can inhale up to 1.68 milligrams of iron per day. Moreover, some
pipe tobaccos contain over 400 micrograms of iron per gram of tobacco (110, 136).
Consistent with these statistics, alveolar macrophage iron content has been shown to be
67% higher in smokers compared to nonsmokers (137) and is positively correlated with
number of cigarettes smoked (138).
Iron loss can occur through several routes, such as blood loss through donation
and phlebotomy, menstruation and child birth. Blood donation and phlebotomy typically
removes one pint (~ 475 cc) of blood and this equates to 0.25 grams (250 mg) of iron
(109, 110). Blood is also lost during menstruation. The average period lasts anywhere
from two to five days and blood loss during this time is estimated to range from 60
milliliters (~ 4 tbs) for a light period to 250 milliliters (~ 1 cup; half of a pint; 125 mg of
iron) for a heavy period (110). On average, however, about one pint of blood is lost
annually during menstruation (110), which is equivalent to the amount of iron loss during
blood donation/phlebotomy. Each child birth results in a loss of blood that is equivalent
to the amount lost during a heavy period (110). Other factors which result in loss of iron
include physical activity (i.e., iron is lost through perspiration and sloughing of the
gastrointestinal tract), ulcers, trauma, hemodialysis, surgical procedures, colon cancer,
uterine cancer, intestinal polyps, hemorrhoids and intravascular hemolysis (109). When
hemolysis occurs, hemoglobin and heme iron are reported to be 1) scavenged by
haptoglobin and hemopexin, respectively, 2) rapidly cleared from circulation and stored
in ferritin, 3) recycled by macrophages or 4) lost by hemoglobinuria and hemosiderinuria,
respectively (109, 110).
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Notwithstanding the above-mentioned routes of blood loss, body iron stores can
be reduced at the level of absorption. Dietary exposures which decrease iron absorption
are fiber, soy protein, inositol phosphate-6 (IP6) (i.e., phytates/phytic acid) such as wheat
bran, rice bran, whole wheat, corn, peas, rye, oats, brown rice, nuts and legumes (130,
131) as well as oxalates such as spinach, bran flakes, rhubarb and beets (130). In
addition, polyphenols such as flavonoids, phenolic acids, phenolic alcohols, stilbenes and
lignans are ring structures that contain more than one hydroxyl group which bind nonheme iron and render it unavailable for absorption (131). Calcium has been shown to
inhibit non-heme iron absorption (and heme-iron, to a lesser extent) and ovotransferrin
(i.e., ovalbumin) contained in eggs exhibits an iron-binding affinity similar to that of
lactoferrin (110). Lactoferrin (found in bodily fluids such as perspiration, tears, seminal
fluid, vaginal fluid, breast milk and to a lesser extent in saliva) (110) binds ferric iron
with 240-times greater affinity than transferrin (110) and deprives microorganisms (e.g.,
bacteria, fungi) access to growth medium. In contrast to transferrin, however, iron that is
sequestered by lactoferrin is not used by healthy cells (i.e., the sole function of lactoferrin
is to bind excess iron) (109, 110). Consistent with these observations, it has been reported
that one boiled egg can reduce absorption of iron in a meal by as much as 28%. (109).
Finally, medications such as acid reducers (e.g., omeprazole (Prilosec), pantoprazole
(Protonix)), Imipramine (i.e., an antidepressant) and aspirin have also been shown to
reduce iron absorption. According to Weinberg, gastrointestinal microbleeding induced
by aspirin “results in the loss of iron comparable to that of menstrual blood loss.” (110).
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CHAPTER 3: IRON IN HUMAN HEALTH AND DISEASE

Iron in human health The importance of iron in human health was evident as
early as the 17th century when iron was used to treat chlorosis, a condition which results
from iron deficiency. However, it was not until 1932 when it was demonstrated that iron
was required for hemoglobin synthesis that the metal began to become a fixture in the
research community (109).
Functional dependencies on iron As mentioned in chapter 2, humans require
iron for cellular respiration, DNA synthesis, DNA repair, as a cofactor in biochemical
reactions, oxygen transport, endocrine regulation, thermoregulation and bone health.
Three out of the four redox cofactors (i.e., complexes) in the electron transport chain and
the electron carrier cytochrome c contain hemes and iron-sulfur clusters, respectively. All
contain iron ions whose redox state serves to accept or donate electrons to keep the chain
operational where ferrous iron acts as an electron donor and ferric iron acts as an electron
acceptor (139).
With respect to DNA synthesis and repair, the activity of ribonucleotide
reductase, the rate limiting enzyme involved in the conversion of ribonucleotides to
deoxyribonucleotides is iron dependent (140). Iron is also vital for the enzymatic activity
in xenobiotic (e.g., plant alkaloids, fungal toxins) and medication metabolism. All
cytochrome P450 (CYP450) enzymes contain iron in their active site where the redox
potential of iron is used to catalyze the oxidation (i.e., activation) of most medications
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(141-144). These enzymes are expressed in every tissue except skeletal muscle and
erythrocytes (142). The reactions catalyzed by CYP450 enzymes begin with the
abstraction of hydrogen from NADPH by cytochrome P450 reductase (142). The
hydrogen is then used by CYP450s to reduce one of the two atoms of molecular oxygen
to water. The other oxygen atom is retained in a highly reactive form, which in turn is
used to force subsequent catalytic reactions upon the substrate (142-144).
The enzymatic activities of aconitase (i.e., a regulatory protein), nicotinamide
adenine dinucleotide phosphate (NADPH) oxidoreductase and myeloperoxidase are
dependent upon iron as a cofactor. In addition, catalase is an enzyme which uses iron as
an electron donor and participates in the prevention of hydrogen peroxide (H2O2) induced
cellular damage by converting the compound to water and molecular oxygen (145).
Xanthine oxidase contains riboflavin (i.e., vitamin B2), molybdenum and ferrous iron in
its active site (146). Finally, iron appears to be a negative regulator of nitric oxide (NO)
synthase (147). Conversely, NO is a negative regulator of iron, whereby increased NO
decreases labile iron by increasing ferritin mRNA expression and ferritin synthesis (148)
and NO has been observed to be up-regulated in iron deficiency anemia (149).
The genesis of oxygen transport occurs upstream within the bone marrow
beginning with the synthesis of erythrocytes (i.e., erythropoiesis) and requires 25-30 mg
of iron per day. The iron is obtained from reticuloendothelial macrophages which
phagocytose and catabolize 20 mL of senescent erythrocytes each day resulting in the 2530 mg of required iron (150). Erythroid regulation of iron metabolism is controlled by
erythroferrone (ERFE), a newly identified hormone produced by erythroblasts in
response to erythropoietin which negatively mediates hepcidin expression during iron24

deficient states. Briefly, the kidney acts as a sensor of oxygen levels in circulating
erythrocytes. When oxygen levels decrease, erythropoietin is synthesized by interstitial
fibroblasts within the renal medulla (151), which is released into circulation and
upregulates erythroblast formation in the bone marrow. In turn, erythroblasts express
ERFE, which lowers serum hepcidin and increases iron absorption (151). Thus, iron
utilization for erythropoiesis increases after stimulation by erythropoietin or in response
to hypoxemia (152). Conversely, inhibitors of erythropoiesis induce a rise in serum and
tissue iron levels (153).
Iron affects endocrine signaling in myriad ways. For example, increases in
adipocyte ferritin synthesis has been shown to reduce adiponectin expression and
increases insulin resistance (154, 155). In addition, iron and leptin appear to negatively
regulate one another, as increases in leptin induce hepcidin expression (which decreases
iron absorption) (156). Paradoxically, increases in iron are monotonically associated with
decreases in leptin. For example, in a 2015 cross-sectional study conducted by Gao et al.
using data from a cohort of 76 individuals, the authors sought to examine the relationship
between serum ferritin and leptin and found a significant negative association between
the two analytes (r = -0.53, P < 0.0001). Moreover, to extend these findings, the authors
conducted an animal study using C57BL6/J mice, where the animals were fed one of two
diets: 1) a high-iron diet (i.e., 2,000 mg/kg, N = 36) or 2) a low-normal iron diet (i.e., 35
mg/kg, N = 36) for 2 months. At the end of the study, Gao et al. found that serum leptin
decreased with increasing dietary iron (r = -0.26, P < 0.01) where mice in the high-iron
group had 42% lower serum leptin concentrations compared to mice in the low-normal
iron group (157).
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The relationships between sex hormones and body iron appear to be quite
complex. For example, testosterone increases expression of erythropoietin, which
decreases hepcidin expression to sequester iron for erythropoiesis (158). It has also been
shown that testosterone directly suppresses hepcidin expression and increases iron
absorption independent of erythropoietin signaling (159). Consistent with these results,
Liu et al. reported that serum ferritin levels are inversely associated with total
testosterone, sex-hormone binding globulin (SHBG) and free testosterone (160) and
Winters et al. have demonstrated that SHBG is inversely related to insulin resistance
(161) and metabolic syndrome (162). Yang et al. have recently shown that E2 contained
in oral contraceptives suppresses hepcidin expression both in vitro and in vivo and
increases iron absorption by binding to an estrogen response element in the hepcidin
promoter gene. (163, 164). In an animal study using newly hatched White Leghorn
chicks, E2 administration decreased total iron binding capacity (TIBC, i.e., the ratio of
serum iron to transferrin saturation) in serum by ~ 20% from levels in a control of group
of animals (n = 4) irrespective of iron content of diet and raised non-heme iron content of
livers of animals in the experimental group (n = 4) by 40-50% over that of the control
group irrespective of iron content of diet. (165). More alarming is that redox cycling of
estrogen metabolites has been reported to release ferric iron from ferritin which in turn
generates hydroxyl radicals via the Fenton reaction (discussed in greater detail below)
(166).
Human and animal studies have both reported links between excess body iron and
decreased bone mineral density (BMD), lower serum osteocalcin, delays in bone
mineralization, lower rates of bone formation and lower osteoblast numbers (167).
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Individuals with beta-thalassemia, for example, consistently exhibit low levels of
circulating osteocalcin (168) and osteoblast cells express transferrin receptor and ferritin
throughout differentiation in vitro, suggesting that iron is important in osteoblast
maturation and function (167). Iron suppresses osteoblast maturation and function in a
dose-dependent and time-dependent manner (167) in cells isolated from primary fetal rat
calvaria and it is hypothesized that that the effect is mediated by ferritin and its
ferridoxase activity (169). As previously mentioned, ferritin light chain participates in
ferridoxase turnover and studies have reported that ferritin light chain expression is
normally high in osteoblasts (167). Thus, as intracellular concentrations of iron increase,
ferridoxase turnover activity of ferritin light chain may diminish, leading to an increased
number of immature osteoblasts. Moreover, cell line studies where DMT1 is mutated to
increase iron absorption demonstrate that the ensuing iron overload leads to increased
osteoblast autophagy and apoptosis (170). Taken together, it appears as though the effect
of increased iron on bone health results in premature cell death and/or proliferation of
immature osteoblasts. Finally, one group of authors have published data which indicates
that serum ferritin is inversely correlated with osteocalcin and osteocalcin is associated
with glucose and insulin metabolism by exerting a direct effect on beta cells via
stimulating insulin production and enhancing adiponectin production from adipocytes
(171). Thus, these researchers have recently developed a hypothesis which links high
body iron to low osteocalcin, low adiponectin and increased insulin resistance (172).
Iron has been implicated in the body’s ability to thermoregulate for quite some
time. For example, several authors have reported that iron deficiency leads to impaired
thermoregulation in response to acute cold exposure (173-176). Conversely, it has also
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been hypothesized that ‘hot-flashes’ experienced by post-menopausal females are directly
related to increases in body iron following the onset of menopause (177).
Iron in human disease An approach often employed by epidemiologists to
implicate a given exposure in the development of disease is to demonstrate that the
disease has a genetic or heritable component. Most diseases of iron overload result from
loss of function mutations (e.g., hereditary hemochromatosis), resulting in suppressed
hepcidin production. To this end, the following iron loading conditions have all been
studied extensively and linked to adverse health outcomes: hereditary hemochromatosis,
TFR2-related hemochromatosis, ferroportin disease, juvenile hemochromatosis (type 1
and 2), beta thalassemia, sickle cell anemia, X-linked sideroblastic anemia, pyruvatekinase deficiency, hereditary spherocytosis, Fanconi anemia, Diamond-Blackfan anemia,
chronic renal failure, Friedreich ataxia, hereditary atransferrinemia and hereditary
aceruloplasminemia (178-181). Tables 6a-6e highlight each iron loading disorder, genetic
mutation, genetic locus, mode of inheritance, mechanism, affected iron parameter and
disease association(s)/clinical feature(s). For convenience, each disorder is categorized by
subtype.
Iron in infectious disease Nearly all pathogenic microorganisms need iron for
survival, growth and multiplication (110). Under normal physiologic conditions an
immunological challenge results in an increased expression of interleukin-6 (IL6). In
turn, hepcidin mRNA expression is reduced and interferon gamma (INF-γ) is induced.
This results in the halt of export of iron from cells via degradation of ferroportin and a
reduction of transferrin receptor expression, which enables invaded cells (e.g.,
macrophages) to starve invading pathogens. Several infectious microorganisms such as
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Mycobacterium tuberculosis, Candida albicans, Borrelia burgdorferi, Staphylococcus
aureus, Pseudomonas aeruginosa, Helicobacter pylori, Salmonella, Toxoplasma gondii
directly induce hepcidin expression via pathogen associated molecular patterns (PAMPs),
which also prompts the body to withhold iron and trigger the innate immune response via
activation of toll-like receptors (182). Studies have shown that circulating hepcidin binds
to TLR2, TLR3, TLR4, TLR7, TLR8, TLR9 and TLR10 (183). Pathogens, however,
have evolved at least four strategies to acquire iron from hosts: 1) hemolysis (e.g.,
Streptococcus pneumoniae, Staphylococcus aureus), 2) transferrin or lactoferrin
scavenging (e.g., Neisseria meningitis (i.e., transferrin scavenging), Helicobacter pylori
(i.e., lactoferrin scavenging), Vibrio vulnificus (i.e., transferrin scavenging), 3)
siderphores (e.g., Escherichia coli, Listeria monocytogenes, Haemophilus influenzae
(183)), Neisseria meningitidis (183) or 4) target, infect and utilize intracellular
macrophage iron (e.g., Coxiellaceae, Francisella tularensis, Legionnaires pneumoniae,
Mycobacterium tuberculosis). Moreover, hepatitis C virus has been shown to increase
hepatic iron level in Huh7 and Huh7.5 cell lines by suppressing hepcidin expression
(184) and five iron-dependent and iron-regulated steps are required for the replication of
the human immunodeficiency virus (HIV) (185).
Increases in body iron burden have been linked to the suppression of the
complement system (186) and have been observed to have adverse effects on major
aspects of macrophage/monocyte function such as decreasing immune and nonimmune
phagocytosis, decreasing chemotaxis, altering cytokine production and release as well as
decreasing antigen processing for subsequent presentation to B- and T- lymphocytes
(186). Increased iron concentration in macrophages reduces their response to activation
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by interferon-gamma (INF-γ) and diminishes their antimicrobial toxicity. Moreover, cellline studies have demonstrated that addition of iron to culture results in decreased
antibody- (Ab) mediated and mitogen-stimulated phagocytosis by macrophages and
monocytes (186). Conversely, orally-administered lactoferrin has been shown to restore
humoral immunity in immunocompromised mice (187). It has been hypothesized that the
above associations between iron and macrophage/monocyte function is due the ability of
iron to negatively regulate NO synthesis. Given that NO is integral for macrophage
cytotoxicity (188), this hypothesis warrants further investigation.
Increases in body iron have also been implicated in alterations in T-lymphocyte
subsets. For example, individuals with high iron stores demonstrate a reduction in
circulating interleukin-2 (IL2) and subsequent impairment of the generation and activity
of CD8+ cytotoxic T lymphocytes (CTLs) (186, 189) and natural killer cell (NKC)
activation and proliferation. Moreover, these lymphocytes in individuals with increased
body iron exhibit decreases in proliferative capacity, numbers and activity of helper
(CD4) T cells (186) by increasing expression of IL-4, IL-10, and decreasing levels of IL12 and INF-γ. Thus, increases in iron appear to polarize helper T-cell subsets into Th2
effector cell subtypes which are implicated in reduced immunological surveillance and
anergy (183). This is thought to arise via the same mechanism implicated in macrophage
anergy whereby iron antagonizes NO, which decreases Th1 proliferation (190) and
polarizes the Th2 response. In turn, increased Th2 production of IL4 induces a
suppression of INF-γ and this culminates in the activation of transferrin receptor mRNA
synthesis which could lead to further increases in body iron. Clinical studies which
support these in vitro results have shown that iron demonstrates an antagonistic effect for
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individuals undergoing interferon therapy (191) and that treatment response is restored
upon iron chelation therapy (191). In line with these observations, body iron also appears
to have an effect on interferon therapy. The higher iron content of the liver, the less likely
it is that a patient will respond to treatment (109). Related to this, Alexander et al. (192),
performed weekly phlebotomies on 18 subjects with chronic hepatitis C infection who
did not respond to initial interferon therapy. Phlebotomy continued until serum ferritin
was < 50 ng/mL and the authors observed that “iron depletion was associated with a
response rate of 22% in those who did not initially respond to monotherapy.” Taken
together, it appears that the effects of iron on immunological regulation is related to
immunological defense and surveillance.
Iron in chronic disease As a dietary exposure, iron appears to have a curvilinear
relationship with human health and disease, as both severe iron-deficiency and varying
degrees of iron excess have been implicated in the pathogenesis of several adverse health
outcomes. As mentioned, the idea that excess iron could be potentially toxic to humans
was first suggested by Jerome Sullivan in 1981 in his canonical article “Iron and the sex
difference in heart disease risk” (36). In it, Sullivan hypothesized that blood loss via
menstruation is the primary factor that protects premenopausal females from ischemic
heart disease. A few years later in 1984, Halliwell and Gutteride demonstrated iron’s
toxicity via oxygen radical generation in biological systems (193). Finally, in 1992 with
Lauffer’s publication of Iron and Human Disease, iron became widely known as a biometal that accumulates with increasing age (194)
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Though iron is an essential micronutrient required for survival it is also a
transition metal. Thus, iron can exert a detrimental effect on cellular, organ, and systemic
homeostasis via the Fenton Haber-Weiss reaction, which can be summarized as follows:

1): Fe3+ + · O2- → Fe2+ + O2
2): Fe2+ + H2O2 → Fe3+ + OH- + · OH
3): · O2- + H2O2 → OH- + O2 + · OH
High levels of insoluble iron can react with superoxide radicals and ferrous iron can react
with H2O2, initiating the Fenton reaction (reactions 1 and 2). The end-product of these
reactions includes the generation of unstable free radicals and oxidized ferric iron (195).
Iron is also a key metal that catalyzes the Haber Weiss reaction, which is a secondary
reaction to the Fenton reaction (196). A superoxide radical (· O2-) generated from the
Fenton reaction reacts with H2O2 which in turn generates a hydroxyl radical (196). Thus,
iron is a pro-oxidant and is capable of generating reactive oxygen species (ROS). In turn,
ROS contribute to oxidative stress (OS) and inevitably induce lipid peroxidation,
endothelial dysfunction, and microsatellite mutations within regions of the genome (197).
It is noteworthy to mention that the above reaction is an intracellular phenomenon. Thus,
several authors have concluded that increased intracellular iron, in comparison to
extracellular iron, has been shown to exhibit greater systemic toxicity and cellular
damage.
In developed nations including the Unites States, the seven leading causes of
human mortality are cardiovascular disease (e.g., coronary heart disease), cancer,
cerebrovascular disease (e.g., stroke), chronic obstructive pulmonary disease (COPD),
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accidents, Alzheimer’s disease (AD), and diabetes (198). With the exclusion of accidents
and diabetes, the ensuing review will examine the effect of iron deficiency and excess on
the development of human chronic disease. A review of the effect of iron in the
epidemiology of diabetes and other metabolic dysfunction appears in chapter 4.
Iron and cardiovascular disease Cardiovascular disease (CVD) is the leading
cause of mortality in the U.S., accounting for 25.4% of total deaths (199). The postulation
that iron influences the development of CVD originated with J.L. Sullivan in 1981 when
the author published an article in the Lancet examining gender differences in the risk of
heart disease (36). Sullivan proposed that the rate difference in incident CVD between
men and females was likely due to iron loss through menstruation in premenopausal
females. Thus, Sullivan’s hypothesis stated that iron excess was a risk factor for the
development of CVD, while iron deficiency appeared to convey a protective effect.
The iron-heart hypothesis has received support from in vitro models (200, 201),
animal studies (200, 201) and epidemiological studies (202-211). For example, in a
prospective study in a Finnish population (n = 1,931), Salonen et al (200) demonstrated
that serum ferritin concentration was positively associated with risk of myocardial
infarction (MI). Compared to men with serum ferritin levels < 200 ng/mL, men with
serum ferritin concentrations ≥ 200 ng/mL exhibited more than a 2-fold increased risk of
acute MI (200). In a study of 9,920 Canadian men and women, Morrison et al (201) have
shown that the risk of fatal MI increases significantly in persons with serum iron
concentrations ≥ 175 μg/dL combined with total cholesterol level ≥ 240 mg/dL. Tzonou
and colleagues (202) examined the role of dietary iron in the development of coronary
heart disease (CHD) in a case-control study in Greece. The study was comprised of 329
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cases and 570 controls with no matching on age or gender. Cases were all recruited from
the same hospital on the basis of CVD development. Hospital controls were selected on
the basis of absence of CVD. The authors demonstrated a positive association between
iron intake and CHD among cases > 60 years of age. The odds ratio that the authors
reported for each monthly increment of 50 mg of iron was 1.47 (95% CI: 1.02-2.12). The
effect of dietary iron was stronger for women (OR for each monthly increment of 50 mg
dietary iron: 3.61; 95% CI: 1.45-9.01). Although slightly attenuated when adjusted for
total cholesterol and blood pressure, the risk estimates remained significant for both men
(OR = 1.36) and women (OR = 3.51). Thus, the results published by Tzonou et al support
Sullivan’s hypothesis. Findings from van der A, et al (203) support the increased risk of
CVD in females with diets high in heme iron. Participants were grouped into quartiles
based upon increasing levels of dietary iron. In the study (n = 16,136), the authors found
a 65% increase in CVD risk in middle-aged women who consume > 2.27 mg/day heme
iron (Q4 vs Q1: HR = 1.65; 95% CI: 1.07-2.54). The significance of the risk estimates
did not change when the authors adjusted for total energy intake or total cholesterol
intake. Results from the Bruneck Study, however, have shown that serum ferritin is one
of strongest predictors for progression of atherosclerosis in the presence of increasing
concentrations of LDL cholesterol (204). The authors demonstrated that a 1-SD increase
in ferritin concentration at LDL levels of 2.5 mmol, 3.6 mmol, and 4.9 mmol precipitated
an increase in progression of atherosclerosis. The reported hazard ratios (HR) for each
increasing concentration of LDL were 1.55 (95% CI: 1.30-1.85), 1.77 (95% CI: 1.402.24), and 2.05 (95% CI: 1.50-2.80), respectively. These results suggest an interaction
between iron and LDL cholesterol. A study conducted by Bazrgar et al (205) supports
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this speculation. The authors examined the association between APOE status in patients
with thalassemia major and the risk of left ventricular dysfunction. Participants (n = 202)
were divided into three groups, based upon level of cardiac impairment (i.e., group 1= no
cardiac impairment; group 2 = LV dilation with normal systolic function; group 3 = LV
systolic dysfunction). Participants in group 3 were significantly more likely to carry the
high risk APOEε4 allele, compared to participants in group 1 or group 2. Briefly, gene
products of APOE function as lipid transporters and scavengers of free radicals (205).
The locus itself is known to contain three variant alleles: APOEε2, APOEε3, and
APOEε4. APOEε2 encodes greater concentrations of mRNA and displays high
scavenging activity while APOEε4 encodes lower concentrations of mRNA and has
exhibits decreased scavenging activity (205). The scavenging capacity of APOEε3 lies
between APOEε2 and APOEε4. Products of the APOE gene thus work to clear oxidized
LDL (oxLDL) from systemic circulation (205, 206). It has been well established that oxLDL is one of the main contributors to atherosclerosis and that iron is a potent oxidizing
agent (206). Hence, the synergistic relationship between iron and LDL cholesterol
appears biologically plausible. Interestingly, cholesterol lowering medications (i.e.,
statins) have been shown to reduce serum ferritin levels, offering further support for iron
in the iron-heart hypothesis (207).
Genetic studies of CVD have contributed additional insights to risk susceptibility.
For example, a prospective cohort study (n = 1,150) conducted by Tuomainen et al (208)
demonstrated that heterozygous male carriers of the risk allele (i.e., C282Y) of the HFE
gene, a mutation implicated with hereditary hemochromatosis, experience a 2.3-fold
increased risk of acute MI (p = 0.03). These results were subsequently substantiated in a
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study by Roest et al (209), who have shown that female HFE heterozygotes also have an
increased risk of mortality from cardiovascular disease (OR = 1.6; 95% CI: 1.1-2.4)
Further supporting the iron-heart hypothesis are studies which demonstrate a
decreased risk of CVD among regular blood donors. Another prospective cohort study (n
= 2,862) conducted by Salonen et al (210) demonstrated that blood donors experienced
fewer CVD events (i.e., acute MI) compared to non-donors (0.7% vs 12.5%, respectively;
p = 0.035). Results from Ascherio et al (211), however, do not corroborate these
findings. The authors argue that healthier individuals are more likely to donate blood and
therefore do not constitute a random sample. It should also be noted that the literature
offers further discordant support for the iron-heart hypothesis. For example, during a 14year follow-up study, Sempos et al (212) found no increased risk for CVD with
increasing levels of transferrin saturation in a cohort of 4,518 men and women. These
results have been confirmed in the Helsinki Heart Study (213) and the Health
Professionals’ Follow-up Study (214). A retrospective cohort study published from data
gathered during the NHANES I Follow-up Study demonstrated a negative association
between serum iron concentration, transferrin saturation, and CVD (215). In a controlledfeeding study Derstine and colleagues (216) reported no association between iron status
and strong risk factors for cardiovascular disease (i.e., LDL oxidative susceptibility). It is
interesting, however, that participants in the aforementioned study were administered
food sources containing only non-heme iron (e.g., peanut butter). The literature clearly
demonstrates that heme iron from animal sources (202, 203, 217), which is more readily
absorbed in the gastrointestinal tract, is more closely linked to the association between
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excess iron and cardiovascular disease risk. Derstine et al offered no reasoning for the
exclusion of heme iron from each participant’s diet.
Taken together, it appears that the iron-heart hypothesis finds support from human
studies examining the relationship between excess iron stores (derived from heme-iron
intake) and acute or ischemic cardiovascular-related phenomena. Thus, iron in excess
appears to exert its effect in initiating or promoting CVD events (218). It should be noted
that many markers of iron status (i.e., ferritin and transferrin) are acute-phase reactive
proteins often present during infection and inflammation. Studies that have controlled for
these related factors by concomitantly measuring serum C-reactive protein (CRP) (219,
220) and α-1 acid glycoprotein (AGP) (220) nevertheless reveal significant associations
between excess iron stores and risk of CVD. Given that the aforementioned relationship
between iron and CVD appears to be significantly modified in persons with APOEε4
status and/or abnormal lipid profiles (e.g., hyperlipidemia), further research is required to
quantify iron’s unique contribution to the development of CVD.
Iron and cancer Malignant neoplasms (i.e., cancers) are the second leading
cause of mortality in the U.S., accounting for approximately 23.2% of total deaths (198).
The relationship between iron excess and cancer has been studied extensively. Multiple
disciplines, ranging from genetics to epidemiology have reported upon the toxicity of
iron in the human body. Emerging from these investigations is a seemingly coherent
communiqué: iron in excess is positively associated with cancer mortality and the
initiation or promotion of specific cancers. As mentioned previously, iron is capable of
generating ROS, inducing lipid peroxidation, or endorsing microsatellite mutations. The
culmination of the preceding events invariably leads to mutations within DNA as well as
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organelle, cellular, and tissue damage (221-224). Moreover, forward propagation of these
aberrant intracellular states often initiate irreversible mutations in essential DNA repair or
tumor suppressor genes. In turn, an entire diabolical cascade of chemical events may
ensue, leading to the dysfunction and destruction of mitochondria, organelles, and tissues.
It remains unresolved, however, if iron conforms more suitably to the role of tumor
initiator or promoter.
Iron does not have carcinogenic properties, per se. Nevertheless, many studies
have clearly linked iron to the development of malignancy. For example, using NHANES
II data, Wu et al (225) demonstrated a dose-response effect of iron on cancer mortality.
An investigation utilizing NHANES I data support the aforementioned results (226).
Regarding cancer subtype, iron has been most strongly linked to the development of
colorectal cancer (227-239) and breast cancer (240-255). These studies demonstrate that
iron-specific parameters derived from study participants are often indicative of iron
overload (as opposed to iron-deficiency) in these cancers. Furthering the association
between iron excess and cancer are studies demonstrating an association between
colorectal and breast cancer with the HFE C282Y mutation (256-262). Iron’s association
with lung cancer is less clear, however. Four of six investigations establish a point
estimate greater than one (263-266). However, only one of the six (263) estimates do not
cross unity. Interestingly, iron appears to espouse a dual-role in prostate cancer (267275). Iron tends to be inversely associated incident prostate cancer (267-271) and
positively associated with advanced, aggressive, and fatal prostate cancer (272). The
subjects from each of the aforementioned studies were all middle aged and older,
rendering it difficult to distinguish iron from other milieu as a tumor initiator. Given the
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associations reported in the above investigations, however, regarding iron as a tumor
promoter seems plausible. This speculation is further supported by human and animal
studies demonstrating a clear association between primary iron overload (i.e., hereditary
hemochromatosis) and secondary iron overload with digestive tract and liver cancer (276283). These sites are of particular interest, given their primary function in iron absorption,
metabolism, and storage. Interestingly, tumor cells have been observed to express a high
number of transferrin receptors (197), owing to their high rate of proliferation. Thus, it
would be a formidable task to abrogate the role of iron in the promotion of malignancy in
humans. Moreover, irrespective of initiating events, the alterations observed in iron status
and metabolism in the above-mentioned cancers indicate that iron bolsters the
aggressiveness and metastases of malignancy.
Although iron is clearly implicated in the development and propagation of
colorectal and breast cancer, investigations examining the role of iron in other types of
cancer show no such associations. For example, inverse associations between iron status
and renal cancer, pancreatic cancer, Barrett’s esophagus, and oral cancer have been
reported in several studies (284-286). Nevertheless, these results do not diminish the
significance of the role of iron in other tumor subtypes. For example, it is well known
that iron chelators have been used in the treatment of certain types of cancer (287-290).
Moreover, regular blood donation (291), phlebotomy (291), and anemia (292) are
inversely associated with the subsequent development of malignancy.
The association of iron with childhood malignancy has not yet been directly
examined. However, one can speculate that iron does indeed appear to be indirectly
involved in the development of childhood malignancy. For example, Dorak et al (293)
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have noted that the HFE C282Y mutation is a male-specific risk factor for childhood
acute lymphoblastic leukemia (ALL). In addition, other studies have teased apart an
association between high birth weight (i.e., macrosomia) and childhood leukemia (294297). Lending support to this association are studies demonstrating a relationship
between macrosomic infants of diabetic mothers and childhood cancer (298-301).
Moreover, as indicated by Shetty et al in 2008, human and animal studies have shown a
positive linear relationship between labile iron concentration and glycated hemoglobin
(HbA1C) (302). In addition, macrosomic infants have also been shown to have increased
numbers of hematopoietic stem cells (303), which has been correlated with increased
cancer risk.
Iron and cerebrovascular disease Cerebrovascular disease is the third leading
cause of mortality in the US, responsible for approximately 5.6% of total deaths (198).
However, there is a paucity of literature specific to the association between iron and
cerebrovascular disease (i.e., stroke). The available studies report that both iron
deficiency and iron excess are risk factors for cerevrovasular disease. For example, a case
report by Hartfield, et al (304) indicated that iron deficiency was the only common
feature among six infant stroke patients. In a case-control study (15 cases:143 controls)
examining the relationship between iron and childhood stroke, Maquire et al (305) have
shown that cases were approximately twelve times more likely (OR = 12: 95% CI: 4-37)
to have iron-deficiency anemia compared to controls. In another case-report by Munot
and colleagues (306), the authors noted that dietary iron-deficiency was the only common
factor among four children suffering from ischemic stroke. Conversely, Roest et al (209)
demonstrated that adult female heterozygote carriers for the HFE mutation experienced
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an increased risk of cerebrovascular disease (OR = 2.4; 95% CI: 1.3-3.5). Moreover, in
an NHANES I follow-up study (n = 5,033), Gillum et al (307) found an increase risk of
stroke incidence in white females aged 45-74 with both high and low transferrin
saturations. Compared to females with transferrin saturation between 30-36%, those with
levels > 44% experienced a RR of 1.96 (95% CI: 1.15-3.36), while those with transferrin
saturation < 20% experienced a RR of 1.80 (95% CI: 1.20-2.71). The authors found no
such associations in white men aged 45-74 or in African Americans (i.e., male or female).
Iron and chronic obstructive pulmonary disease In the US, COPD is the fourth
leading cause of mortality, accounting for 5.3% of total deaths (196). Compared to
cardiovascular disease and cancer, less is known about the relationship between iron and
chronic obstructive pulmonary disease (COPD). A literature search revealed that lavage
samples taken from patients (n = 44) with COPD exhibited elevated concentrations of
iron and ferritin compared to healthy controls (n = 50) (308). A recent biomarker study
demonstrated the identification of four sensitive and specific biological markers for
COPD diagnosis and progression. Three out of four of these markers were iron-specific
(i.e., haptoglobin, ceruloplasmin, and hemopexin) (309). The study demonstrated that
each of these markers are elevated in patients with COPD, indicative of inflammation. In
the presence of infection and inflammation, the iron-regulatory peptide hepcidin is
synthesized by the liver. This hormone binds to and degrades the ferroportin receptor on
basolateral membrane of enterocytes and outer membrane of macrophages, thereby
prohibiting the release of stored iron. In addition, hepcidin sequesters the absorption of
dietary iron by enterocytes. Thus, it is reasonable to speculate that patients with COPD
may experience higher levels of stored iron compared to their abstaining counterparts.
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Supporting this assertion is a recent study of European iron/steel foundry workers (n =
459). In 2011, Bala & Tabaku discovered that iron workers experienced greater than a 2fold increase in risk of developing COPD compared to non-foundry workers (310). The
authors controlled for other germane occupational exposures as well as smoking status.
Given the dearth of available evidence, however, it can be concluded that the association
between iron and COPD is tentative, at best. More research in this area is required prior
to further extrapolation.
Iron and Alzheimer’s disease Alzheimer’s disease (AD) is the sixth leading
cause of mortality in the US, accounting for up to 5.1% of total deaths (196). The
relationship between iron and AD has recently been well-studied. Evidence indicates that
transferrin receptors (TfRs) are fairly ubiquitous in the human brain (311). Interestingly,
TfRs are more highly concentrated in the substania nigra, locus ceruleus, putamen,
caudate nucleus, globus pallidus, and hippocampus (311) - regional sites commonly
associated with neuronal dysfunction and degradation in Alzheimer’s disease (AD) (312314). Studies have supported this biochemical association by establishing that iron
accumulates in regions of the brain of those affected by AD (315-317). In addition, field
dependent relaxation rate increase (FDRI) (318, 319) and serial susceptibility weighted
(SWI) (318, 320) magnetic resonance imaging (MRI) studies have revealed an agerelated increase in iron concentrations in the putamen, caudate, and globus pallidus.
The iron-AD association is further supported by studies demonstrating that iron
influences γ-secretase cleavage activity of amyloid precursor protein (APP) (321). Both
human (322, 323) and animal studies (324) have confirmed that an increase in labile
brain iron coincides with early Aβ plaque formation. Finally, carriers of the HFE C282Y
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and H63D variants (mutations in the hereditary hemochromatosis) have been shown in
epidemiological studies to display a small increased risk of AD as well as an earlier age
of onset of the disease (325-328). However, it should be noted that not all studies
examining this association have reported similar findings (329, 330). Similar to persons
with high iron stores and abnormal lipid profiles in CVD, significant interactions between
the APOEε4 variant and the C282Y and H63D variants have been established in the
epidemiological literature for AD as well (331). Heterozygous carriers of both risk
variants appear to experience an increased risk of AD compared to heterozygous carriers
of either single risk variant alone (331). Thus, the above pathways seemingly converge to
implicate a vascular pathway in the development of AD (332). Taken together, the
aforementioned results support the hypothesis that iron contributes to the
neurodegeneration exhibited in AD via the Fenton Haber-Weiss reaction. The role of iron
as an initiator or promoter of this pathway, however, remains to be elucidated.
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CHAPTER 4: LITERATURE REVIEW: IRON AND METABOLIC DYSFUNCTION

Epidemiology of Type 2 Diabetes Mellitus (T2DM)
History & Definition Two decades ago T2DM was characterized by a triad,
comprised of 1) pancreatic beta cell dysfunction, 2) excess glucose production by the
liver and 3) insulin resistance, defined then as an impairment of insulin-mediated glucose
uptake into target tissues (e.g., skeletal muscle) (333). This paradigm has more recently
been abandoned by most groups in favor of a simpler model where the hallmarks of
T2DM are now considered to be elevated fasting insulin concentrations and low insulin
secretion by beta cells (334).
Currently, the WHO and IDF define normoglycemia (i.e., normal glucose
tolerance (NGT)) as two-hour postprandial (i.e., following a meal) plasma glucose
concentrations less than 7 mmol/L (126 mg/dL), impaired glucose tolerance (IGT) as
fasting plasma glucose (FPG) concentration less than 7 mmol/L (126 mg/dL) and twohour postprandial plasma glucose concentrations between 7.8 mmol/L and 11.1 mmol/L
(140mg/dL and 200mg/dL), impaired fasting glucose (IFG) as FPG concentrations
between 6.1 mmol/L and 6.9 mmol/L (110mg/dL and 125mg/dL) and two-hour
postprandial plasma glucose concentrations less than 7.8 mmol/L (140mg/dL) and T2DM
as the presence of FPG concentrations greater than or equal to 7 mmol/L (126 mg/dL) or

44

two-hour plasma glucose concentrations greater than or equal to 11.1 mmol/L
(200mg/dL) (335)
Descriptive Epidemiology Given these criteria, the number of individuals
affected with T2DM worldwide in 2010 was estimated to be 285 million (333). By the
year 2030, this figure is projected to rise to 439 million individuals (336), representing a
54% increase (395). This is not surprising, given the reported 11% conversion rate per
year among those with IGT progressing to T2DM, accounting for an increase in the
incidence of T2DM of 2 to 4 million new cases per year (333). The risk of T2DM appears
to track across increasing levels of FPG concentrations. For example, higher incidence of
T2DM is observed among individuals with FPG between 95 to 99 mg/dL compared with
those with FPG < 85 mg/dL (HR = 2.33, 95% CI: 1.95-2.79) (337). When classified
according to glycated hemoglobin A1C (HbA1c) concentrations, individuals
demonstrating the highest risk of developing T2DM are those whose HbA1c level is
between 5.7 and 6.4 % (39 to 46 mmol/L) (337).
In 2001, the estimated number of individuals in the U.S. affected with T2DM was
18.1 million, imposing a substantial burden on the healthcare system, with total
healthcare costs exceeding $132 billion dollars (333). In 2008, this equated to a mean
annual cost per T2DM diagnosis of $881, which was reported to be 21% of the gross
domestic product per capita at that time (338).
The National Health Interview Survey (NHIS) and data collected from NHANES
have indicated that the prevalence of T2DM doubled from 1990 to 2008 in the U.S. and
that there has been no significant change in prevalence from 2008 to 2012 (339). The
prevalence of T2DM, however, increases with age from < 1% among those aged 20 years
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and younger to 12.3% in those aged 21 to 65 years of age to 25% in those aged 65 years
and older (337). Given that one of the largest segments of the population (i.e., Baby
Boomers, ages 51-69) is ‘aging-in’ to the group with the highest prevalence of T2DM,
the aforementioned stable pattern may soon be disrupted.
Among U.S. adults, the current estimated prevalence of T2DM is reported to
range from 11-14%, with males displaying a slight increase in prevalence compared to
age-matched females (13.6% vs. 11.2%, respectively) (337). Moreover, the prevalence of
T2DM in the U.S. varies across ethnicities, with Non-Hispanic whites demonstrating the
lowest prevalence (7.6%), followed by Asian Americans (9%), Hispanic Americans
(12.8%) and African Americans (13.2%) (334, 337). The ethnicities with the highest
reported prevalence of T2DM are Native Americans and Alaska natives (15.9%) (333).
The same trend appears when examining risks between ethnicities among
females, with African American females showing an elevated risk (RR = 1.34, 95%CI:
1.12-1.61) compared to their non-Hispanic white counterparts (340). Hispanic American
females show a greater increased risk than both ethnicities (RR = 1.86, 95%CI: 1.402.47) (340). Finally, Haffner et al. reported that the observed differences in insulin
sensitivity between ethnic groups (i.e., African Americans and non-Hispanic whites)
persist after adjustment for BMI, waist-to-hip ratio (WHR), level of physical activity and
differences in diet (334). Moreover, the authors concluded that ethnic origin remained a
powerful independent predictor of T2DM, accounting for an excess risk of approximately
15% in the Hispanic American population (334). In line with these data, Hispanic
Americans demonstrate a higher prevalence of T2DM than do Non-Hispanic whites
residing within the same neighborhood (334).
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The increased risk of complications among those who eventually progress to
T2DM begins years (possibly decades) before diagnosis (341). At diagnosis,
approximately 50% of those who have developed T2DM demonstrate overt hypertension
or signs of macroangiopathy (341), which increases the risk for subsequent adverse
health outcomes/complications such as cardiovascular disease, diabetic neuropathy,
nephropathy and retinopathy (336).
Pathophysiology Periods of insulin resistance across the human lifespan are
quite common. For instance, puberty, pregnancy and aging are all marked by increases in
insulin resistance. However, insulin resistance appears to be a necessary, but not
sufficient, condition which must manifest during the progression from normoglycemia to
T2DM. Stated otherwise, as long as beta cells exhibit the capacity to compensate for
varying degrees of insulin resistance, glucose tolerance remains within normal
physiological limits (341).
To develop a complete understanding of the etiology of T2DM, we must first
examine the physiology of beta cells as individuals progress across the spectrum from
insulin sensitive to insulin resistance. Following a meal, beta cells secrete insulin in a
biphasic pattern and the amount of insulin secreted is positively related to systemic
glucose concentration. In other words, any acute rise in plasma glucose concentration
induces a burst of insulin secretion lasting 5 to 10 minutes (342) and this is referred to as
first phase insulin secretion. The first phase typically occurs within 30 minutes of
ingesting a meal, serves to prime target (i.e., metabolically active) tissues for forthcoming
nutrients and is the main effector which quickly reduces blood glucose levels following a
meal (343). The second phase of insulin secretion occurs approximately one- to two-
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hours following a meal (i.e., postprandially) and serves to further reduce systemic
glycemia.
As glucose tolerance moves from normal to impaired, first phase insulin secretion
by beta cells is markedly attenuated (344). This results in an elevated postprandial rise in
glycemia over the ensuing two hours. It is postulated that this postprandial rise in
glycemia induces beta cells to secrete increasing amounts of insulin following the first
phase. Thus, second phase insulin secretion, while less rapid (343), is higher than that of
the first phase and functions as a compensatory response (333).
To initially compensate for the perturbance in homeostasis, beta cells begin to
hypertrophy, leading to increased beta cell mass (344) and increased insulin output,
which results in hyperinsulinemia. The aforementioned compensation does not persist
indefinitely, however. As insulin resistance worsens, the pulsatile pattern of first phase of
insulin secretion is lost as beta cells begin to undergo apoptosis (333) due to oxidative
stress. Eventually, the second phase of insulin secretion begins to decline as apoptosis
continues until beta cells no longer secrete insulin (342) and the individual reaches a
hyperglycemic state.
Once present, insulin resistance persists (333). However, it appears that it is not a
worsening of insulin resistance, per se, which leads to the observed increases in blood
glucose concentrations. In other words, a change in the degree of insulin resistance does
not appear to account for blood glucose concentrations progressing from NGT to IGT to
T2DM (342), as it is common for individuals who develop insulin resistance to never
progress to T2DM (344). As mentioned, it appears as if it is the worsening of beta cell
compensation that is what is driving the individual across the spectrum from NGT to IGT

48

to T2DM and that this dysfunction occurs well before blood glucose values mark the
presence of IGT (342).
In terms of explaining the etiology and pathogenesis of T2DM, there are two
leading hypotheses. One hypothesis states that FFAs and high triglycerides lead to the
observed metabolic dysfunction and this is otherwise known as the “lipocentric” view of
T2DM (333), which will be discussed in greater detail subsequently. Given that the
oxidation of FFAs and glucose both contribute to the pool of metabolic fuel available for
energy expenditure, their relative utilization is typically adjusted to match energy supply
and demand. It has been postulated that glucose oxidation (i.e., glycolysis) is reduced in
favor of FFA oxidation with increasing FFAs within the cytoplasm (345). Moreover,
studies have also demonstrated that increased cytoplasmic concentrations of FFAs result
in the skewing of the NAD/NADH ratio within the mitochondria, which leads to
increased concentrations of acetyl-CoA and increased hepatic glucose production (346).
Briefly, during beta oxidation NAD is the oxidizing agent which converts FFAs to acetylCoA (346) As the concentration of FFAs increases, the rate of beta oxidation of FFAs to
acetyl-CoA within the mitochondria also increases (345, 346). Over time, this is thought
to increase the pool of acetyl-CoA with concomitant increases in hepatic glucose output.
It must be noted, however, that if the concentration of FFAs does not decrease, the
intracellular pool of NAD can become depleted and the NAD/NADH ratio can therefore
become skewed, leading to mitochondrial dysfunction. This is thought to lead to the
inhibition of FFA beta oxidation, increases in FFA storage as triglycerides, increased
glucose output and, as mentioned, mitochondrial dysfunction and apoptosis. Stated
differently, given that glycolysis is an energy-conversion pathway, one might hypothesize
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that increased FFAs might concomitantly lead to increased intracellular glucose
concentrations via competitive inhibition of glycolysis by FFAs as well as increased
glucose output via the skewing of the NAD/NADH ratio within the mitochondria.
Consistent with this hypothesis, Lam et al. have shown in an animal model that elevation
of FFAs is linked to increased hepatic glucose production by increasing gluconeogenesis
and this was attributed to an increased intracellular pool of acetyl-CoA (347).
In addition to the above-mentioned metabolic dysregulation, the by-products of
excess FFAs (i.e., ceramides) have also been shown to contribute to oxidative stress,
which induces beta cell dysfunction and apoptosis (333). Studies which have shown
increased triglyceride concentrations in muscle and liver to be a reliable (i.e., consistent)
marker of insulin resistance lend further support to this hypothesis (348). Finally, it has
been reported that in patients with overt T2DM that the deterioration of insulin sensitivity
and secretion due to chronic hyperglycemia (i.e., glucotoxicity) is further aggravated by
elevated FFAs (341). Given that elevated FFA concentrations appears to be a consistent
feature of subjects with abdominal obesity as well as those diagnosed with T2DM, this
hypothesis is plausible.
A second hypothesis proposes that small intracellular amyloid fibrils of islet
amyloid polypeptide (IAPP, amylin) leads to beta cell failure during the initial stages of
the disease and that T2DM may be a manifestation of beta cell Alzheimer’s Disease
(349). Amylin is co-secreted with insulin from beta cells and plays a role in glycemic
regulation by slowing gastric emptying and promoting satiety (350). The net effect of
amylin co-secretion with insulin is therefore to reduce postprandial glucose
concentrations. According to this hypothesis, however, co-secretion of amylin is lost,
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which leads to the accumulation of the amyloid fibrils through a process that has not been
well-characterized. It is thought, however, that the accumulation of amyloid fibrils
culminates in mitochondrial dysfunction via interaction with cyclophilin D (CypD), an
integral protein of the mitochondrial permeability transition pore (mPTP) (351). Du et al.
have shown that the interaction of amyloid fibrils with CypD promotes free radical
production as well as the opening of the mPTP, which leads to mitochondrial apoptosis
(352).
This hypothesis is consistent with research related to other amyloid diseases, such
as Alzheimer’s Disease, where the same process is thought to occur. A recent study by
Perry et al. lends additional support to this hypothesis. The authors demonstrated that
glucagon-like peptide (GLP-1) can modify IAPP processing and protect against oxidative
injury (353). Briefly, GLP-1 is an endogenous insulinotropic gut hormone which appears
to regulate plasma glucose levels by stimulating insulin secretion via the pancreas in a
nutrient-dependent manner (347, 354). The signal transduction pathway of GLP-1 has
been elucidated. Briefly, GLP-1 appears to act directly through the cAMP-PKA pathway
to enhance and sensitize beta cells to glucose-stimulated insulin secretion (355).
Following a meal, GLP-1 stimulates beta cells to increase the rate of glucose metabolism
and the production of ATP, which increases the cytoplasmic ATP:ADP ratio. In turn, this
leads to depolarization of the plasma membrane via closure of ATP-sensitive potassium
channels, thereby permitting the opening of voltage-dependent calcium channels. The
influx of cytosolic calcium then triggers the fusion of insulin containing secretory
vesicles with the plasma membrane, followed by exocytosis of insulin into circulation.
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Interestingly, studies have demonstrated that levels of GLP-1 are reduced among those
with T2DM (355), which lends further support to this hypothesis.
Analytic Epidemiology Several studies support the hypothesis that a genetic
predisposition for T2DM exists. For example, kinship studies demonstrate an increased
(i.e., 2- to 3-fold) risk of developing T2DM among individuals with any first-degree
relative diagnosed with the disease (334). Moreover, the risk is amplified (i.e., 5- to 6fold) among individuals whose parents have been diagnosed with T2DM (334).
Investigators agree, however, that any genetic basis for T2DM is complex and that the
inherited risk among those with a predisposition for the disease does not follow typical
Mendelian patterns (333). In line with this conclusion, candidate gene studies have
consistently shown small effect sizes (e.g., 20% - 30%) between single nucleotide
polymorphisms (SNPs) in genes involved in beta cell function and T2DM (342, 356).
Moreover, effect sizes for SNPs involved in insulin signaling or the glucose transport
system are even smaller (356). Thus, environmental factors appear to mediate the
development of the disease. For example, the prevalence of diabetes among the Pima
Indians living in Mexico is less than 20%, while the risk for T2DM among Pima Indians
living in the U.S. is twice that (~ 38%) (337). Given that individuals in each group are
very closely related, the observed difference in prevalence rates among these two groups
lends support to the role of environmental risk factors.
Apart from a presumed increased risk of T2DM due to genetic predisposition,
obesity is among the most highly publicized risk factors for the development of T2DM.
Eckel et al. indicate that ~90% of obese patients progress to T2DM (357). Moreover,
there appears to be a progressive decrease in insulin sensitivity with increasing degrees of
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obesity, especially among those with a family history of T2DM (337). In addition,
McColloch et al. have reported that increases in body mass index (BMI) over time appear
to be the most important risk factor for progression to T2DM after adjusting for age and
race/ethnicity (337). It should be noted here that visceral (i.e., intra-abdominal) fat, as
opposed to subcutaneous or retroperitoneal fat, however, appears to confer the greatest
risk (333).
Other commonly reported risk factors for the development of T2DM are level of
education, socioeconomic status (SES), developed environments, sedentary
behavior/level of physical activity, smoking status, consumption of alcoholic beverages,
disrupted sleep and diet. Each will briefly be summarized below.
Level of education has consistently been shown to be inversely associated with
risk of T2DM across age groups, genders and ethnicities (358-361, 338, 362, 363). In
addition, studies have also indicated that there is an inverse relationship between
socioeconomic status and the prevalence of T2DM (333, 364). Interestingly,
investigations measuring both educational attainment and neighborhood SES indicate that
the latter (i.e., low neighborhood SES) appears to confer a greater risk for the
development of T2DM, even among those who have high educational achievement (359).
In line with these data, Papier et al. have shown that residence in an urban area as a child
is associated with the development of T2DM among both males and females (OR = 1.40,
95%CI: 1.10-1.70 and OR = 1.40, 95%CI: 1.01-1.79, respectively), regardless of level of
affluence reached as an adult (338).
The association between developed environments and an increased risk of T2DM
was highlighted several years ago when populations who rarely experienced T2DM
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moved from an agrarian- and/or farming-existence to more developed economies (333).
As already mentioned, the prevalence of T2DM among Pima Indians residing in Mexico
compared to that of the Pima Indians residing in the southwest U.S. should closely
parallel each other if no environmental component were involved in the etiology of
T2DM. Moreover, Saharan nomadic tribes and Australian aborigines exhibit dramatic
increases in the prevalence of T2DM when moving from an agrarian lifestyle to a
developed environment (333).
Physical inactivity (e.g., infrequent exercise, gardening, housework, prolonged
television watching and/or computer usage) (338, 334) appears to increase the risk of
T2DM (365) and the observed risk persists both in the presence and absence of weight
gain (365). For example, low aerobic capacity and muscle strength among a Swedish
cohort of males at 18 years of age was shown to be associated with an increased risk of
T2DM after a twenty-five-year follow-up period (337). Of note, the same increased risk
was noted for males with normal BMI, supporting the hypothesis that lack of physical
exertion is a more reliable predictor of T2DM compared to caloric restriction to maintain
a given BMI (334). In line with these observations, weight loss via caloric restriction
coupled with increased physical activity has been shown to reduce FFAs and triglycerides
in adipocytes (347) and reduce the risk of T2DM.
Several studies have shown that current cigarette smoking and excessive alcohol
intake increase the risk of T2DM (338). In a meta-analysis of 25 prospective cohort
studies, current smokers had a 40% increased risk of developing T2DM (i.e., compared to
nonsmokers) (pooled, adjusted RR = 1.40, 95%CI: 1.30-1.60). Moreover, the risk appears
to be dose-dependent, with increasing risk with increasing number of cigarettes smoked
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per day as well as with pack per year increases (344). Studies examining the effect of
smoking cessation have indicated that the risk of developing T2DM reverted to that of
never smokers after 20 years of smoking cessation (344)
Sleep apnea, leading to a disrupted sleep cycle, has become a well-established risk
factor in the development of T2DM (341, 336). Interestingly, McColloch et al. have
shown that both lack of sleep as well as excessive sleep appears to confer sS an increased
risk of developing T2DM. Compared with approximately 8 hours a day per night, short
duration of sleep (defined as < 5 to 6 hours of sleep per night) and long duration of sleep
(defined as > 8 to 9 hours of sleep per night) were significantly associated with an
increased risk of T2DM (334). Thus, it appears that the association between sleep and
risk of T2DM follows a U-shaped curve. Further research is warranted to understand the
impact of sleep patterns on risk of developing T2DM.
The literature indicates that several dietary exposures are associated with either
decreasing or with increasing the risk of developing T2DM. Among the exposures which
appear to reduce the risk of T2DM are nuts, brown rice, fiber, specific fruits (e.g.,
blueberries, grapes, apples, bananas, and pears), black coffee, green tea, vitamin D,
vitamin E, magnesium and zinc (130, 131). Exposures which are associated with an
increased risk of T2DM are sugar intake (e.g., sugar-sweetened soft drinks, sweets),
white rice, red meat and processed meat (130, 131) independent of BMI, physical
activity, age or family history (334). With regard to red meat and processed meat, iron
has consistently been linked to an increased risk of T2DM.
Iron and T2DM The hypothesis that there is an association between iron and
T2DM originally derives from studies demonstrating an increased prevalence of T2DM
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among individuals with hereditary hemochromatosis (HH) (366), which, as mentioned in
chapter 2, manifests due to two missense mutations (C282Y and H63D) in the
hemochromatosis gene (HFE) located on the short arm (p) of chromosome 6 (366).
As also mentioned, the HFE gene encodes for the HFE protein, which binds to TfR1
and reduces its afﬁnity for transferrin. Mutations of the HFE gene, however, result in
a loss of this repressor function, which leads to increased iron sequestration in
several tissues. Up to 60% of those affected with the condition eventually develop
T2DM (Swaminathan), and several authors hypothesize that this is due to an increased
accumulation of iron in the pancreas of those who go untreated.
The hypothesis that increased body iron is implicated in the development of
T2DM has received experimental support from cell line studies as well as from animal
models. For instance, Bothwell et al. reported that the exocrine cells of the pancreas tend
to accumulate a greater portion of the metal, yet remain functional (367). Interestingly,
the authors report that while beta cells acquire less iron than exocrine cells, they appear to
be more sensitive to the metal, which is most likely due to their low expression of
antioxidants (e.g., catalase and superoxide dismutase 2 (SOD2)) (367). Ultimately, this
sensitivity is thought to manifest as an impairment of insulin synthesis (368). In a mouse
model of HH, iron excess and oxidative stress were shown to meditate apoptosis of
pancreatic islets with a resultant decrease in insulin secretory capacity (369). Finally,
several epidemiological investigations, including 10 cohort studies, 8 case-control studies
and 8 cross-sectional studies have reported associations between iron stores and T2DM.
Each study will be briefly summarized below.
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During a 12-year prospective cohort study using data obtained from 33,541
participants in the Health Professionals’ Follow-up Study, Jiang et al. grouped
participants into quintiles of increasing intake of heme iron and heme iron from red meat,
respectively. Compared to the lowest quintile of heme iron intake, participants in the
highest quintile of heme iron intake had a RR of 1.28 (95% CI: 1.02-1.61, Ptrend = 0.05)
for developing T2DM. Moreover, participants in the highest quintile of heme iron from
red meat (compared to the lowest quintile of heme iron from red meat) had a RR of 1.63
(95% CI: 1.26-2.10, Ptrend < 0.001) for developing T2DM (1).
In another prospective nested case-control study (n = 698 cases, n = 716 controls)
matched on age, race, fasting status and BMI, Jiang et al. followed 32,826 females
participating in the Nurses’ Health Study over 10 years from 1989 through 1990. The
authors observed a higher incidence of T2DM among cases as well as higher serum
ferritin among cases compared to controls (109 ± 105 ng/mL (cases) vs 71.5 ± 69 ng/mL
(controls), P < 0.001). Moreover, the authors reported that the risk of incident T2DM
increased across increasing quintiles of ferritin among cases (RRQ2 = 1.09 (95%CI: 0.701.70), RRQ3 = 1.26 (95%CI: 0.82-1.95), RRQ4 = 1.30 (95%CI: 0.83-2.04) and RRQ5 =
2.68 (95%CI: 1.75-4.11, Ptrend < 0.001). The associations persisted after adjustment for
menopausal status, alcohol consumption and C-reactive protein (370).
Lee et al. followed 35,698 postmenopausal females aged 55 to 69 years for 11
years to examine the effect of dietary exposures on incident T2DM. Over the follow-up
period, baseline heme iron intake was associated with incident T2DM across increasing
quintiles of intake (RRQ2 = 1.07 (95%CI not provided), RRQ3 = 1.12 (95%CI not
provided), RRQ4 = 1.14 (95%CI not provided) and RRQ5 = 1.28 (95%CI: 1.04-1.58), Ptrend
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= 0.02) after adjustment for non-dietary and dietary risk factors. The authors were also
able to show an interaction between heme iron intake, alcohol consumption and T2DM.
For example, the association between heme iron intake and T2DM was marginal among
non-drinkers, but grew in magnitude among participants who consumed greater quantities
of alcohol. In a model restricted to those who consumed at least 15 grams of alcohol per
day, the RR across increasing quintiles of heme iron intake were RRQ2 = 2.26 (95%CI:
0.79-6.44), RRQ3 = 3.22 (95%CI: 1.16-9.84), RRQ4 = 1.92 (95%CI: 0.63-5.87) and RRQ5
= 4.42 (95%CI: 1.37-14.25), Ptrend = 0.05 (371).
In 2004, Song et al. followed 37,309 participants aged 45 years and older in the
Women’s Health Study for an average of 8.8 years who were free from cardiovascular
disease, cancer, and T2DM at baseline to examine the association between red and
processed meat intake and incident T2DM. During 326,876 person-years of follow-up,
the authors reported positive associations between intakes of red meat and processed
meat and risk of type 2 diabetes after adjustment for age, BMI, total energy intake,
exercise, alcohol intake, cigarette smoking, and family history of diabetes. Compared to
the females in the lowest quintile of red meat intake to females in the highest quintile of
red meat intake, the RR for developing T2DM was 1.28 (95%CI: 1.07-1.53, Ptrend <
0.001). Moreover, the RR for developing T2DM was 1.23 (95%CI: 1.05-1.45, Ptrend =
0.001) among females in the highest quintile of processed meat intake compared to those
in the lowest quintile of processed meat intake. The authors also reported an increased
risk of developing T2DM among females who more frequently consumed processed
meat, defined as consuming processed meat ≥ 5 days per week compared to consumption
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less than once a month (RR 1.43, 95%CI: 1.17-1.75, P < 0.001) after adjustment for
dietary fiber intake, magnesium, glycemic load and total fat intake (372).
Fumeron et al. randomly selected 1,277 (i.e., 644 males and 633 females)
participants from a pool of 4,501 individuals in the DESIR cohort to examine parameters
of iron status at baseline with subsequent development of T2DM over a 3-year follow up
period. The authors reported that baseline serum ferritin concentrations were positively
correlated with fasting plasma insulin as well as fasting plasma glucose. Moreover,
baseline serum ferritin concentration was reported to be an independent predictor of
increases in plasma insulin concentrations over the 3-year follow-up period (P = 0.002).
Finally, the authors noted that baseline serum ferritin and transferrin were independently
associated with the onset of hyperglycemia over the 3-year follow-up period, regardless
of gender (P < 0.001) (373).
Rajpathak et al. conducted a prospective cohort study within the Nurses' Health
Study, following 85,031 healthy females aged 34-59 years from 1980 to 2000 to examine
the association between total iron intake, total dietary iron intake, supplemental iron
intake and nonheme iron intake and the development of T2DM. Following the 20-year
follow-up period, the authors reported no associations between total, dietary,
supplemental or nonheme iron and the risk of T2DM. However, the authors did observe
positive associations across increasing quintiles of heme iron intake and the risk of
T2DM: RRQ2 = 1.08 (95%CI: 0.97-1.19), RRQ3 = 1.20 (95%CI: 1.09-1.33), RRQ4 = 1.27
(95%CI: 1.14-1.41) and RRQ5 = 1.28 (95%CI: 1.14-1.45, Ptrend < 0.0001) after adjustment
for age, BMI and other nondietary and dietary risk factors (374).
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Using data obtained from 360 T2DM cases and 758 controls nested within the
EPIC study, Fourouri et al. sought to examine the association between sex-specific
baseline quintiles of serum ferritin concentration and T2DM. The authors reported that
the baseline serum ferritin geometric mean was higher among cases than control
participants in both males and females (males: 96.6 ng/mL (cases) vs 67.8 ng/mL
(controls), P < 0.001; females 45.9 ng/mL (cases) vs 34.8 ng/ml (controls), P = 0.005).
Moreover, the risk of incident T2DM was higher among those in the highest quartile of
serum ferritin compared to those in the lowest quartile (OR = 7.4, 95%CI: 3.5-15.4, P <
0.0001) after adjustment for age, BMI, sex, family history, physical activity, smoking, Creactive protein, IL-6 and fibrinogen (375).
In 2007, Jehn et al. conducted a case-cohort study that was nested within the
Atherosclerosis Risk in Communities (ARIC) Study (n = 599 cases, n = 690 controls
obtained from a random sample of the cohort) to examine the association between serum
ferritin and risk of T2DM after an 8-year follow-up period. Compared to cases in the
lowest quintile of serum ferritin, cases in the highest quintile of serum ferritin had an
increased risk of developing T2DM (HR = 1.74, 95%CI: 1.14-2.65, Ptrend < 0.001) after
adjustment for age, gender, menopausal status, ethnicity, center, smoking status and
alcohol intake (377).
In a study published in 2008, Le et al. reported results from prospective cohort
data from 5,512 male and female participants in the Aerobics Center Longitudinal Study
(ACLS) between 1995 and 2001. Over the 5-year follow-up period, the authors reported
that serum ferritin concentrations were significantly higher in males than in females
(148.5 ± 104.7 ng/ml vs. 52.2 ± 45.9 ng/ml) and that male participants in the highest
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quartile of serum ferritin had a greater risk of developing T2DM compared to those in the
lowest quartile of serum ferritin (HR: 1.67, 95%CI: 1.05- 2.66, P = 0.027). While a
similar trend was observed for females, the comparisons across quartiles of serum ferritin
were not statistically significant (377).
In contrast to the above positive associations between iron and the development of
T2DM, in 2002 Mainous et al. reported that elevated serum transferrin saturation was not
significantly associated with the development of T2DM in participants in NHANES. For
example, the authors reported that the incidence of T2DM was 7.5% among individuals
with serum transferrin saturation > 55% and 10.2% among individuals with serum
transferrin saturation ≤ 45% (P = 0.38) and concluded that increased body iron was not
associated with an increased risk of T2DM (378). It must be noted, however, that while
Mainous et al. have published several studies using NHANES data, it is not clear as to
how the authors accounted for the complex study design or sampling strategy.
In 1988, Jones et al. were among the first groups to publish a case-control study
evaluating the association between indices of body iron and T2DM (n = 25 cases, n = 37
controls). The authors reported that serum ferritin concentration was increased in both
males (124 ± 113 ng/mL (cases) vs 44 ± 38 ng/mL (controls), P < 0.001) and females
(132 ± 118 ng/mL (cases) vs 25 ± 12 ng/mL (controls), P < 0.001) (379).
Several years later in 2006, Adou-Shousha aimed to investigate the correlation
between serum ferritin concentrations, sTfR and IL-8 concentrations among 20 females
with T2DM who were matched on age to 10 healthy controls. The authors reported that
serum ferritin was positively associated with IL-8 concentrations in those with T2DM (P
= 0.0029) and not in controls. A similar positive association was observed between sTfR
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and IL-8 concentrations across groups (P = 0.032) (380). Taken together, these results
support the association between increased iron and T2DM.
In 2008, Smotra conducted a case-control study (n = 50 cases, n = 50 controls) in
a tertiary care hospital in North India to examine the relationship between serum ferritin
concentrations and serum insulin concentrations among those with and without T2DM.
The authors matched cases to controls on age, sex and BMI and reported a positive
correlation between serum ferritin and serum insulin concentrations (r = 0.77, P = 0.01)
and this corresponded to poor glycemic control (i.e., higher HbA1c concentrations)
among those with T2DM (381)
Waheed (2009) published a small case-control study (n = 30 cases, n = 30
controls) using data collected from diabetic clinics of Rawalpindi in Pakistan. The
authors reported that cases had higher fasting glucose concentrations, HbA1c, total
cholesterol, LDL cholesterol, triglycerides and ferritin compared to controls (P < 0.001),
while HDL cholesterol was lower in those with T2DM (P < 0.001) (382).
Using controls obtained from two population-based studies (i.e., Copenhagen City
Heart Study (CCHS, N = 9,121) and The Copenhagen General Population Study (CGPS,
N = 24,195), Ellervik et al. 5:1 matched controls to 6,129 T2DM cases from the Steno
Diabetes Centre on age and sex. Compared to cases with transferrin saturation < 50%,
cases with transferrin saturation ≥50% had increased odds of developing T2DM: OR =
1.7 (95%CI: 1.4-2.1; P = 0.001) (383).
In contrast to the above positive associations between indices of body iron and
prevalence of T2DM, some authors have reported no associations between indices of
body iron and T2DM (i.e., the associations were not statistically significant). For
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instance, Skomro et al. consecutively enrolled 58 T2DM cases and 48 controls into a
sleep study in 2001, seeking to examine the association between sleep complaints and
T2DM. However, the authors also collected data on biochemical parameters (including
creatinine, urea, folate, vitamin B12 and serum ferritin) and reported that cases had
higher serum ferritin compared to controls (154.7 ± 178.6 µg/L (cases) vs 107 ± 95
(controls)) but this was not statistically significant (P = 0.14). While not statistically
significant, the results appear support the aforementioned association between increased
body iron and T2DM (384)
A few years later, Elis et al. sought to evaluate the relationship between diabetic
retinopathy and serum ferritin levels in a sample of T2DM cases and controls. The study
sample was comprised of 3 groups: 1) individuals with T2DM and severe diabetic
retinopathy (n = 22), 2) individuals with T2DM without retinopathy (n = 29) and 3)
individual controls free from disease (n = 40). The groups were matched on age, gender
and hemoglobin levels and comparisons between serum iron, transferrin and serum
ferritin concentration were made across each of the three groups. While the authors
reported higher concentrations of serum ferritin in the T2DM groups, the comparisons
were not statistically significant compared to controls (P = 0.21). Moreover, the authors
reported that there was no apparent correlation between serum iron or serum ferritin and
HbA1c concentration between the groups comprised of individuals with T2DM. Thus,
the authors concluded that iron does not appear to have a major role in the development
of T2DM or diabetic retinopathy (385). Given the overall small sample size (n = 91),
which was stratified into groups of 3, it appears that one cannot draw any valid
conclusions based upon these data.
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Finally, Rajpathak et al. conducted a nested case-control study (280 cases and 280
age and sex matched controls) within the placebo arm of the Diabetes Prevention
Program and reported that cases had higher sTfR levels compared to controls (3.50 ± 0.07
mg/L vs. 3.30 ± 0.06 mg/L, P = 0.03) and that serum ferritin levels did not differ
statistically between cases and controls. Cases in the highest quintile of sTfR
concentrations were observed to have an increased risk of developing T2DM compared to
those in the lowest quintile of sTfR concentrations (OR = 2.26 (95%CI: 1.37-4.01, P =
0.008) (386). The results of this study allude to an increased requirement for iron as
opposed to an increased storage of iron being associated with T2DM, which could be an
artefact of the tendency of iron as a pro-oxidant to promote disease progression.
Among the cross-sectional studies reporting associations between body iron and
T2DM, Hughes et al. in 1998 were one of the first groups to show that serum ferritin
concentrations were higher in individuals with T2DM than those unaffected with the
condition. Using data obtained from participants in The National University of Singapore
Heart Study (i.e., a cross-sectional study comprised of a random sample of individuals
aged 30-69 years) the authors observed mean serum ferritin concentrations of 231 µg/L
(range: 205-257 µg/L) in males affected with T2DM (n = 72), compared to 181 µg/L
(range: 167-195 µg/L) in males who were unaffected (n = 248, P < 0.01). Moreover, the
same trend was observed among females, where those affected with T2DM (n = 54) had
higher mean serum ferritin concentrations than unaffected females (n = 282) (128 µg/L
(range: 98-150 µg/L) vs 77 µg/L (range: 64-90 µg/L, P < 0.01)) after adjustment for age
and ethnicity (387).
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A year later Cogswell et al. examined the association between serum ferritin
concentration, glucose tolerance status, insulin concentration, glucose concentration and
glycosylated hemoglobin among 9,486 U.S. adults aged 20 years using data obtained
from NHANES III (1988–1994). The authors created a dichotomous categorical variable
from ferritin concentrations (i.e., < 300 µg/L vs. ≥ 300 µg/L in males and < 150 µg/L vs.
≥ 150 µg/L in females) and reported an increased risk for T2DM for both males and
females using these cutoffs (OR = 4.94 (95%CI: 3.05–8.01) for males and 3.61 (95%CI:
2.01–6.48) for females) after adjustment for age, sex, ethnicity, education, BMI, alcohol
consumption, alanine aminotransferase concentration, C-reactive protein concentration,
and examination session attended (388).
In 2006, Shi published the results from a cross-sectional household survey
administered to 2,849 males and females aged 20 years and older in the Jiangsu Province
of China and reported that both mean hemoglobin and serum ferritin concentrations
increased with increasing FPG. Moreover, the authors observed an increased risk of
T2DM for females in the highest quartile of hemoglobin concentration as well as those in
the highest quartile of serum ferritin concentration compared to females in the lowest
quartiles of hemoglobin and ferritin concentration, respectively (OR = 2.15 (95%CI:
1.03-4.51), hemoglobin; OR = 3.79 (95%CI: 1.72-8.36, serum ferritin). In addition,
females in the highest quartile of dietary iron intake had an increased risk of T2DM
compared to females in the lowest quartile of dietary iron intake (OR = 5.53 (95%CI:
1.47-20.44). Similar trends were observed in males. However, none of the comparisons
across quartiles were statistically significant (389)
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In another cross-sectional study conducted a few years later, Kim et al. (2008)
analyzed data obtained from 6,346 nonpregnant females participating in NHANES III
(1988–1994). The authors categorized females into three groups: 1) those who selfreported a history of gestational diabetes (n = 87), 2) those with diagnosed T2DM (n =
244), or 3) those with neither condition (i.e., controls) (n = 6,015) and observed that
serum ferritin was higher in females with T2DM compared to controls (120.3 ng/mL vs
66.3 ng/mL, P < 0.05) (390).
Luan (2008) examined the association between self-reported dietary iron intake
(i.e., total iron intake and nonheme iron intake), serum ferritin and T2DM among 2,997
individuals aged ≥ 18 years using data obtained from household surveys administered in
the Liaoning Province in northern China. The authors reported that serum ferritin was
positively associated with the risk of T2DM after adjustment for age, sex, non-dietary
exposures and dietary exposures. No associations were observed between total iron
intake, nonheme iron intake and risk of T2DM. However, higher self-reported heme iron
intakes were significantly associated with an increased risk of T2DM after adjustment for
age, sex, nondietary factors and dietary exposures (391).
Sun (2008) et al. sought to examine the association between serum ferritin
concentrations and T2DM in a sample of 3,289 participants aged 50-70 years of age from
Beijing and Hanghai China during 2005. Not surprisingly, the authors noted that median
ferritin concentrations were higher in males compared to females (155.7 ng/mL in males
and 111.9 ng/mL in females). In addition, the authors reported an increased risk of T2DM
among participants in the highest quartile of serum ferritin concentration compared to
those in the lowest quartile of serum ferritin concentration (OR = 3.26, (95%CI: 2.36-
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4.51)) after adjustment for other dietary exposures, BMI, inflammatory markers, and
adipokines (392).
A few years later, Kim et al. analyzed clinical and laboratory data obtained from
6,378 males and 5,712 females aged 20-89 years undergoing general medical checkups at
the Health Promotion Center at Asan Medical Center in Seoul, Korea. The study sample
included 1,054 subjects diagnosed with T2DM, 3,783 subjects with IFG and 7,253
subjects with NGT. The authors observed that serum ferritin concentrations were the
highest those with T2DM, followed by those in the IFG group and the NGT group,
regardless of gender (186 ± 127 ng/mL (T2DM), 176 ± 108 ng/mL (IFG), and 156 ± 92
ng/mL (NGT), respectively, in males; 85 ± 62 ng/mL (T2DM), 75 ± 55 ng/mL (IFG), and
59 ± 47 ng/mL (NGT), respectively, in females)). In addition, the authors reported an
increased risk for T2DM among those in the highest quartile of serum ferritin
concentrations compared to those in the lowest quartile of serum ferritin concentrations
(OR = 1.71 (95%CI: 1.38-2.12) in males and OR = 1.50 (95%CI: 1.05-2.13) in females)
(393).
Finally, Lee et al. (2011) examined the association between serum ferritin
concentrations and T2DM among 6,311 individuals aged 20 years and older using data
obtained from the 2008 Korean National Health and Nutrition Examination Survey. The
authors reported that T2DM was more prevalent among individuals in the highest quartile
of serum ferritin concentrations compared to those in the lowest quartile of serum ferritin
concentrations in males (n = 2,684) (prevalence = 5.27% (95%CI: 3.13-7.41) vs. 1.42
(95%CI: 0.40-2.44, P < 0.001), pre-menopausal females (n = 2,120) (prevalence = 7.34%
(95%CI: 6.28-8.40) vs. 1.95 (95%CI: 0.95-2.95, P < 0.001), and post-menopausal
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females (n = 1,507) (prevalence = 15.97% (95%CI: 10.91-21.02) vs. 8.68 (95%CI: 5.0112.34, P < 0.001) (394)
More recently, two groups have each conducted separate meta-analyses
examining the association between iron parameters (i.e., serum ferritin, heme iron intake)
and T2DM with the above-mentioned studies. In 2013, Orban et al. included a total of 13
studies in the calculation of pooled effect sizes for the association between the highest
versus the lowest categories of serum ferritin concentration and risk of T2DM (Table 8).
Overall, the pooled effect size across studies comparing the highest versus the lowest
category of serum ferritin among study participants with T2DM was 1.67 (95%CI: 1.411.99, P < 0.001, I-squared = 61%). A strength of the meta-analysis was that the authors
were able to conduct subgroup analyses among studies adjusting for inflammation (e.g.,
C-reactive protein (CRP)) and reported a pooled effect size among studies controlling for
CRP of 1.61 (95%CI: 1.18-2.20, P = 0.002) compared to 1.67 (95%CI: 1.23-2.27, P =
0.001) for studies not controlling for CRP (395).
In 2012, Zhao et al. published a meta-analysis which included a subset of the
aforementioned studies (N = 12) which excluded a report that did not collect data on
heme and non-heme iron intake (Table 8), and reported a pooled effect size of 1.31
(95%CI: 1.20-1.43, I-squared = 0%) comparing individuals in the highest category of
heme iron intake to those in the lowest category of heme iron intake. Moreover, when the
authors stratified their analyses by study design (i.e., cohort vs cross-sectional) using the
same studies as Oraban et al., they reported a similar pooled effect size for the association
between serum ferritin and T2DM among cohort studies: RR = 1.66 (95%CI: 1.15-2.39,
I-squared = 66.3%). The pooled effect size for the association between serum ferritin and
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T2DM among cross-sectional studies was higher (RR = 2.29 (95%CI: 1.48-3.54, Isquared = 88.7%)) (396). These results indicate that the pooled effect sizes obtained by
Orban et al. may not be heavily influenced by study design, given that the pooled effect
size for cohort studies calculated by Zhao et al. were of the same magnitude of as those
calculated by Orban et al., who did not stratify effect size calculation by study design.
Interventional Epidemiology Additional support for a positive association
between body iron and T2DM has been obtained interventional studies among HH
patients whose body iron stores were reduced with phlebotomy and/or iron chelation
therapy (397, 398). These investigators report that HH patients experienced
improvements in glycemic control and 30-40% of patients in the study conducted by
Facchini et al. were able to eliminate oral hypoglycemic therapy or were able to decrease
their current dosage (398).
Conclusion Taken together, it appears as though iron stores are positively
associated with the development of T2DM. It should be noted, however, that each of the
above studies used serum ferritin and/or transferrin saturation as indices of iron stores. As
already mentioned in Chapter 1, these parameters demonstrate diurnal variation and/or
can be influenced by inflammation. Therefore, predictive, non-invasive, and inexpensive
analytes unaltered by inflammation would be valuable for use in monitoring the iron
status of those at risk for developing T2DM. To my knowledge, no study to date has
employed the algorithm developed by JD Cook et al. in 2003 (50) as an index for iron
repletion when examining the association between iron stores and T2DM. As mentioned,
the index is a mathematically-derived ratio of soluble transferrin receptor and ferritin
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found in serum and appears to be a more stable index of iron stores than either analyte
used independently (51-52).

Epidemiology of metabolic syndrome
History & Definition The modern concept of what is referred to as metabolic
syndrome originated with Gerald Reaven in 1988 (399). Reaven postulated that insulin
resistance was the driver of glucose intolerance, hyperinsulinaemia, increased very-lowdensity lipoproteins (VLDLs), decreased high-density lipoproteins (HDLs) and
hypertension (400.). Twenty years and a few different naming conventions later (e.g.,
Reaven’s syndrome, Syndrome X, CHAOS (i.e., coronary artery disease, hypertension,
atherosclerosis, obesity and stroke), insulin resistance syndrome) the aforementioned
cluster of metabolic abnormalities has become known as the metabolic syndrome (400,
401). The benefit of utilizing the term metabolic syndrome is not so much in identifying
patients with a general risk of cardiovascular disease and T2DM, but more so with the
identification of specific subgroups of individuals with a shared pathophysiology (402). It
should be noted here that the clinical utility of the term, however, has been criticized. It
has been suggested that the ‘syndrome’ may not confer any greater risk than that
explained independently by each of its components. Thus, it appears that the term
metabolic syndrome should not be misused to refer to a disease unto itself (403), as there
is a lack of treatment options available to ameliorate the cluster beyond those already
employed to treat each individual component (404).
The most frequently used definitions to determine the presence of metabolic
syndrome include the National Cholesterol Education Program Adult Treatment Panel III
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(NCEP-ATP III), criteria published in 2001 and updated in 2005, the International
Diabetes Federation Criteria (IDF) proposed in 2004 and the WHO definition published
in 1999 (405). The WHO definition requires that T2DM or impaired fasting glucose first
be present in addition to any two of the following: obesity, dyslipidemia (i.e., increased
triglycerides or decreased HDL), hypertension or microalbuminuria. The IDF criteria
requires that obesity first be present in addition to any two of the following: impaired
fasting glucose, increased triglycerides, decreased HDL or hypertension. The NCEP-ATP
III criteria takes into account the same components as the IDF criteria. However, the
NCEP-ATP III criteria treats all components equally and specifies that if at least three of
the components are manifest, then metabolic syndrome is present. In 2009, several
organizations (i.e., the IDF, the National Heart, Lung, and Blood Institute of the U.S.,
the American Heart Association, the World Heart Federation, the International
Atherosclerosis Society and the International Association for the Study of Obesity)
issued a joint statement on the definition of metabolic syndrome which included criteria
upon which they have all agreed. These criteria are thus referred to as the “harmonized”
criteria for metabolic syndrome. The updated criteria contained in the joint statement is
essentially the NCEP-ATP III criteria with population- and country- specific definitions
for obesity (i.e., waist circumference) (406.).
Descriptive Epidemiology Applying the NCEP-ATP III definition for metabolic
syndrome, the age-adjusted prevalence in the U.S. using data obtained from 8,814
participants in NHANES III has been estimated to be 23.7% (24.0% in males, 23.4% in
females) (407, 408). However, more recent prevalence estimates of metabolic syndrome
among U.S. adults demonstrate an increase in the prevalence of metabolic syndrome in

71

both males (30.3%) and females (35.6%), suggesting that the prevalence of metabolic
syndrome in females has surpassed that among males (409). In line with these data,
Ramos and Olden reported that approximately 50% (n = 643) of their study population of
U.S. females of childbearing age either had metabolic syndrome or were at an increased
risk for developing it (410). Based upon these estimates, it appears that metabolic
syndrome in U.S. females is a growing public health concern.
The prevalence of metabolic syndrome increases with age from 6.7% among
those aged 20-29 years to 44% in those aged 60-69 years (408) to over 50% in those aged
70 years and older (411). Given that the prevalence of each component of metabolic
syndrome (i.e., obesity, hypertension, dyslipidemia and hyperglycemia) has also been
observed to increase with age, it is not surprising that increasing age appears to be a
determinant in the prevalence of metabolic syndrome.
The prevalence of metabolic syndrome has also been observed to differ across
ethnicities. For example, Hispanic Americans having a disproportionately higher
prevalence of metabolic syndrome compared to other ethnicities (35.4%), followed by
non-Hispanic whites (33.4%) and African Americans (32.7%) (409). This pattern holds
when stratified by male gender and ethnicity, where the highest prevalence is found
among Hispanic American males (37%), followed by non-Hispanic white males (25%)
and the lowest prevalence is found among African American males (21%) (407, 411).
The prevalence of metabolic syndrome among adult U.S. females is the highest among
Hispanic American females (41%), followed by African American females (26%) and the
lowest in non-Hispanic white females (21%) (407). The observed differences in the
prevalence of metabolic syndrome across ethnicities has been postulated to be driven by
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disparities in access to healthcare (412, 413), level of education (412), income (412) and
level of urbanization (414).
Pathophysiology Although the etiology of metabolic syndrome is uncertain,
several hypotheses implicate insulin resistance, visceral adiposity and low-grade
inflammation as the drivers of each downstream component (400). As mentioned
previously, insulin resistance has been defined as the inability of insulin to stimulate
adequate glucose uptake in muscle and adipose tissue as well as the inability of insulin to
suppress hepatic glucose output (415). Visceral adiposity (i.e., central obesity) commonly
refers to increased visceral adipose tissue within the peritoneal cavity and inflammation
in metabolic syndrome is defined by the presence of inflammatory cytokines/adipokines.
While adipose tissue is an important source of chronic inflammation, it should be noted
that other cell types within adipose tissue (e.g., macrophages) contribute substantially to
the amount of inflammation present (405).
Among these three factors, visceral adiposity appears to be the most salient in the
etiology of metabolic syndrome (416), as visceral adipose tissue releases FFAs directly
into portal circulation (416). Moreover, the literature indicates that FFAs accumulate in
the liver, pancreas, heart and other organs with increasing adiposity (415). Eventually,
this culminates in organ dysfunction, resulting in impaired insulin, glucose and
cholesterol regulation, which is commonly referred to as “lipotoxicity.” In addition, there
is a significant infiltration of macrophages in adipose tissue with increasing adiposity
(415) and it has been shown that adipose tissue secretes monocyte chemotactic protein-1
(MCP-1), which mediates macrophage recruitment to sites of inflammation. Briefly,
MCP-1 is a chemokine whose production is primarily stimulated by inflammation and
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oxidative stress, regulates migration and infiltration of reticuloendothelial cells (i.e.,
monocytes and macrophages) to tissues secreting the protein.
Levels of systemic and adipose tissue MCP-1 are elevated in rodent models of
obesity and targeted ablation of MCP-1 or its receptor reduces adipose tissue macrophage
infiltration (417). This has been shown to improve insulin sensitivity. Conversely, insulin
resistance and increased infiltration of macrophages within adipose tissue have been
observed in models of MCP-1 overexpression (405). Finally, recruitment of macrophages
via adipocyte secretion of MCP-1 leads to their subsequent activation and secretion of
TNF-alpha and IL-6.
In terms of other metabolic syndrome components, dyslipidemia appears to be
secondary to increased visceral adiposity and the development of insulin resistance due to
the effect of adipose tissue secretion of FFAs. In muscle, FFAs increase insulin resistance
by inhibiting insulin-mediated glucose uptake via decreasing GLUT4 expression (418).
The ensuing increase in circulating glucose thus induces beta cell insulin secretion,
resulting in hyperinsulinemia. Moreover, FFAs directly increase the production of glucose,
triglycerides and the secretion of VLDLs in the liver. For example, FFAs reduce the
conversion of glucose to its storage form (i.e., glycogen) which leads to subsequent
hyperglycemia with a concomitant increase in lipid accumulation in the form of
triglycerides. The ensuing hypertriglyceridemia is the result of both an increase in VLDL
production as well as a decrease in VLDL clearance. In other words, triglycerides stored
in VLDLs are transferred to HDL by the cholesterol ester transport protein (CETP) in
exchange for cholesteryl esters, resulting in triglyceride-enriched HDL and cholesteryl
ester-enriched VLDL particles (419). It has been shown that the triglyceride-enriched
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HDL particle is a more specific substrate for hepatic lipase (420). Thus, HDL is cleared
more rapidly and VLDLs less rapidly from circulation, resulting in fewer HDL particles
to participate in reverse cholesterol transport from the vasculature (419).
Endothelial dysfunction (i.e., hypertension) also appears secondary to increased
visceral adiposity and the development of insulin resistance, most likely due to the
increase in FFAs that are released from visceral adipose tissue. In line with this
hypothesis, 15% of normal-weight individuals in the U.S. have hypertension, whereas the
prevalence of hypertension among obese individuals is 42% (421). Moreover, data from
the Framingham Heart Study indicates that ~80% of essential hypertension in males and
65% in females can be directly attributed to obesity (422). While the relationship between
obesity, insulin resistance and hypertension has been well established, several different
mechanisms have been proposed.
One hypothesis is that FFAs are pressors and can themselves mediate
vasoconstriction, as FFAs have been shown to increase angiotensinogen production by
vascular smooth muscle cells (VSMCs) in culture (423). In line with these data, Egan et
al. have also shown that increased adipocyte mass (i.e., hypertrophy) leads to increased
angiotensinogen production in adipocytes (424). While the liver is the primary site of
angiotensinogen production, it appears as though it is not the only site, and production of
angiotensinogen in other tissues is thought to be affected by increasing concentration of
FFAs (423).
Another hypothesis involves insulin and nitric oxide (NO). Endothelin-1, a potent
vasoconstrictor, is activated by insulin through the MAP kinase (MAPK) pathway (425).
Thus, increasing concentrations of insulin within circulation appears to have a
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vasocontricting effect (421, 426). Under normal physiologic conditions, NO inhibits the
secretion of endothelin-1 (415). However, NO production decreases with increasing
adiposity (427). Thus, in a hyperinsulinemic state the balance between endothelin-1 and
NO is lost (421).
Analytic Epidemiology When considering risk factors associated with the
development of metabolic syndrome, one must consider the risk factors associated with
each component (i.e., obesity, hypertension, dyslipidemia and hyperglycemia) of
metabolic syndrome. The literature indicates that the obesity component of metabolic
syndrome (i.e., defined using WHO criteria as BMI > 29.9) is the single most important
risk factor for the development of metabolic syndrome. Contributing to this trend is the
fact that most parts of the world have moved from an era of persistent famine to one of
nutrient excess comprised of high-fat and high-carbohydrate diets, concomitant
decreases in physical activity and increased smoking and ethanol use.
With respect to other components of metabolic syndrome, the risk factors
implicated in the development of hypertension and hyperlipidemia also appear to overlap
with those of the obesity component (e.g., unhealthy diet which is rich in sodium, lack of
physical activity, smoking, alcohol use). Finally, while the risk factors for the
development of hyperglycemia overlap somewhat with those of obesity, it should be
noted that increased intake of sweets (e.g., sugar-sweetened beverages, candy) are
additional risk factors associated with development of the hyperglycemia component of
metabolic syndrome. Finally, several studies indicate that intake of red meat and indices
of iron status are independently associated with an increased risk of metabolic syndrome.
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Conclusion The development of metabolic syndrome has been shown to increase
the probability of progressing to T2DM up to fourfold (428) and the risk of progression
increases with increasing number of metabolic syndrome components (429). Given that
the prevalence of two or more metabolic syndrome components in the U.S. is 43.9%,
public health officials are interested in determinants of the condition which are
modifiable through primary prevention efforts. While several authors postulate that
conversion from metabolic syndrome to T2DM appears to be primarily driven by the
hyperglycemia component of metabolic syndrome, other groups postulate that dietary
iron is a modifiable exposure that is directly involved in the initiation, promotion and
progression of the condition (430).
Iron and metabolic syndrome Similar to T2DM, the hypothesis that there is an
association between iron and metabolic syndrome derives from studies demonstrating an
increased prevalence of metabolic syndrome among individuals with HH (366). Several
epidemiological investigations, including 2 cohort studies, 2 case-control studies and 13
cross-sectional studies have reported associations between iron stores and metabolic
syndrome. Each study will be briefly summarized below.
In 2007 Vari et al. followed a total of 944 individuals 30-65 years of age who
were enrolled in the DESIR cohort (i.e., 469 males and 278 premenopausal and 197
postmenopausal females) for a period of 6 years. At the end of the follow-up period, the
authors reported increased odds of developing metabolic syndrome among those in the
highest tertile of log(ferritin) concentrations compared to those in the lowest tertile of
log(ferritin) concentrations: OR = 1.49 (95%CI: 1.14-1.94) for males, OR = 2.10
(95%CI: 1.27-3.48) for premenopausal females and OR = 1.80 (95%CI: 1.21-2.68) for
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postmenopausal females. In addition, the authors reported increased odds of developing
metabolic syndrome among those in the highest tertile of transferrin concentrations
compared to those in the lowest tertile of transferrin concentrations: OR = 1.94 (95%CI:
1.53-2.47) for males, OR = 2.22 (95%CI: 1.32-3.75) for premenopausal females and OR
= 2.14 (95%CI: 1.47-3.10) for postmenopausal females. At the end of the follow-up
period, the authors observed that incident metabolic syndrome was associated with higher
serum ferritin and transferrin at baseline across all three groups: OR = 1.46 (95%CI:
1.13-1.89) for males, OR = 1.28 (95%CI: 0.85-1.94) for premenopausal females and OR
= 1.62 (95%CI: 1.10-2.38) for postmenopausal females for serum ferritin. For transferrin,
the OR = 1.41 (95%CI: 1.10-1.81) for males, OR = 1.63 (95%CI: 1.05-2.52) for
premenopausal females and OR = 1.51 (95%CI: 1.02-2.22) for postmenopausal females.
Baseline serum ferritin concentrations were strongly associated with hypertriglyceridemia
component of metabolic syndrome at the end of the follow-up period (431)
Park et al. conducted a prospective cohort study in 2012, following 18.022
Korean men participating in a medical health check-up program who were free from
metabolic syndrome at baseline for a period of 5 years. During 45,919.3 person-years of
follow-up, the authors observed an increased risk of developing metabolic syndrome
across serum ferritin quintiles: HRQ2 = 1.19 (95%CI: 0.98-1.45), HRQ3 = 1.17 (95%CI:
0.96-1.43), HRQ4 = 1.36 (95%CI: 1.12-1.65), and HRQ5 = 1.66 (95%CI: 1.38-2.01, Ptrend
< 0.001) (432).
Xiao et al. were among the first groups to publish a case-control study examining
the association between iron and metabolic syndrome. The group age matched 87
individuals with metabolic syndrome to 102 healthy adults were recruited from the same
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region in China. The authors grouped participants into dichotomous categories of dietary
iron intake (i.e., < 15 mg/d vs. ≥ 15 mg/d) and reported an increased risk of metabolic
syndrome in cases whose intake exceed 15 mg/d (OR = 7.12, no 95%CI provided). When
stratified by type of iron intake (i.e., heme iron intake vs nonheme iron intake) the
authors reported an increased risk of metabolic syndrome among those consuming > 7.5
mg of heme iron per day (OR = 7.73, no 95%CI provided) (433)
A year later, Hamalainen et al. conducted a population based cross-sectional study
using data obtained from 766 Caucasian, middle-aged subjects (341 males and 425
females) from Pieksämäki, Finland who were recruited for a free health check-up in
2004. The authors reported that both hemoglobin and serum ferritin concentrations were
higher in those with metabolic syndrome (P < 0.001 (hemoglobin), P = 0.018 (ferritin)),
noting that hemoglobin concentration was higher in those with any metabolic syndrome
component (P < 0.001) and that serum ferritin was higher in those with abdominal obesity
(P < 0.001), high triglycerides (P = 0.002) or elevated glucose concentrations (P = 0.02)
(434)
Finally, several cross-sectional studies have highlighted an association between
iron stores and metabolic syndrome. For example, in a population-based cross-sectional
study using subjects participating in NHANES III between 1988 and 1994, Jehn et al.
found that metabolic syndrome was more common in those in the highest quartile of
serum ferritin concentration compared to those in the lowest quartile of serum ferritin
concentration in males (27.3% vs. 13.8%; P < 0.001), pre-menopausal females (14.9%
vs. 6.4%; P = 0.002), and post-menopausal females (47.5% vs. 28.2%; P < 0.001) (12).
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In 2005, Bozzini et al. reported increased odds of developing metabolic syndrome
among cases (n = 269) compared to age-matched counterparts who did not have
metabolic syndrome (n = 210): OR = 1.53 (95%CI: 1.27-1.84) (15). During that same
year Choi (2005) examined the association between serum ferritin, alanine
aminotransferase (ALT) levels and cardiovascular risk factors of metabolic syndrome
among 959 postmenopausal Korean females. The authors reported that cases
demonstrated higher serum ferritin (74.7 ± 2.0 ng/mL vs 59.6 ± 2.0 ng/mL, P < 0.001)
and ALT levels (21.3 ± 1.6 IU/L vs 18.7 ± 1.5 IU/L, P < 0.001). Moreover, increasing
concentrations of serum ferritin corresponded to the presence of a greater the number of
metabolic syndrome components (P < 0.001) (435).
Similar to the results reported by Choi et al., in 2008 Shi et al. observed an
increasing number of metabolic syndrome components with increasing serum ferritin
concentrations in their study sample. Moreover, the authors reported that individuals with
insulin resistance had increased serum ferritin concentrations compared to individuals
without insulin resistance (124.5 ng/mL vs 80.1 ng/mL, P < 0.001). In addition, the
authors noted that serum ferritin concentrations were higher among individuals with
triglyceride concentrations ≥ 150 mg/dL compared to those whose triglyceride
concentrations were < 150 mg/dL (76.8 ng/mL vs 40.1 ng/mL, P < 0.001) and higher
among those with fasting plasma glucose concentrations ≥ 110 mg/dL compared to those
whose fasting plasma glucose concentrations were < 110 mg/dL (75.7 ng/mL vs 41.7
ng/mL, P = 0.005) (436).
Later that year, Sun et al. conducted a cross-sectional survey using data obtained
from 3,289 participants aged 50 to 70 years residing in Beijing and Shanghai China,
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reporting an increased risk of metabolic syndrome for those in the highest quartile of
serum ferritin concentrations compares to those in the lowest quartile of serum ferritin
concentrations (OR 2.80 (95%CI: 2.24-3.49)) after adjustment for other dietary
exposures, BMI, inflammatory markers, and adipokines (392).
Ryu (2008) conducted a cross-sectional study of 1,444 adults between the ages of
40 and 70 participating in a survey conducted as part of the Korean Rural Genomic
Cohort Study (KRGCS), reporting that the prevalence of metabolic syndrome was higher
among those in the highest quartile of serum ferritin concentration compared to those in
the lowest quartile of serum ferritin concentration (37.1% vs. 22.4%, P = 0.006) in males
and (58.8% vs. 34.8, P < 0.001) in females. Moreover, the authors observed an increased
risk of metabolic syndrome among those in the highest quartile of serum ferritin
concentration compared to those in the lowest quartile of serum ferritin concentration
(OR = 2.21 (95%CI: 1.26-3.87, P = 0.024) in males and OR = 2.10 (95% CI: 1.40-3.17, P
= 0.001) in females. In line with the observations of Choi et al. and Shi et al., the authors
noted that increasing serum ferritin concentrations corresponded to a greater number of
metabolic syndrome components (437).
In a smaller cross-sectional study of 482 Tehrani females, subjects in the highest
quintile of red meat intake (i.e., ≥ 63.7 g/d) had greater odds of metabolic syndrome (OR
= 2.33; 95%CI: 1.24-4.38; Ptrend < 0.01) (14). The aforementioned group found a similar
association using the same subjects classified according to dietary patterns, where
females in the highest quintile of Western diets (i.e., characterized by high red-meat and
refined grain intakes) had increased odds of metabolic syndrome (OR = 1.68; 95%CI:
1.10-1.95; Ptrend < 0.01) (14). As previously mentioned, a limitation of a cross-sectional
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study design is that one cannot decipher whether increases in body iron occurred before,
during or after the development of metabolic syndrome.
Kim (2011) investigated the association of serum ferritin concentrations with
insulin resistance and impaired glucose metabolism among 12,090 subjects (6378 men
and 5712 females between the ages of 20-89 years) undergoing general medical checkups
at the Health Promotion Center at Asan Medical Center in Seoul, Korea. The study
sample was comprised of 7,253 participants with NGT, 3,783 participants with IGT and
1,054 participants with T2DM. The authors reported an increased risk of metabolic
syndrome among those with NGT when in the highest quartile of serum ferritin
concentrations compared to those in the lowest quartile of serum ferritin concentrations
(OR = 2.85 (95%CI: 1.99-4.07)) in males and OR = 1.21 (95%CI: 0.82-1.79)) in females
(393).
Kang (2012) examined data obtained from 7,346 individuals (i.e., 3229 males,
4,117 females) participating in the 2007-2008 Korean National Health and Nutrition
Examination Survey (KNHANES). The authors reported an increasing risk of metabolic
syndrome among those in the highest quartile of serum ferritin concentrations compared
to those in the lowest quartile of serum ferritin concentrations (OR = 1.67, 95%CI: 1.242.23 in males and OR = 1.41, 95%CI: 1.06-1.88) in females after adjusting for
menopausal status. Moreover, the authors also observed that increasing serum ferritin
concentrations were associated with components of metabolic syndrome, such as
increased triglyceride concentrations in males and glucose intolerance in females (7).
During the same year, Gabrielson et al. followed a group of 110 individuals to
investigate the effect of iron intake on adiponectin, which is an insulin-sensitizing

82

adipokine that is commonly decreased among those with metabolic syndrome. The
authors reported that serum ferritin concentrations were increased and adiponectin
concentrations were decreased among those with metabolic syndrome compared to those
without metabolic syndrome (260 ± 23 ng/mL vs 185 ± 21 ng/mL) (438).
In another population-based cross-sectional study conducted in Taiwan, Chang et
al. found that individuals in the highest tertile of serum ferritin concentrations had a
higher risk of metabolic syndrome compared to those in the lowest tertile of serum
ferritin concentrations (OR = 1.72, 95%CI: 1.21-2.45) (16). The authors further reported
that serum ferritin concentrations demonstrated a linear relationship with individual
components of metabolic syndrome. For instance, individuals in the highest tertile of
serum ferritin had higher fasting serum glucose concentrations (OR = 2.16, 95%CI: 1.752.65) and higher serum triglycerides (OR = 2.58, 95%CI: 1.07-3.22) (13).
Li et al. (2013) sought to explore the relationship between serum ferritin and
metabolic syndrome among 8,441 adults aged 18 and older participating in the China
Health and Nutrition Survey. The authors observed that serum ferritin concentrations
were significantly higher among those with metabolic syndrome (106.0 ng/mL vs 73.2
ng/ml, P < 0.001) after adjustment for age, nationality, BMI, smoking status and alcohol
consumption. Finally, the authors noted that the risk for metabolic syndrome increased
across increasing quartiles of serum ferritin concentrations for both males and females
(Ptrend < 0.001) (9).
Tang et al examined data obtained from 3,274 males participating in the 2009–
2013 Fangchenggang Area Males Health and Examination Survey (FAMHES). The
authors reported that those with metabolic syndrome had higher serum ferritin
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concentrations compared to those without metabolic syndrome (median: 447.4 ng/mL
(range: 294.1-612.4) vs. 302.4 ng/mL (range: 215.0-435.8), P < 0.01). Moreover, the
authors observed positive correlations between serum ferritin concentrations and
components of metabolic syndrome: blood pressure (BP) (Systolic BP: r = 0.11, Diastolic
BP: r = 0.16), waist circumference (r = 0.33), fasting glucose concentration (r = 0.09),
triglyceride concentration (r = 0.32) and low HDL cholesterol (r = 0.13) (P < 0.001 for all
comparisons). Finally, the authors observed an increased risk of metabolic syndrome
among those in the highest quartile of serum ferritin concentrations compared to those in
the lowest quartile of serum ferritin concentrations (OR = 2.29, 95%CI: 1.47-3.54) (439).
More recently, two groups have each conducted separate meta-analyses
examining the association between iron parameters (i.e., serum ferritin) and metabolic
syndrome with many of the above-mentioned studies. In 2014, Abril-Ulloa et al. included
a total of fifteen studies in the calculation of pooled effect sizes (i.e., two prospective, one
case-control and twelve cross-sectional studies, Table 9) and reported separate pooled
effect sizes for both males and females. Overall, the pooled effect size across studies
comparing the highest versus the lowest category of serum ferritin among study
participants with metabolic syndrome was 1.73 (95%CI: 1.54-1.95, I-squared = 75.4%).
For males, the pooled effect size for the association between the highest reported
category of ferritin across studies to that of the lowest category of ferritin was 1.69
(95%CI: 1.29-2.21). Among females, the pooled effect size was 1.65 (95%CI: 1.41-1.94).
A strength of the meta-analysis was that thirteen of the fifteen studies included used the
NCEP-ATP III definition to determine the presence of metabolic syndrome. Moreover,
the authors were able to conduct subgroup analyses among studies adjusting for C-
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reactive protein (CRP) and reported a pooled effect size among studies controlling for
CRP of 1.92 (95%CI: 1.61-2.30) compared to 1.52 (95%CI: 1.36-1.69) for studies not
controlling for CRP. This finding is interesting, as one would expect the effect size to be
attenuated by controlling for factors related to inflammation (11).
Jin et al. published another meta-analysis reporting upon the association between
serum ferritin and metabolic syndrome in 2015. In contrast to the former group, Jin and
colleagues reported pooled effect sizes among studies examining the association between
mean ferritin concentrations in study participants with metabolic syndrome compared to
mean ferritin concentrations among study participants without metabolic syndrome. The
authors included eight studies (four prospective, two case-control and two cross-sectional
studies, Table 9), none of which overlapped with those analyzed by Abril-Uloa et al. in
their meta-analysis, and reported a pooled effect size of 1.20 (95%CI: 0.69-1.71, Isquared = 96%) (440) comparing the standardized mean difference in serum ferritin
concentrations among study participants with metabolic syndrome to those without
metabolic syndrome. It is plausible that the reported effect size was not statistically
significant due to the high reported heterogeneity across studies, the inconsistent
application of criteria to determine the presence of metabolic syndrome and the scaling of
the dependent variable (i.e., continuous vs categorical) among the studies included in the
meta-analysis. Despite these limitations, the reported effect size is in the same direction
and of similar magnitude to those reported by Abril-Uloah.
Interventional Epidemiology Additional support for a positive association
between body iron and metabolic syndrome has been obtained from an interventional
study published by Houschyar et al. in 2012. The authors randomly allocated 64
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individuals with metabolic syndrome to a treatment arm (i.e., iron reduction by
phlebotomy, N = 33) or control arm (N = 31). Those in the treatment arm had 300 mL of
blood removed at study entry and, depending upon baseline serum ferritin concentration,
between 250 mL and 500 mL removed after four weeks. The primary outcomes of the
study at the end of six weeks were 1) change in systolic blood pressure (SBP) and 2)
change in HOMA-IR. Secondary outcomes measured by the group were 1) change in
HbA1C, 2) change in plasma glucose concentration, 3) change in lipid profile and 4)
change in heart rate beats per minute (bpm). The authors observed a significant reduction
in SBP in the treatment group at the end of the study period (148.5 ± 12.3 mmHg to
130.5 ± 11.8 mmHg, representing a difference of -16.6 mmHg (95%CI: -20.7 to -12.5, P
< 0.001), which corresponded to a reduction in serum ferritin concentrations in the
treatment group from 188.3 ± 212.4 to 104.6 ± 132.5. While those in the control group
also experienced a reduction in serum ferritin concentrations from 173.2 ± 132.9 to 149.4
± 124.9, this was not statistically significant. The average between-group reduction in
serum ferritin concentration was 74.2 ng/mL (P < 0.001), favoring the treatment group.
The change in SBP among those in the control arm was not significant (144.7 ± 14.4
mmHg to 143.8 ± 11.9 mmHg). While HOMA-IR decreased in both arms (treatment
HOMA-IR: 4.8 ± 7.2 to 3.6 ± 2.7; control HOMA-IR: 4.5 ± 3.8 to 4.1 ± 3.6), neither
reduction was statistically significant. The greater reduction in HOMA-IR in the
treatment arm, however, correlated with serum ferritin reduction (r = 0.39, P = 0.03).
Finally, those in the treatment arm experienced significant reductions in all secondary
outcomes (i.e., decreased HbA1C (from 5.56 ± 0.61 to 5.36 ± 0.58, P < 0.001)), blood
glucose concentrations (from 110.7 ± 29.4 to 98.5 ± 24.0, P < 0.001), LDL/HDL ratio
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(from 2.48 ± 0.88 to 2.21 ± 0.80, P < 0.01) and heart rate (from 72.1 ± 8.2 bpm to 70.0 ±
5.8 bpm, P < 0.001) (28).
Conclusion Taken together, it appears as though iron stores are positively
associated with the development of metabolic syndrome, including several individual
components of metabolic syndrome (e.g., visceral adiposity, dyslipidemia, hypertension,
as well as with increasing fasting insulin concentration and blood glucose levels). It
should be noted, however, that each of the above studies used serum ferritin and/or
transferrin saturation as indices of iron stores. As already mentioned, these parameters
demonstrate diurnal variation and/or can be influenced by inflammation. Therefore,
predictive, non-invasive, and inexpensive analytes unaltered by inflammation would be
valuable for use in monitoring the iron status of those at risk for developing metabolic
syndrome. To my knowledge, no study to date has employed the algorithm developed by
JD Cook et al. in 2003 (50) as an index for iron repletion to examine the association of
the former with metabolic syndrome.

Epidemiology of non-alcoholic fatty liver disease (NAFLD)
History & Definition Non-alcoholic fatty liver disease is a chronic disease that
spans a spectrum of hepatic pathology ranging from simple steatosis (i.e., defined as
greater than 5% of total liver weight due to an accumulation of triglycerides inside
hepatocytes, in the absence of hepatitis B and C virus or excessive ethanol intake) (441,
442) to steatohepatitis, fibrosis and cirrhosis (443, 444). Studies whose aim has been to
quantify the prevalence of NAFLD have been hindered by the fact that individuals at any
stage of the disease are relatively asymptomatic (444) and techniques/tools (e.g.,
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ultrasonography, ALT assay, aspartate aminotransferase (AST) assay) which are
commonly used in a clinical setting to diagnose the condition are neither sensitive nor
specific (Table 7). Moreover, the gold standard for diagnosing and staging NAFLD is a
liver biopsy (444), which is invasive and often cost-prohibitive at both the patient- and
population-level.
Descriptive Epidemiology Before investigators in NHANES III (1988-1994)
began performing gallbladder ultrasonography on all participants aged 20-74 years of
age, there was no representative data in the U.S. available to study the epidemiology of
NAFLD (442). These studies, however, revealed that the prevalence of NAFLD in the
U.S. increased from 18% from 1988-1991 to 29% in 1999 (35). However, more recent
and representative prevalence estimates of NAFLD using more sophisticated imaging
techniques emerged from the Dallas Heart Study (DHS). The DHS was a multi-ethnic
population-based cohort which collected data from July 2000 through January 2002
(446). During this time period, 2,287 participants were screened using proton magnetic
resonance spectroscopy to measure fat content of the liver. Based upon these data, the
prevalence of NAFLD in the U.S. in 2002 was estimated to be 30%. Supporting these
imaging data are observational studies which report that the prevalence of NAFLD tends
to closely parallel the prevalence of obesity (442). Given that ~1/3 of the U.S. population
is considered obese, the prevalence of NAFLD in the U.S. population is thus likely to be
approximately 30% (446).
Due to the asymptomatic presentation of NAFLD, most cases are diagnosed in the
5th and 6th decades of life (443). NAFLD is rarely observed in individuals younger than
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20 years (~1%), but increases to 18% in those aged 20-40 years and to 39% among those
aged 60 and older (442).
The prevalence of NAFLD varies across genders and ethnicities. Prior to the
aforementioned population-based studies, NAFLD was traditionally thought to affect
more females than males (442). However, authors have since demonstrated that males are
twice as likely to develop NAFLD than females (441). For example, NHANES data
indicate that the prevalence of NAFLD in U.S. males is estimated to be 53.1% versus
29.1% in females (442). In addition, data from the Modena and Bologna/Turin study
indicates that NAFLD exhibits a gender dimorphic pattern in which males tend to
develop the disease approximately 10 years before their female counterparts (447).
Interestingly, postmenopausal females are twice as likely as premenopausal females to
develop NAFLD (444, 448). Moreover, the prevalence of NAFLD in females exceeds
that in males following menopause (447).
Data from the DHS indicates that the prevalence of NAFLD in Hispanic
Americans is 45%, 33% in non-Hispanic whites and 24% in African Americans (443).
Moreover, data from several other population-based studies are in alignment with the
DHS, showing that Hispanic Americans demonstrate a higher prevalence of NAFLD
compared to non-Hispanic whites and African Americans across all age categories and
genders (442, 446). Explanations for the observed differences in the prevalence of
NAFLD are hypothetical and relatively vague. Moreover, some authors posit that the
observed differences may be related to the ethnic differences in body fat distribution
and/or fat metabolism, with African Americans having more subcutaneous fat but less
visceral fat. It has also recently been suggested that African Americans have different
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lipoprotein metabolism (i.e., lower serum concentrations of triglycerides than age and
gender-matched counterparts) compared to other ethnicities (449). Lastly, the higher
observed prevalence of NAFLD in Hispanic Americans has also been attributed to
intrinsic factors such as a genetic predisposition for greater adiposity and insulin
resistance compared to other ethnicities (442).
Pathophysiology Several studies have reported that NAFLD is highly correlated
with obesity, T2DM (442, 444), biomarkers of dyslipidemia (e.g., high triglyceride
concentrations and low HDL concentrations) and insulin resistance. However, insulin
resistance appears to be considered the pathophysiological hallmark of NAFLD (442), as
mild insulin resistance/hyperinsulinemia is commonly observed at the earliest stages of
NAFLD in the absence of obesity (450) and more severe insulin resistance (e.g., such as
that observed in metabolic syndrome and T2DM) correlates with more advanced stages
of NAFLD (442).
To my knowledge, a single hypothesis has been put forward to explain the
etiology of NAFLD, which highlights the role of increased concentrations of FFAs
leading to insulin resistance and subsequent hepatic steatosis. In the normal hepatocyte,
energy received from circulating glucose, fructose and lipids is stored as glycogen and
triglycerides, respectively. Under normal physiologic conditions, any increase in lipid
concentration within the hepatocyte results in 1) the redistribution of the lipids to
peripheral storage within adipose tissue or 2) the lipids are directly converted to
metabolic fuel through oxidation. In other words, it appears that hepatocytes have very
little capacity for the storage of triglycerides (i.e., the storage form of FFAs) and do so
only when all other mechanisms for lipid utilization, trafficking or storage have been
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exhausted. In NAFLD, lipid trafficking appears to be dysregulated, which culminates in
increased intrahepatocellular lipids, particularly as saturated FFAs (e.g., palmitic acid,
stearic acid) (451).
Within the hepatocyte, these excess FFAs appear to directly contribute to
organelle dysfunction and failure. As mentioned previously, FFAs contribute to
mitochondrial dysfunction by skewing the NAD/NADH ratio which leads to increased
concentrations of acetyl-CoA and hepatic glucose production. Over time, this culminates
in elevated triglyceride storage within the hepatocyte, organelle failure and apoptosis.
Moreover, FFAs can induce endoplasmic reticulum stress by increasing ceramide
concentration (452) as well as by other poorly understood mechanisms (452).
There is also substantial evidence which demonstrates that FFAs can directly
induce cellular toxicity by increasing oxidative stress and activation of pro-inflammatory
pathways (457). For example, FFA accumulation within the hepatocyte is associated with
Kupffer cell activation (452). Kupffer cells are resident macrophages within the liver
parenchyma in close physical proximity to hepatocytes, endothelial cells, sinusoids and
stellate cells (452). It is worth noting that stellate cells reside between hepatocytes and
the small blood vessels of the liver and are normally quiescent. It appears that their main
function is to store vitamin A and maintain the basement membrane matrix. Activation of
stellate cells leads to collagen secretion and formation of scar tissue and appears to be a
central step in the initiation of hepatic fibrosis. Interestingly, not only is the activation of
Kupffer cells thought to play a central role in the pathogenesis and progression of liver
disease by contributing to parenchymal inflammation, hepatocyte ballooning and injury
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and initiation of fibrosis via TNF-alpha secretion (452), Kupffer cells have also been
shown to modulate stellate cell activation (454)
In terms of linking FFAs to inflammation and NAFLD, TNF-alpha secretion by
macrophages promotes lipolysis and increases FFA concentration (455) and has been
observed to increase in a stepwise-fashion from obesity to simple steatosis (452).
Interestingly, TNF-alpha both promotes and is activated by insulin resistance via
activation of IKK-B (inhibitor of nuclear factor kappa B kinase subunit beta (NF-kB))
(456), which mediates the activity of NF-kB (i.e., a proinflammatory protein complex).
This complex regulates inflammatory mediators including C-reactive protein (CRP),
plasminogen activator inhibitor (PAI-1), TNF-alpha and IL-1B (456).
As mentioned previously, TNF-alpha has been shown to antagonize adiponectin
(452) and vice versa (457). Thus, it has been postulated that adiponectin may protect the
liver from inflammation via this antagonistic effect on TNF-alpha. Lending support to
this line of reasoning, recombinant adiponectin has been shown to inhibit TNF-alpha
concentration, improve insulin sensitivity and reduce steatohepatitis in two mouse models
of hepatic steatosis (452). Taken together, these results support the hypothesis of FFAs
leading to insulin resistance and subsequent NAFLD, where FFA accumulation leads to
insulin resistance and subsequent hepatic steatosis, which is amplified by increasing
insulin resistance.
Analytic Epidemiology The risk for developing NAFLD correlates positively
with BMI, as prevalence of the disease ranges from 30% in normal weight individual of
the general population to 57% among overweight individuals (446) to 80%-90% among
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obese individuals (449). Given that 66% of U.S. population is estimated to be overweight
(i.e., as indexed by BMI), this is obviously a growing public health concern.
Suzuki et al. have speculated that FFA oxidation in the liver may decrease
following menopause while lipogenesis may be enhanced (447). Thus, it appears that
menopausal status (i.e., pre- vs. post-menopause) be considered a risk factor. In line with
this observation, other authors report that postmenopausal females receiving hormone
replacement therapy are significantly less likely to develop NAFLD compared to females
who do not (442, 447) and Carulli et al. have postulated that circulating levels of
estrogens within the physiological range might be responsible for a protective effect on
the development of hepatic steatosis (458). In support of the latter hypothesis, NAFLD in
animal models has been reversed by the administration of estradiol (459). Interestingly, it
appears that no connection has been made between the development of NAFLD among
pre- and post-menopausal females and the cessation of menstruation among
postmenopausal females.
Given that much of the research community concurs that NAFLD is the ‘hepatic
manifestation of metabolic syndrome,’ additional risk factors independent from those
already associated with the development of metabolic syndrome are not commonly
reported in the NAFLD literature. Similar to T2DM and Metabolic syndrome, however,
several small case studies have indicated that parameters of iron status may be involved
in the initiation, promotion and progression of NAFLD.
Iron and non-alcoholic fatty liver disease

Given that parameters of iron status

and their association with NAFLD have received little attention in the epidemiological
literature, it follows that presenting the results of investigations relating the risk of
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developing NAFLD to iron stores in a systematic manner is a challenge. Among the
studies examining the relationship between iron and NAFLD, dysmetabolic iron overload
syndrome (DIOS) appears to be a common feature of NAFLD, with a prevalence of
~33% (460) among those diagnosed with the condition. In subjects with DIOS, serum
ferritin is elevated, while transferrin saturation is within the normal reference range (461).
As mentioned, associations between iron stores and NAFLD have been most often
reported in case-studies. For example, in 2004, Younossi et al. obtained biopsies from 65
patients with NASH, noting that 31% of patients were either heterozygous or
homozygous for the C282Y polymorphism at the HFE locus rs1800562, and the presence
of this mutation resulted in a higher histological grade of iron, increased hepatic iron
content and an increase in histological fibrosis (462). Gene expression data published by
Mitsuyoshi et al. in 2009 support the results of Younossi et al. The former group obtained
biopsy specimens from 74 patients with NAFLD and observed an increase in hepatic iron
score (HIS) as the stage of fibrosis progressed. Moreover, sTfR1 expression significantly
increased with progressing stage of fibrosis (463). In addition, Nelson et al. published a
study in 2011 with data obtained from 849 patients enrolled in the Nonalcoholic
Steatohepatitis Clinical Research Network demonstrating that participants whose
reticuloendothelial system (RES) cells (i.e., monocytes and macrophages) contained
stainable iron were also more likely to have advanced pathohistological features such as
fibrosis, portal inflammation, hepatocellular ballooning and biopsy-confirmed NASH
compared to participants without stainable hepatocellular iron. In this study, the presence
of stainable RES iron was independently associated with advanced hepatic fibrosis
following multiple regression analysis controlling for age, gender, diabetes status, and
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BMI (OR = 1.60, 95%CI: 1.10 – 2.33, P = 0.015) (464). In 2012, Shim published a study
showing that elevated serum ferritin was an independent predictor of histologic severity
and advanced fibrosis in subjects with NAFLD (465). Later that year another group (466)
conducted a genetic association study examining the effects of the C282Y (rs1800562)
and H63D (rs1799945) polymorphisms on serum hepcidin, hepatic iron deposition, and
histology of NAFLD. The authors observed that subjects with NAFLD and C282Y (but
not H63D) mutations had lower median serum hepcidin levels and higher mean
hepatocellular iron grades compared to wild-type subjects. Nelson et al. also observed an
inverse relationship between hepatic iron stores and serum hepcidin concentration across
all HFE genotypes, indicating that elevated iron stores are associated with NAFLD
independent of HFE genotype (466). The latter observation is supported by a study
conducted in 1999 by Mendler et al. who reported that patients with no HFE mutations
had similar degrees of iron overload as those with mutations in the HFE gene, apart from
compound heterozygotes (i.e., individuals heterozygous for both HFE mutations), who
presented with significantly more iron burden (467). A meta-analysis published in 2012,
which includes the study conducted by Mendler et al., lends support to these individual
investigations, as the authors concluded that elevated iron in NAFLD is independent of
HFE genotype (468). It thus appears that insulin resistance in NAFLD is associated with
more subtle degrees of iron overload than is observed in iron-loading disorders, such as
HH and beta-thalassemia (469).
Mechanistically, iron appears to have a direct role in the activation of hepatic
Kupffer cells and hepatic stellate cells. For example, iron has been shown to activate
inflammatory signaling via hepatic macrophages in vitro and ferritin treatment of isolated
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rat hepatic stellate cells has been shown to increase NF-kB signaling. As mentioned, the
activation of stellate cells appears to be a central step in the initiation of hepatic fibrosis.
Animal studies have also shown that hepatic sTfR-1 is upregulated due to a high-fat diet,
which may lead to increased hepatocellular uptake of dietary iron despite an already
increased hepatocellular iron load. In alignment with these studies, Otogawa et al have
observed an increase in red cell fragility in response to a high-fat diet in rabbits and this
fragility leads to increased erythrophagocytosis by Kupffer cells (470). From a
pathophysiological perspective, Kupffer cells can also accumulate iron via phagocytosis
of necrotic hepatocytes (471). These latter findings may, in part, explain the observed
increases in hepatic reticuloendothelial iron that has been observed in some NASH
cohorts (154).
Serum hepcidin levels also appear to increase as individuals transition from
NAFLD to NASH, and DMT-1 is upregulated in patients with NASH, despite the
observed increased serum hepcidin concentrations (472), indicating a perturbation in iron
metabolism where the requirement for iron is increased along with iron storage.
Finally, dietary iron loading in leptin-receptor deficient mice has been recently
reported to lead to inflammasome and immune cell activation, which directly corresponds
to hepatocellular ballooning. In other words, mice who lack satiety signals and have high
intakes of dietary iron appear to have Kupffer cell activation and increased oxidative
stress, which leads to liver dysfunction.
Interventional Epidemiology Valenti et al. demonstrated in a case-control study
that iron depletion by phlebotomy improves insulin resistance in patients diagnosed with
NAFLD (473). More recently, a meta-analysis of studies examining the effect of
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phlebotomy on insulin resistance lends further support to the initial results of Valenti et
al. The primary outcome analyzed across all studies in the meta-analysis conducted by
Jaruvongvanich et al. (Table 10) was the pooled mean difference (MD) of the
homeostasis model assessment of insulin resistance (HOMA-IR) (468). The authors
found that study subjects with NAFLD who underwent phlebotomy had lower HOMA-IR
indices with an MD of 0.84 (95%CI: 0.01 to 1.67, I-squared = 34%), lower triglyceride
levels (MD = 9.89, 95%CI: 4.96-14.83, I-squared = 22%) levels and increased high
density cholesterol level (MD = 3.48, 95%CI: 2.03-4.92, I-squared = 18%) compared to
controls (i.e., subjects with NAFLD who did not receive phlebotomy) and concluded that
phlebotomy decreased insulin resistance and liver transaminase levels in patients with
NAFLD.
Conclusion Taken together, it appears as though iron stores are positively
associated with NAFLD. Compared to T2DM and metabolic syndrome and a lack of
several population-based studies, however, the strength of the associations between iron
stores and NAFLD are unclear. Moreover, each of the above studies employed invasive
and costly methods to assay iron status. Predictive, non-invasive, and inexpensive
analytes unaltered by inflammation would be valuable for use in monitoring the iron
status of those at risk for developing NAFLD. To my knowledge, no study to date has
employed the algorithm developed by JD Cook et al. in 2003 (50) as an index for iron
repletion to examine the association of the former with NAFLD.
Given that the prevalence of NAFLD is increasing and that quantification of the
presence of the condition often involves cost-prohibitive and/or invasive methods, an
index with high sensitivity and specificity which utilizes biochemical parameters would
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be of significant value. To this end, several indices and algorithms have been developed.
However, the sensitivity and specificity of each index varies (Table 7) in terms of
accurate classification across populations. Thus, an index referred to as the U.S.-FLI has
was recently developed to determine the presence of NAFLD among multi-ethnic
cohorts. As mentioned, the index accounts for age and ethnicity and has been shown to
outperform its predecessor, the FLI (35).
The U.S.-FLI has not been employed thus far to estimate the prevalence of
NAFLD in U.S. females as a subgroup. Moreover, no investigations to date have
examined the association between body iron as indexed by Cook’s equation and NAFLD
as indexed by the U.S.-FLI.

Epidemiology of insulin resistance
History & Definition It is well-established in the literature that insulin resistance
is involved in the development of T2DM (366-398), metabolic syndrome (7,9,12-15, 392,
393, 431-440) and NAFLD (460-473), often decades before glucose intolerance occurs or
any of the above conditions are diagnosed. Insulin resistance has traditionally been
framed in terms of the effects of insulin on glucose metabolism, otherwise known as the
“glucocentric” view of insulin resistance. The traditional “glucocentric” view of insulin
resistance has shifted over the past decade, however, to a “lipocentric” view of insulin
resistance due to advances in our understanding of the etiology of insulin resistance. The
“lipocentric” view of insulin resistance will be discussed subsequently.
Descriptive Epidemiology In the U.S. population, the prevalence of insulin
resistance has been estimated at 45% (9.6% in normal weight adults aged 40-79 years,
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and ~ 50% in overweight adults aged 40-79 years) (474). Prevalence estimates for insulin
resistance may be underreported, however, as the gold-standard for diagnosis of insulin
resistance is the hyperinsulinemia-euglycemic clamp, which is both invasive as well as
cost-prohibitive at the patient-level as well as in population-based studies. In addition, the
prevalence of insulin resistance alone has rarely been quantified in the absence of T2DM,
metabolic syndrome or NAFLD.
Pathophysiology As previously mentioned, however, the traditional
“glucocentric” view of insulin resistance has shifted over the past decade to a
“lipocentric” view of insulin resistance due to results emerging from recent
investigations. For example, in vivo research conducted using 13C-MRS (13C-Magnetic
Resonance Spectroscopy) to examine the cellular mechanisms of insulin resistance in
humans is a technique which allows for the real-time, non-invasive measurement of the
concentration of intracellular metabolites containing naturally occurring isotopes of 1H,
13C, and 31P (475, 476). Using this approach with sets of age- and weight-matched
subjects with and without T2DM, Peterson and colleagues have demonstrated that the
rate of insulin-stimulated muscle glycogen synthesis (i.e., assessed via the incorporation
of 13C-glucose into gastrocnemius/soleus muscle glycogen) is decreased by ~50% in
T2DM subjects (475, 476). Extrapolating these data to the whole-body, the group
concluded that almost all the insulin resistance observed in these subjects could be
attributed to defects in insulin-stimulated muscle glycogen synthesis. Further analysis of
the glycogen synthesis pathway revealed that the rate-limiting step leading to insulin
resistance was reduced insulin-stimulated glucose transport activity. Finally, through
additional 13C and 31P MRS studies, the group determined that the accumulation of

99

FFAs within the myocyte induces insulin resistance (i.e., via reducing insulin action) by
directly inhibiting activation of glucose transport activity by reducing transcription of
GLUT4 (476), the insulin-regulated glucose transporter primarily involved in regulating
whole-body glucose homeostasis.
To appreciate the impact of FFAs on GLUT4 transcription, we must examine the
tissue distribution and mechanism of action of GLUT4. The tissues which remove
glucose from circulation for utilization via GLUT4 are skeletal muscle, liver and adipose
tissue. Under normal physiologic conditions, insulin secretion 1) stimulates glucose
uptake in skeletal muscle and adipocytes by translocation of GLUT4 to the cell surface,
2) stimulates the synthesis of glycogen from glucose and inhibits glycogenolysis in
skeletal muscle and hepatocytes and 3) decreases hepatic gluconeogenesis (i.e., the
generation of glucose from non-carbohydrate substrates such as amino acids,
triglycerides, pyruvate and lactate) (477), in order to prevent an influx of additional
glucose into the bloodstream. Moreover, insulin secretion inhibits lipolysis (i.e., fat
breakdown) in adipocytes and stimulates glucose uptake in adipose tissue (478). Thus,
the net effect of insulin secretion by beta cells is to increase glucose uptake via GLUT4,
reduce circulating glucose levels by suppressing hepatic glucose production and to
increase the conversion of glucose to glycogen or fat (477).
Experimental models have demonstrated that altering GLUT4 activity directly
impacts insulin action. For example, mice with targeted downregulation of GLUT4 in
skeletal muscle and adipose tissue have been shown to develop insulin resistance in each
tissue (478). Moreover, it has also been shown in mouse models that overexpression of
GLUT4 in adipose tissues is associated with improved insulin sensitivity (480). Taken
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together, it appears that the “lipocentric” view of insulin resistance usurps the previous
“glucocentric” view of insulin resistance, as the former view places FFAs at the
beginning of the pathway which leads to beta cell dysfunction by decreasing GLUT4
expression and this is thought to result in hyperglycemia with subsequent
hyperinsulinemia as a compensatory response.
It is worth noting that with increasing FFAs, it has been postulated that glucose
oxidation (as well as glycolysis) is reduced in favor of FFA oxidation. As a consequence,
the metabolic by-products of excess FFA oxidation (i.e., ceramides) (452) contribute to
oxidative stress, which is thought to lead to further increases beta cell dysfunction and
apoptosis (333). For instance, studies have shown that ceramide directly impairs insulinstimulated glucose uptake and GLUT4 translocation when added to cultured adipocytes
and myocytes (481). These effects appear to be mediated by the effects of ceramide to
inhibit tyrosine phosphorylation of insulin receptor substrate 1 (IRS-1, which transmits
signals from insulin to downstream intracellular pathways such as PI3K/Akt and MAP
kinase) (478). Moreover, FFAs are endocytosed and metabolized directly by beta cells
(477), which has been hypothesized to lead directly to beta cell dysfunction (477).
Moreover, FFAs can be re-esterified to triglycerides by several tissues including muscle,
fat and liver (341), which leads to the increased storage of these lipids.
As mentioned in the section covering T2DM, studies have demonstrated that
FFAs contribute to mitochondrial dysfunction by skewing the NAD/NADH ratio and this
is thought to lead to inhibition of FFA beta oxidation, increases in FFA storage as
triglycerides, mitochondrial dysfunction and eventual mitochondrial apoptosis. Thus, the
manifestation of diminished GLUT4 activity via increased FFA concentrations, coupled
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with increasing hyperinsulinemia and hyperglycemia, results in a variety of metabolic
abnormalities including several perturbations downstream of insulin resistance. These
perturbations manifest in hepatic steatosis (previously discussed in the NAFLD section),
elevated triglycerides, low levels of high-density lipoproteins (HDL) and increased
secretion of very low-density lipoproteins (VLDL) (previously discussed in the metabolic
syndrome section).
Iron & insulin resistance In a three-year prospective study among 1,277
French adults, Fumeron et al. reported that baseline serum ferritin level was an
independent predictor of increases in serum insulin concentrations at the end of the
follow-up period. The authors reported that each 1 ng/mL increase in ferritin was
associated with an 0.05 ± 0.02 µU/mL increase in serum insulin concentration (P =
0.002) (373). Two other cross-sectional studies have indicated that increased body
iron is associated with insulin resistance.
The first cross-sectional study examined the effect of dietary patterns (i.e.,
healthy, Western, traditional) on iron status and insulin resistance in 486 Tehrani females.
In these subjects, a Western dietary pattern classification scheme was developed using
factor analysis, where red meats and refined grains had the highest factor loadings of 0.56
and 0.66, respectively (14). The authors observed that females who were in the highest
quintile of Western dietary pattern scores (i.e., the highest red meat and refined grain
intake) had greater odds of insulin resistance, as measured by the homeostasis model
assessment-insulin resistance (HOMA-IR) (OR = 1.26; 95%CI: 1.00-1.78; Ptrend < 0.01).
Given the cross-sectional study design, however, it is not possible to conclude whether
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increased body iron preceded increases in HOMA-IR, accompanied increases in HOMAIR or followed increases in HOMA-IR.
In another population-based cross-sectional study involving 1,013 Finnish men,
subjects in the highest quintile of serum ferritin concentrations had 21.6% higher fasting
serum insulin concentrations (95%CI: 7.3%-37.9%; P < 0.001) (24). In these subjects,
fasting blood glucose was also higher in those in the highest quintile of serum ferritin
concentrations (6.1%; 95%CI: 2.3%-9.9%; P < 0.001).
Conclusion Taken together, these three investigations suggest that iron is
associated with insulin resistance and may be involved in the etiology of insulin
resistance. Additional prospective studies are needed, however, to confirm this
hypothesis.
In terms of linking iron to the etiology of insulin resistance by way of a testable
hypothesis, we must first examine several lines of evidence demonstrating the effects of
insulin administration on iron parameters, as well as the effects of iron on factors
reported in the literature to be associated with insulin resistance, such as chemokines,
cytokines, adipokines and insulin-sensitizing agents. Most importantly, an association
between iron and the purported driver of insulin resistance, FFAs, must be demonstrated.
Effects of insulin administration on iron parameters Two groups thus far have
shown that administration of insulin to cultured adipocytes increases iron uptake in these
cells by increasing the expression of sTfR1 (482, 483) and decreased insulin-stimulated
glucose transport (484). Another group have replicated these findings using the HepG2
hepatic cell line and the HL-7702 hepatic cell line (485). Moreover, these results garner
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additional support from a rodent model demonstrating that insulin injections lead to
subsequent increases in sTfR1 in vivo (486).
Related to these observations, studies have also shown that serum transferrin
receptor 2 (sTfR2) can be regulated by insulin-like growth factor 1 (IGF1, a hormone
produced in the liver that shares structural similarity to insulin), where IGF1 expression
increased sTfR2 cycling (167). Finally, several authors have reported that
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) can also act as a transferrin
receptor and is a preferred receptor for transferrin in some cell lines (CHO-TRVb, J774
cell lines) (77, 78, 487, 488). This is an interesting finding, as GAPDH is the same
enzyme involved in the breakdown of glucose to pyruvate during glycolysis (487).
It is also worth mentioning here that the finding from Davis et al. and Tanner
et al. is notable, especially when considering other studies which have suggested that
iron within the adipocyte might interfere with cellular insulin sensitivity and contribute to
increased lipolysis (16). This leads to one to hypothesize that increased lipolysis by iron
within the adipocyte could increase the pool of FFAs. Moreover, one can hypothesize
that insulin resistance might amplify these effects, as insulin appears to enhance iron
uptake by increasing serum transferrin receptor expression with increasing concentrations
of insulin.
Iron and chemokines Zager et al. have shown that both iron sucrose as well as
iron gluconate increase plasma and renal MCP-1 concentration (489). Given that iron is a
pro-oxidant it is feasible that iron could also contribute to increased MCP-1 expression.
Iron and cytokines The effects of iron on the immune system was reviewed
previously in chapter 3. However, no special attention was given to the cytokines
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associated with the development of insulin resistance nor was any attention given to how
iron is associated with insulin resistance or conditions associated with insulin resistance.
Several studies have been published which report elevated levels of ferritin and TNFalpha, IL-6, IL-8 and C-reactive protein (CRP) (380, 382, 490). For instance, in an ageand sex- matched case-control study, Elsammak et al. have reported that both serum
ferritin and TNF-alpha increase among individuals with NGT (N = 18), T2DM (N = 22),
Hep C infection with T2DM (N = 23) and Hep C infection (TNF-alpha: 0.32 (0-5.8)
pg/mL, 0.85 (0-10.5) pg/mL, 19.8 (0.51-139) pg/mL, 25.5 (0.43-124.0) pg/mL,
respectively; serum ferritin: 159 ± 76.9 ng/mL, 86.9 ± 41.8 ng/mL, 285.8 ± 124.3 ng/mL,
258.1 ± 116.2 ng/mL, respectively). Moreover, the authors reported that the degree of
insulin resistance decreased among those with both HepC infection and T2DM, T2DM,
Hep C infection and NGT (HOMA-IR: 6.1 ± 2.36, 4.53 ± 2.84, 3.69 ± 2.2, 1.32 ± 0.49,
respectively). In addition, Abou-Shousha et al. have shown that serum ferritin, sTfR and
IL-8 are all elevated in states of insulin resistance. Taken together, these results indicate
that iron, cytokines and insulin resistance are positively associated and emphasize the
importance of excluding and/or controlling for Hep C infection and adjusting for CRP
concentrations during the analysis of the effect of iron on any outcome in which insulin
resistance plays a role.
Iron and adipokines Leptin and adiponectin are two-well characterized
adipokines produced and secreted by adipose. Briefly, leptin was identified in 1994 by
Halaas et al. as a 16kDa protein encoded by the obese (ob) gene. The group discovered
the protein to be directly involved in body weight, where its secretion from adipose tissue
is activated by the ventromedial hypothalamus of the brain via gastric stretching
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following a meal and provides a feedback signal of satiety to the brain so that food intake
be halted (491).
Adiponectin was first identified in 1995 by Scherer as 30kDa protein secreted by
adipose tissue and is now recognized for its insulin-sensitizing, anti-inflammatory,
antiatherogenic and cardioprotective properties (492). Adiponectin secretion is quite
distinct from that of leptin. Adiponectin is less dependent on state of satiety compared
to leptin. Rather, adiponectin exhibits an ultradian pulsatility (i.e., a pattern
characterized by periods of secretion longer than an hour and shorter than a day) and
diurnal variation (i.e., adiponectin secretion declines up to 30% during sleep) (493).
Collectively, these adipokines have been shown to decrease triglycerides
synthesis, promote FFA degradation (i.e., leptin, adiponectin) (334) and enhance insulin
action in both skeletal muscle and liver (i.e., adiponectin) (478). In line with these data,
studies which show that leptin concentrations are increased and levels of adiponectin are
decreased in obese individuals with insulin resistance as well as in animal models of
obesity with insulin resistance (494, 495), suggest that obesity leads to a state of leptin
resistance and adiponectin deficiency.
Interestingly, TNF-alpha, whose expression is reported to increase in insulinresistant conditions, appears to have an antagonistic relationship with adiponectin.
Studies have shown that TNF-alpha expression dose-dependently reduces adiponectin
expression in adipocytes by suppressing its promoter activity (496). Conversely,
adiponectin attenuates the secretion of TNF-alpha from monocytes and macrophages
(496). Moreover, increased adiponectin levels appear to reduce TNF-alpha-induced
expression of adhesion molecules in vascular smooth muscle cells (VSMCs) (497).
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Data published by Green et al. suggests that dietary iron overload induces insulin
resistance in mice (484). In their study, the authors concluded that iron accumulation
within adipose tissue may result in decreased expression of adiponectin (484). In line
with this data, other studies have shown that serum ferritin concentrations are inversely
related to adiponectin concentrations (498).
Iron and insulin-sensitizing agents Thiazolidinediones (TZs) are a class of
medications also known as the glitazones, which are commonly used to treat
T2DM. Administration of TZ has been shown to improve insulin sensitivity (i.e. via
lowering circulating glucose and insulin concentrations) by increasing adiponectin gene
expression (411) as well as increasing the rate of mitochondrial beta oxidation of FFAs,
which decreases FFA concentrations and reduces FFA turnover (411). It has also been
suggested that TZs increase mitoNEET expression, a putative direct mitochondrial target for
TZs (499). mitoNEET is an iron-sulfur protein residing within the outer mitochondrial
membrane (499) and increases in mitoNEET expression have been shown to increase the rate
beta oxidation (500), which, as mentioned above, decreases FFA concentrations (411). This
leads one to hypothesize that TZs may be involved in balancing the NAD/NADH ratio, as
previously discussed.
Iron and FFAs The observation that FFAs are siderophores is based upon a
serendipitous discovery in 1991 which began with publications demonstrating that
alveolar macrophages in smokers accumulate large amounts of iron (501). Given that
macrophages phagocytose senescent erythrocytes, the authors hypothesized that the
erythrocytes in smokers were somehow accumulating iron. Although organic extracts
of cigarette smoke do not contain significant amounts of iron, previous work by Qian and
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Eaton had shown that particulate matter from cigarette smoke contained significant
amounts of FFAs. This lead the authors to hypothesize that FFAs bind iron and transfer it
to erythrocyte membranes. The authors then used mass spectroscopy to identify the
purported iron-binding FFAs in cigarette smoke as strearic and palmitic acid. While
Qian and Eaton did not provide data on the definitive structure of the presumed iron:FFA
complex, they did hypothesize that the complex forms as a result of the interaction
between iron and the carboxylic esters of FFAs (e.g., RCOO:Fe), where the hydrocarbon
tails of FFAs are capable of forming a metal chelate, which readily binds iron through an
ionic interaction. It therefore became plausible that once erythrocytes had reached the end
of their lifespan, they were then phagocytosed by macrophages and this accounted for the
observation that alveolar macrophages in smokers had increased amounts of iron.
Nalini and Balasubramanian were the next group to demonstrate that FFAs
bind iron, showing that 3 to 4 moles of FFAs are required to bind 1 mole of iron
(502). More recently, Boiteau et al. have shown that marine microbes employ the
same mechanism to bind iron in conditions of iron scarcity (503). Other authors (504)
have gone so far to suggest that iron absorption in the GI tract may also involve FFAs in
addition to more widely-known mechanisms of iron absorption, discussed in chapter 2.
Conclusion It appears biologically plausible that iron stores are associated with
the initiation, promotion and progression of insulin resistance. Lending support to this
hypothesis are studies showing that FFAs are siderophores for iron and that iron activates
Kuppfer cells, increases both inflammation and the expression of inflammatory mediators
and, as mentioned in Chapter 2, is a pro-oxidant capable of generating ROS and the
propagation of lipid peroxidation. Much more population-based research is needed to
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tease apart the magnitude of the associations between iron stores and insulin resistance.
To this end, predictive, non-invasive, and inexpensive analytes unaltered by
inflammation would be valuable for use in monitoring the iron status of those at risk for
developing insulin resistance. To my knowledge, no study to date has employed the
algorithm developed by JD Cook et al. in 2003 (50) as an index for iron repletion for use
in examining the association between the former and insulin resistance.
Summary
The relationships between T2DM, metabolic syndrome, NAFLD and insulin
resistance and increased body iron warrants further investigation. Given the iron-replete
status of much of the U.S. population, in particular post-menopausal females, it is
necessary to increase the sensitivity and specificity of existing estimates of body iron
status or to develop novel, non-invasive, and cost-effective procedures to assay individual
iron status across the reproductive lifespan.
Predictive biomarkers obtained from serum which correlate with the above
mentioned etiological and pathological hallmarks of metabolic dysfunction are of interest
in epidemiology and public health due to their value in disease screening, prevention, and
treatment. Thus, assays apart from hemoglobin, hematocrit, serum iron, transferrin
saturation, total iron binding capacity, or serum ferritin, unaltered by inflammation or
liver function would provide increased value in monitoring the iron status of females
across the reproductive lifespan.
To my knowledge, the index of iron repletion developed by Cook et al. in 1993
(50), has received no attention in the epidemiological literature with regard to its
association with metabolic dysfunction (i.e., Type 2 diabetes mellitus (T2DM) defined by
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the World Health Organization (WHO); metabolic syndrome defined by the National
Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP III); non-alcoholic
fatty liver disease (NAFLD) defined by the U.S. Fatty Liver Index (U.S.-FLI); insulin
resistance defined by the HOMA-IR) in any population sample.
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CHAPTER 5: RESEARCH METHODS
Study population
The study population was comprised of nonpregnant, community-dwelling
females aged 12-49 participating in the continuous NHANES 2003-2010 survey with
complete data for all parameters of interest. Since 1999, the National Health and
Nutrition Examination Survey (NHANES) has collected cross-sectional data every two
years on the health and nutritional status of the community-dwelling U.S. population.
NHANES data were not obtained using a simple random sample. Rather, the survey
obtains a stratified, multistage (i.e., four stages) probability sample designed to represent
the U.S. population on the basis of age, sex, and race-ethnicity. The NHANES sampling
procedure consisted of four stages. Stage one consisted of primary sampling units
(PSUs), which were selected from strata defined by geography and proportions of
minority populations. Primary sampling units were mostly single counties or, in a few
cases, groups of contiguous counties selected with probability proportional to a measure
of size (PPS). Most strata contained two PSUs. Additional stages of sampling were
performed to select various types of secondary sampling units (SSUs), namely the
segments, households, and individuals that were selected in Stages 2, 3, and 4. In stage
two, the PSUs were divided into segments (generally, city blocks or their equivalent). As
with each PSU, sample segments were selected with PPS. During stage three, households
within each segment were listed, and a sample was randomly drawn. In geographic areas
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where the proportion of age, ethnic, or income groups selected for over-sampling is high,
the probability of selection for those groups was greater than in other areas. Finally, in
stage four, individuals were chosen to participate in NHANES from a list of all persons
residing in selected households. Individuals were selected at random within designated
age-sex-race/ethnicity screening sub-domains. On average, 1.6 persons were selected per
household (505). Because of the differential probabilities of selection, sampling weights
were created that reflected the base probabilities of selection, adjustment for nonresponse, and post-stratification. All subjects have hitherto provided written informed
consent and the study was approved by the National Center for Health Statistics
Institutional/Ethics Review Board.
Data collection procedures
The current work was a secondary analysis of an ongoing population-based
cross-sectional study. Briefly, NHANES data were released for public consumption in
2-year cycles. Just as each year's sample was representative of the resident, communitydwelling U.S. population, the same was true for each 2-year cycle of data. In order to
have sufficient sample sizes to obtain stable estimates for population subgroups of
interest, however, data cycles spanning the years 2003-2010 were pooled to increase
statistical power. Baseline data for continuous NHANES were collected during an inhome interview and a subsequent visit to a mobile examination center. During the inhome interview, a standardized questionnaire was used to collect demographic and
health-related information including age, race-ethnicity, sex, level of education, alcohol
consumption, reproductive health, and use vitamin supplementation. The response rate
for all females during the interview for 2003-2004, 2005-2006, 2007-2008 and 2009-
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2010 were 80%, 80.9%, 78.6% and 79.7%, respectively (506-509). During the mobile
examination, biochemical parameters were collected along with anthropometric
measurements. The response rate during the examination for 2003-2004, 2005-2006,
2007-2008 and 2009-2010 were 76%, 77.8%, 75.5% and 77.4%, respectively (506-509).
Subjects with probable hemochromatosis (N = 304) based upon abnormal values of
several iron markers (i.e., serum iron > 175 μg/dL, serum ferritin > 200 μg/L, and
transferrin saturation > 60%), with reported hepatitis C infection (N = 328) or who
reported being pregnant (N = 695) were excluded.
Variable ascertainment and Instrumentation
Predictor Variables In 2003, Cook et al. (50) developed an algorithm to calculate an
index of iron repletion, which is given by the equation FeCOOK (mg/kg) = (−[log10(𝑅 ∗
1000/𝐹) − 2.8229])/0.1207, where R = serum transferrin receptor (mg/L) and F =
serum ferritin (mcg/L). When the index was developed, serum transferrin receptor
concentrations were input into the equation in micrograms per liter. I thus converted
milligrams per liter to the required unit by multiplying by 1,000. Serum transferrin
receptor is primarily derived from developing red blood cells, reflects the magnitude of
erythropoiesis and the body’s demand for iron. Ferritin is an intracellular protein whose
primary function is iron storage. When measured independently, levels of serum
transferrin receptor decrease and levels of ferritin increase with increasing iron
intake/absorption. When employing the equation developed by Cook et al., however, the
derived value scales proportionately with increasing/decreasing iron repletion, where
positive values indicate storage of iron and negative values indicate tissue iron
deficiency. In order to develop a more complete understanding of the index, the reader is
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encouraged to visit Appendix 1 for a thorough treatment of FeCOOK and a demonstration
of the mechanics of the index via eight simulations.
Contributing to the practical value of the equation, iron repletion can be assessed
using serum alone, obviating the need for the collection of whole blood. Furthermore,
since the function is a ratio of two analytes in serum, it is not adversely affected by
hemoconcentration or hemodilution, as hemoglobin or hematocrit would be. Finally,
unlike ferritin, the derived value of the function is less altered by chronic inflammation.
During NHANES data collection, serum ferritin was measured using two
methods. In 2003, a single-incubation two-site immunoradiometric assay (BioRad
Laboratories, Hercules, CA) was used. The assay was discontinued by the manufacturer
in early 2004, so ferritin was measured in 2004– 2010 by the Roche Tina-quant ferritin
immunoturbidimetric assay on the Hitachi 912 clinical analyzer (Roche Diagnostics,
Indianapolis, IN) (510), where latex-bound ferritin antibodies react with the antigen in the
same to form an antigen-antibody complex and this was measured turbidimetrically.
Because of methodological differences between the BioRad and Roche ferritin assays,
concentrations obtained for 2003 samples with the BioRad assay were statistically
adjusted in order to be comparable with those obtained for 2004-2010 samples with the
Roche assay. This was accomplished before the data release by the National Center for
Health Statistics NCHS by applying 3 piecewise linear-regression equations described in
detail elsewhere (510).
In accordance with the methods of Cogswell et al. (511), I converted the Roche
sTfR concentrations to those equivalent to the Flowers assay used in the development of
the body iron model in the original studies. I then applied the same conversion equation
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in the current study derived from a previous comparison of the 2 assays used by Cogswell
et al. (511): Flowers sTfR = [1.5(Roche sTfR) + 0.35 mg/L]. I used the original Roche
ferritin concentrations for the body iron calculation because a previous comparison of the
Roche assay with the enzyme-linked immunosorbent assay method used by Skikne et al.
(512) and Cook et al. (50) in the calculation of body iron showed no difference between
these 2 methods.
From 2003–2010, hemoglobin and hematocrit were measured as part of a
complete blood count in the NHANES mobile examination centers with the Beckman
CoulterMAXM hematology flow cytometer (Beckman Coulter Inc, Fullerton, CA), where
the lytic reagent used for the complete blood count (CBC) parameters prepares blood so
that the system can count leukocytes and sense the amount of hemoglobin. The lytic
reagent rapidly and simultaneously destroys the erythrocytes and converts a substantial
proportion of the hemoglobin to a stable pigment while it leaves leukocyte nuclei intact.
The absorbance of the pigment is directly proportional to the hemoglobin concentration
of the sample. The accuracy of this method equals that of the hemiglobincyanide method,
the reference method of choice for hemoglobinometry recommended by the International
Committee for Standardization in Hematology (ICSH).
Hematocrit was computed as the product of red blood cell count (RBC) and mean
corpuscular volume (MCV) / 10. Serum iron and unsaturated iron-binding capacity were
measured at Collaborative Laboratory Services in Ottumwa, Iowa, by the automated
Beckman LX20 (Beckman Coulter, Fullerton, CA). Total iron-binding capacity (TIBC)
was calculated indirectly from serum iron and unsaturated iron-binding capacity plus the
iron concentration. Transferrin saturation (%) was calculated by dividing the
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concentration of serum iron (μmol/L) by the total iron-binding capacity (μmol/L). Dietary
and supplemental iron intake was assessed during the in-home interview using a
standardized 24-hour dietary recall questionnaire.
Outcome Variables Insulin resistance in the current work was determined among
subjects using the homeostasis model assessment (HOMA-IR) developed by Matthews et
al. in 1985 to describe glucose and insulin homeostasis via a set of mathematicallyderived nonlinear equations (513). The physiological basis for HOMA-IR is encapsulated
by the relationship between basal concentrations of glucose and insulin which reflect the
action of a negative feedback-loop between hepatic glucose release and pancreatic beta
cell activity (513). In this feedback loop, hepatic insulin resistance can be estimated
based on reduced insulin secretion by beta cells, which leads to increased hepatic glucose
efflux. The resulting increase in plasma glucose stimulates increased secretion of insulin
within the portal vein until glucose levels return to normal, thereby completing the
feedback loop. The basal plasma insulin levels necessary to maintain normal glucose
levels are directly proportional to the degree of insulin resistance (513). Based upon the
aforementioned interactions between liver and pancreatic beta cells, Matthews et al.
developed an approximating equation for insulin resistance, which is derived from the
use of the insulin-glucose product, divided by a constant, and was calculated as
𝐻𝑂𝑀𝐴 − 𝐼𝑅 =  ((𝐹𝑃𝐼𝑥𝐹𝑃𝐺))/22.5
where FPI fasting plasma insulin concentration (mU/L) and FPG = fasting plasma
glucose (mmol/L). The product of FPG × FPI provides an index of hepatic insulin
resistance. The constant of 22.5 is a normalizing factor (i.e., the product of fasting plasma
insulin of 5 µU/mL and fasting plasma glucose of 4.5 mmol/L is assumed to be typical of
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a typical healthy individual). HOMA-IR has been validated in several study populations
to be an accurate, reliable, and non-invasive means with which to determine the presence
of insulin resistance in humans.
In the 2003-2004 NHANES sample, fasting plasma insulin concentration
(uIU/mL) was measured using the Tosoh AIA-PACK IRI assay (Tosoh Bioscience,
Prussia, PA), which is a two-site immunoenzymometric assay performed entirely within
the AIA-PACK. For this assay, insulin present in the test sample was bound with a
monoclonal antibody which was immobilized on a magnetic solid phase and enzymelabeled monoclonal antibody within the AIA-PACK. The magnetic beads were washed to
remove unbound enzyme-labeled monoclonal antibodies and were then incubated with
the fluorogenic substrate, 4-methylumbelliferyl phosphate (4MUP). The amount of
enzyme-labeled monoclonal antibody bound to the beads was directly proportional to the
IRI concentration in the test sample. For the years spanning 2005-2010, the Merocodia
Insulin ELISA assay (Mercodia Inc, Winston Salem, NC) was used to measure fasting
plasma insulin. This assay is a two-site enzyme immunoassay which utilizes the direct
sandwich technique where two monoclonal antibodies are directed against separate
antigenic determinants of the insulin molecule. Specimen, control, or standard were
pipetted into the sample well followed by the addition of peroxidase-conjugated antiinsulin antibodies. Insulin present in the sample binds to anti-insulin antibodies bound to
the sample well, while the peroxidase-conjugated anti-insulin antibodies also bind to the
insulin at the same time. After washing to remove unbound enzyme-labelled antibodies, a
labelled substrate was added which binds to the conjugated antibodies. Acid was then
added to the sample well to stop the reaction and the colorimetric endpoint was read on a
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microplate spectrophotometer set to the appropriate light wavelength. No conversion was
necessary for entry of insulin into the HOMA-insulin resistance equation, as uIU/mL is
equivalent to mU/L.
Fasting plasma glucose concentration (mmol/L) was determined by a standard
hexokinase method using the Roche Cobas Mira platform for years 2003-2004, the
Roche/Hitachi 911 platform for years 2005-2006 and the Roche Modular P chemistry
analyzer (Roche Diagnostics, Indianapolis, IN) for years 2007-2010, where the enzyme
catalyzes the reaction between glucose and adenosine triphosphate (ATP) to form
glucose-6-phosphate (G6P) and adenosine diphosphate (ADP). In the presence of
nicotinamide adenine dinucleotide (NAD), G-6-P is oxidized by the enzyme glucose-6phosphate dehydrogenase (G6PD) to 6-phosphogluconate and reduced nicotinamide
adenine dinucleotide (NADH). The increase in NADH concentration is directly
proportional to the glucose concentration and can be measured spectrophotometrically at
340 nm.
To determine the presence of non-alcoholic fatty liver disease (NAFLD) among
subjects, I used the U.S.-Fatty Liver Index (U.S.-FLI) developed by Ruhl et al. in 2015
which was calculated as
U.S.-FLI = 𝑒^(−0.8073(𝑁𝐻𝐵) + 0.3458(𝐻) + 0.0093(𝑎𝑔𝑒) + 0.6151(ln(𝐺𝐺𝑇)) +
0.0249(𝑤𝑐) + 1.1792(ln(𝑖𝑛𝑠)) + 0.8242(ln(𝑔𝑙𝑢)) − 14.7812)/(1 + 𝑒^(−0.8073(𝑁𝐻𝐵) +
0.3458(𝐻) + 0.0093(𝑎𝑔𝑒) + 0.6151(ln(𝐺𝐺𝑇)) + 0.0249(𝑤𝑐) + 1.1792(ln(𝑖𝑛𝑠)) +
0.8242(ln(𝑔𝑙𝑢)) − 14.7812)) * 100,

where NHB = non-Hispanic black ethnicity (i.e., scored as ‘1’ if the participant is of that
ethnicity, ‘0’ otherwise), H = Hispanic ethnicity (i.e., scored as ‘1’ if the participant is of
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that ethnicity, ‘0’ otherwise), GGT = gamma-glutamyl transferase (U/L), wc = waist
circumference (cm), ins = insulin (uIU/mL), glu = glucose (mg/dL). As is evident in the
equation, the U.S.-FLI is an algorithm based upon demographic measures (i.e., ethnicity,
age) an anthropomorphic measure (i.e., waist circumference) and analytes obtained from
serum (i.e., GGT, insulin, glucose). The U.S.-FLI ranges from 0 to 100 (35) and has been
validated with a sensitivity of 62% and specificity of 88% (PPV = 5.2, NPV = 0.43) when
using a cut-off of ≥ 30 to define the presence of fatty liver (35).
Ruhl et al. derived the U.S.-FLI using stepwise regression with backward
elimination after noting that the development of the fatty liver index (FLI) by Bedogni et
al. (30) 1) assumed that insulin was not a widely available measurement in populationbased studies, 2) was based upon a homogeneous sample (i.e., the FLI did not account for
ethnicity) and 3) did not account for age. As previously mentioned, the prevalence of
NAFLD is associated with insulin resistance, varies across ethnicities and increases with
age. Thus, an index of fatty liver which incorporates these three factors might be
considered more reliable in risk stratification. Moreover, the U.S.-FLI incorporates GGT,
which has been shown in previous research (e.g., used alone or with ALT and AST) to be
a reliable marker of liver injury. Levels of GGT increase due to excessive alcohol intake,
hyperlipidemia, obesity, diabetes or when using certain medications (e.g., aspirin,
phenobarbital, phenytoin, steroids, tamoxifen, tetracycline). GGT is expressed within the
blood-brain barrier, astrocytes, white blood cells, participates in receptor-ligand
interactions at cell membranes and concentration of GGT appears to better differentiate
between alcoholic fatty liver disease and non-alcoholic fatty liver disease compared to
ALT or AST (514). GGT functions to maintain the available pool of intracellular cysteine
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by breaking down extracellular glutathione (GSH). Thus, as levels of intracellular
cysteine diminish due to hepatic injury, concentration of GGT increases to convert
circulating GSH to its amino acid constituents (i.e., cysteine, glycine, glutamic acid) in
order to restore the pool of available cysteine.
From 2003-2006, GGT (U/L) was measured using the Beckman Synchron LX20
(Beckman Coulter, Fullerton, CA). The LX uses an enzymatic rate method to determine
the GGT activity in serum or plasma. In the reaction, the GGT catalyzes the transfer of a
gamma-glutamyl group from the colorless substrate, gamma-glutamyl- p-nitroaniline, to
an acceptor, glycylglycine where the production of a colored product, p-nitroaniline,
occurs. The system monitors the rate of change in absorbance at 410 nm over a fixedtime interval. The rate of change in absorbance is directly proportional to the activity of
GGT in the sample. From 2007-2010, GGT was measured using the Beckman Synchron
LX20 and the Beckman Unicel DxC800 Synchron platform (Beckman Coulter, Fullerton,
CA). The DxC800 uses the same chemistry as the LX20 and measurements appear to
have been used to cross-validate those obtained from the LX20.
In the current work, the presence of hepatic fibrosis was determined using the
method developed by Angulo et al. in 2007, called the NALFD fibrosis score (NFS). The
NFS was derived as follows:
NFS = −1.675 + 0.037(age) + 0.094(BMI) + 1.13(IFG or T2DM) + 0.99(𝐴𝑆𝑇/𝐴𝐿𝑇) –
0.013(platelets) −0.66(albumin),
where BMI = body mass index, IFG = impaired fasting glucose (defined as having a
fasting plasma glucose concentration of ≥ 110 mg/dL and T2DM = type 2 diabetes
mellitus (i.e., scored as ‘1’ if either condition is present, ‘0’ otherwise)). AST = aspartate

120

aminotransferase (U/L) and ALT = alanine aminotransferase (U/L). Platelets are entered
into the equation in units of cells per liter (i.e., 1000 cells/uL) and albumin is entered into
equation as g/dL. According to Augulo et al., advanced fibrosis is defined as having an
NFS > 0.676 (515).
During the NHANES mobile examination, unassisted standing height was
measured in meters as the maximum value recorded by a fixed stadiometer whose inputs
were sent to a computer for reading and storage. Weight (kg) was measured in a standing
position by a digital weight scale. Waist circumference was measured in a standing
position, above the uppermost lateral border of the right ilium to the nearest 0.1 cm using
a soft tape measure. BMI was calculated after obtaining a subject’s height and weight via
the following standard equation: (𝑤𝑒𝑖𝑔ℎ𝑡(𝑘𝑔))/(ℎ𝑒𝑖𝑔ℎ𝑡(𝑚)^2) and categorized in
accordance with the WHO BMI classification scheme (i.e., < 18.5 underweight, 18.5 –
24.9 normal weight, 25.0 – 29.9 overweight or > 29.9 obese). After resting quietly in a
sitting position for 5 minutes and determining the maximum inflation level after cuff
adjustment, three to four systolic and diastolic blood pressure measurements were
obtained using a mercury sphygmomanometer in accordance with the protocol of the
American Heart Association.
From 2003–2010, platelets were measured as part of a complete blood count in
the mobile examination centers with the Beckman CoulterMAXM hematology flow
cytometer (Beckman Coulter Inc, Fullerton, CA), where the lytic reagent used for the
complete blood count (CBC) parameters modifies the blood in a reaction so that the
system can count platelets based upon the principles of light scattering. Platelets were
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identified by their size (< 30 FL, low angle light scatter) and refractive index (N = 1.35 to
N = 1.40 or high angle light scatter.
The concentration of serum albumin was determined by the Beckman Synchron
LX20 using a bichromatic digital endpoint method. Briefly, using this method albumin
combines with Bromcresol Purple (BCP) reagent in a reaction to form a complex which
absorbs light at 600nm. The system thus monitors the change in absorbance at 600 nm,
which is directly proportional to the concentration of albumin in the sample.
From 2003-2006, triglycerides (mg/dL) were measured with the Beckman
Synchron LX20 (Beckman Coulter, Fullerton, CA), where a timed-endpoint method was
used to determine the concentration of these esters in serum or plasma. Triglycerides in
the sample are hydrolyzed to glycerol and free fatty acids by the action of lipase. A
sequence of three coupled enzymatic steps using glycerol kinase (GK), glycerophosphate
oxidase (GPO), and horseradish peroxidase (HPO) causes the oxidative coupling of 3,5dichloro-2-hydroxybenzenesulfonic acid (DHBS) with 4-aminoantipyrine to form a red
quinoneimine dye. The system monitors the change in absorbance at 520 nm for a fixedtime interval. The change in absorbance is directly proportional to the concentration of
triglycerides in the sample. From 2007-2010, trigylcerides were also measured using the
Backman Synchron LX20 and the Beckman Unicel DxC800 Synchron platform
(Beckman Coulter, Fullerton, CA). The Unicel DxC800 Synchron uses the same
chemistry as the LX20 and measurements appear to have been used to cross-validate
those obtained from the LX20.
HDL cholesterol (mg/dL) was measured using the direct HDL method, where the
lipoprotein is obtained from serum and quantified via an enzymatic reaction on the
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Hitachi 912 Analyzer (Roche Diagnostics, Indianapolis, IN). During the assay reaction,
apolipoprotein B (apoB) containing lipoproteins in the specimen are reacted against a
blocking reagent which renders them non-reactive with a separate enzymatic cholesterol
reagent. The apoB containing lipoproteins are thus effectively excluded from the assay
and only HDL cholesterol is detected at an absorbance of 600nm.
From 2003-2010, there were three HbA1c laboratory platforms and two
laboratories used in NHANES. HbA1c measurement (%) was performed in the first
laboratory on the Primus CLC330 platform (Primus Diagnostics, Kansas City, MO)
platform from 2003-2004 and in the second laboratory on the Tosoh A1C 2.2 Plus
platform (Tosoh Bioscience, Prussia, PA) platform from 2005-2006. From 2007-2010,
HbA1c measurements were performed in the second laboratory on the Tosoh A1C G7
platform (Tosoh Bioscience, Prussia, PA). Laboratory method cross-over studies were
conducted at the time of each of the laboratory instrument changes. Both laboratories
analyzing NHANES HbA1c data from 2003-2010 were standardized by participating in
the National Glycohemoglobin Standardization Program (NGSP).
Covariates Age (defined continuously and categorically defined as 12-21 years
of age, 22-31 years of age, 32-41 years of age and > 41 years of age), ethnicity (defined
as non-Hispanic white, Hispanic and non-Hispanic African American), and education
(defined as (1) less than high school diploma, (2) high school diploma/GED, (3) some
college or (4) college degree/post-graduate degree) were obtained during the structured
in-home interview questionnaire. As mentioned above, anthropomorphic measurements
were obtained during the mobile examination and body mass index was calculated using
these measurements. Alcohol intake (defined as the number of drinks per day and
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categorically defined as 0 drinks/d, 1-3 drinks/d or > 3 drinks/d), smoking status (defined
as the number of cigarettes smoked per day and categorically defined as 0 cigarettes/d, 15 cigarettes/d or > 5 cigarettes/d) and physical activity (defined as the sum of metabolic
equivalent scores (METS) and categorically grouped by METS tertiles) were obtained
using the structured in-home interview questionnaire. Data on dietary recall and food
frequency was obtained during each participant’s mobile examination and again three to
ten days later via telephone interview. Age at menarche (defined continuously and
categorized as < 12 years of age, 12 years of age or > 12 years of age), oral contraceptive
use (dichotomously defined as YES/NO) and parity (defined as the number of children
each female has given birth to and categorically defined as 0 children, 1 child, 2-3
children or > 3 children) was obtained during the in-home interview using a structured
reproductive history questionnaire. Menopause was defined to align with previous
literature (Taylor et al. 2014). Briefly, females aged 18 years of age and older were asked
“Have you had at least one menstrual period in the past 12 months? (Please do not
include bleedings caused by medical conditions, hormone therapy, or surgeries).”
Females who answered “no” to this question were subsequently asked “What is the
reason that you have not had a period in the past 12 months?” Females were classified as
premenopausal if they answered “yes” to the first question or answered “no” to the first
question but indicated the reason as pregnancy, breastfeeding, irregular periods or
medical conditions/treatments. Females were classified as postmenopausal if they
answered “no” to the first question and indicated the reason to be natural menopause or
hysterectomy (516).
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Summary In the current analysis, I have examined the effect of age, ethnicity,
education, body composition, alcohol consumption, smoking history, level of physical
activity, dietary and supplemental iron intake, promoters and inhibitors of iron
absorption, age at menarche, oral contraceptive use, parity, menopausal status, length of
reproductive lifespan and FeCOOK to evaluate their respective impact on metabolic
dysfunction.
Variable coding and data analyses
Descriptive Statistics Continuous variables (e.g., age, age at menarche, age at
menopause, length of reproductive lifespan, hemoglobin, hematocrit, serum iron, total
iron binding capacity, transferrin saturation, dietary iron intake, FeCOOK, fasting plasma
insulin, fasting plasma glucose, gamma-glutamyl transferase, triglycerides, waist
circumference, systolic blood pressure, diastolic blood pressure, HDL cholesterol, HbA1c)
were summarized with standard descriptive statistics including means, medians, standard
deviations, and ranges. Categorical variables (e.g., ethnicity, education, BMI, alcohol
consumption, smoking history, oral contraceptive use, parity, menopausal status, FeCOOK
category, presence/absence of T2DM, presence/absence of metabolic syndrome, U.S.-FLI
category, HOMA-IR category) were summarized as frequencies and percentages. Ninetyfive percent confidence intervals have been provided for descriptive statistics.
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Categorical Outcomes
The presence of Type 2 diabetes mellitus (T2DM) was determined using WHO
guidelines and scored as present (i.e., NO = 0, YES = 1) if any of the following criteria
are met: fasting glucose ≥ 126 (mg/dL), HbA1c ≥ 6.5 (DCCT%), self-reported diagnosis
of T2DM, or self-reported use of medications used to treat T2DM. The presence of
metabolic syndrome (metabolic syndrome) was defined according to the definition set
forth by ATP III as follows: waist circumference > 35 inches in females, elevated blood
pressure (diastolic > 85 mmHg & / systolic > 130 mm Hg in females), HDL cholesterol <
50 mg/dL in females, fasting plasma glucose > 100 mg / dL, and triglycerides > 150
mg/dL and scored as present (i.e., NO = 0, YES = 1) if three or more of the above criteria
are met. NAFLD was scored as present (i.e., NO = 0, YES = 1) using the cutoffs
developed by Ruhl et al. for the U.S.-FLI, where a score ≥30 denotes the presence of
NAFLD (35). NFS was scored as present (i.e., NO = 0, YES = 1) using the cutoff
developed by Angulo et al., where a score > 0.676 denotes the presence of advanced
fibrosis (515). HOMA-IR was modeled by creating the following categories: < 3: normal
insulin resistance, 3-5: moderate insulin resistance, > 5: severe insulin resistance and
collapsed into a binary variable and modeled as follows: 0 – 5 normal to moderate insulin
resistance, > 5 severe insulin resistance.
If data for the primary predictor variable (i.e., FeCOOK) or any outcome variables
with > 2 categories (i.e., NAFLD using U.S.-FLI, insulin resistance using HOMA-IR)
were too sparse, data from the first two tertiles/categories was collapsed in order to create
a dichotomous variable (e.g., 1st and 2nd vs. 3rd tertile/category for a given variable). Odds
of T2DM, metabolic syndrome, NAFLD and/or insulin resistance was determined
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between FeCOOK groups using the standard formula 𝑂𝑅 =  (𝑎𝑖 ∗ 𝑑𝑖))/(𝑏𝑖 + 𝑑𝑖)), where
ai is the number of events for subject i in the highest FeCOOK tertile, bi is the number of
non-events for subject i in the highest FeCOOK tertile, ci is the number of events for
subject i in the lowest two FeCOOK tertiles, and di is the number of non-events for subject i
in the lowest two FeCOOK tertiles.
Categorical outcomes were analyzed using chi-square tests (e.g., one categorical
predictor and categorical outcome variable), logistic regression (e.g., one continuous
predictor variable and one dichotomous outcome variable), or loglinear models (e.g., > 1
categorical predictor variable and one categorical outcome variable), where appropriate,
by applying PROC SURVEY procedures to account for the NHANES study design. Point
estimates (i.e., odds ratios) and ninety-five percent confidence intervals have been
provided.

Continuous Outcomes
U.S.-FLI and HOMA-IR were also modeled as continuous outcomes to examine
the effect of FeCOOK when the latter is treated as both a continuous and categorical
predictor. Diagnostics were performed on the data to determine appropriate statistical
modeling prior to all analyses. When standard modeling assumptions were upheld for
continuous outcomes and when FeCOOK was treated as a continuous predictor, statistically
significant associations were determined using linear regression and/or Pearson
correlation. When standard modeling assumptions were met for continuous outcomes and
when FeCOOK was treated as a categorical predictor, statistically significant differences in
outcomes as a function of FeCOOK tertile were evaluated using independent t-tests.
127

Wilcoxon Rank-Sum tests were applied when standard modeling assumptions were not
met.
Power & Sample Size Given the cross-sectional study design of the current
secondary analysis, total sample size during continuous NHANES from 2003 to 2010 is
immutable. Therefore, I calculated the statistical power to detect each outcome, given the
observed sample size. Power estimates were calculated across varying effect sizes, while
assuming equal alpha allocation across each of the four metabolic conditions (i.e., p =
0.05 / 4 = 0.0125) in accordance with the method proposed by Wittes (517).
Decision Rule The above experiment-wise alpha allocation does not account for
multiple testing, thus the Sidak correction (518) was employed using the formula 1 – (1α)1/n where n is the number of independent tests (e.g., in the current proposed study, 10
tests were conducted for each of the four primary hypotheses) and α is the nominal level
of statistical significance established in the above power and sample size calculations
(i.e., 0.0125) to control for false positive findings. Thus, the level of statistical
significance for any finding must fall below p = 0.00125. All data management and data
analysis programs were written using SAS v9.4 (519).
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Statistical Models (in order of each hypothesis listed in the aims section)

Aims 2A1 – 2A6 & Aims 2B1-2B3

a) 2A1 & 2B1: FeCOOKi = αi + β1iethnicityX1i + εi
b) 2A2: FeCOOKi = αi + β1ieducationX1i + εi
c) 2A3: FeCOOKi = αi + β1iBMIX1i + εi
d) 2A4: FeCOOKi = αi + β1ioral contraceptive useX1i + εi
e) 2A5: FeCOOKi = αi + β1iage at menopauseX1i + εi
f) 2B2: FeCOOKi = αi + β1iage at menarcheX1i + εi
g) 2B3: FeCOOKi = αi + β1iparityX1i + εi
where α is the model intercept, β1 is the beta coefficient associated with predictor
variable 1 through n, modeled independently, for subject i and ε is the associated
error term of the statistical model.
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Aim 3A.1 insulin resistance:

a)

insulin resistancei = αi + β1iFeCOOKX1i + εi

b)

insulin resistancei = αi + β1iFeCOOKX1i + β2iageX2i + εi

c)

insulin resistancei = αi + β1iFeCOOKX1i + β2ethnicity X2i + εi

d)

insulin resistancei = αi + β1iFeCOOKX1i + β2educationX2i + εi

e)

insulin resistancei = αi + β1iFeCOOKX1i + β2BMIX2i + εi

f)

insulin resistancei = αi + β1iFeCOOKX1i + β2age at menarcheX2i + εi

g)

insulin resistancei = αi + β1iFeCOOKX1i + β2oral contraceptive useX2i + εi

h)

insulin resistancei = αi + β1iFeCOOKX1i + β2parityX2i + εi

i)

insulin resistancei = αi + β1iFeCOOKX1i + β2age at menopauseX2i + εi

j)

insulin resistancei = αi + β1iFeCOOKX1i + β2alcohol consumptionX2i + εi

k)

insulin resistancei = αi + β1iFeCOOKX1i + β2smoking historyX2i + εi

l)

insulin resistancei = αi + β1iFeCOOKX1i + β2physical activityX2i + εi

m)

insulin resistancei = αi + β1iFeCOOKX1i + β2C-reactive proteinX2i + εi

n)

insulin resistancei = αi + FeCOOK + age + ethnicity + BMI + alcohol

(Basic Model)

consumption + smoking history + physical activity level + eFe + iFe + Creactive protein + εi, where eFe = enhancers of iron absorption and iFe =
inhibitors of iron absorption.

130

(Full Model)

Aim 3A.2 non-alcoholic fatty liver disease:

a)

logit(NAFLD)i = αi + β1iFeCOOKX1i + εi

b)

logit(NAFLD)i = αi+ β1iFeCOOKX1i + β2iageX2i + εi

c)

logit(NAFLD)i = αi + β1iFeCOOKX1i + β2ethnicity X2i + εi

d)

logit(NAFLD)i = αi + β1iFeCOOKX1i + β2educationX2i + εi

e)

logit(NAFLD)i = αi + β1iFeCOOKX1i + β2BMIX2i + εi

f)

logit(NAFLD)i = αi + β1iFeCOOKX1i + β2age at menarcheX2i + εi

g)

logit(NAFLD)i = αi + β1iFeCOOKX1i + β2oral contraceptive useX2i + εi

h)

logit(NAFLD)i = αi + β1iFeCOOKX1i + β2parityX2i + εi

i)

logit(NAFLD)i = αi + β1iFeCOOKX1i + β2age at menopauseX2i + εi

j)

logit(NAFLD)i = αi + β1iFeCOOKX1i + β2alcohol consumptionX2i + εi

k)

logit(NAFLD)i = αi + β1iFeCOOKX1i + β2smoking historyX2i + εi

l)

logit(NAFLD)i = αi + β1iFeCOOKX1i + β2physical activityX2i + εi

m)

logit(NAFLD)i = αi + β1iFeCOOKX1i + β2C-reactive proteinX2i + εi

n)

logit(NAFLD)i = αi + FeCOOK + age + ethnicity + BMI + alcohol consumption +

(Basic Model)

smoking history + physical activity level + eFe + iFe + C-reactive protein + εi,
where eFe = enhancers of iron absorption and iFe = inhibitors of iron absorption.
(Full Model)
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Aim 3A.3 metabolic syndrome:

a)

logit(metabolic syndrome)i = αi + β1iFeCOOKX1i + εi

b)

logit(metabolic syndrome)i = αi + β1iFeCOOKX1i + β2iageX2i + εi

c)

logit(metabolic syndrome)i = αi + β1iFeCOOKX1i + β2ethnicity X2i + εi

d)

logit(metabolic syndrome)i = αi + β1iFeCOOKX1i + β2educationX2i + εi

e)

logit(metabolic syndrome)i = αi + β1iFeCOOKX1i + β2BMIX2i + εi

f)

logit(metabolic syndrome)i = αi + β1iFeCOOKX1i + β2age at menarcheX2i + εi

g)

logit(metabolic syndrome)i = αi + β1iFeCOOKX1i + β2oral contraceptive useX2i + εi

h)

logit(metabolic syndrome)i = αi + β1iFeCOOKX1i + β2parityX2i + εi

i)

logit(metabolic syndrome)i = αi + β1iFeCOOKX1i + β2age at menopauseX2i + εi

j)

logit(metabolic syndrome)i = αi + β1iFeCOOKX1i + β2alcohol consumptionX2i + εi

k)

logit(metabolic syndrome)i = αi + β1iFeCOOKX1i + β2smoking historyX2i + εi\

l)

logit(metabolic syndrome)i = αi + β1iFeCOOKX1i + β2physical activityX2i + εi

m)

logit(metabolic syndrome)i = αi + β1iFeCOOKX1i + β2C-reactive proteinX2i + εi

n)

logit(metabolic syndrome)i = αi + FeCOOK + age + ethnicity + BMI + alcohol

(Basic Model)

consumption + smoking history + physical activity level + eFe + iFe + C-reactive
protein + εi, where eFe = enhancers of iron absorption and iFe = inhibitors of iron
absorption.

(Full Model)
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Aim 3A.4 Type 2 diabetes mellitus:

a)

logit(T2DM)i = αi + β1iFeCOOKX1i + εi

b)

logit(T2DM)i = αi + β1iFeCOOKX1i + β2iageX2i + εi

c)

logit(T2DM)i = αi + β1iFeCOOKX1i + β2ethnicity X2i + εi

d)

logit(T2DM)i = αi + β1iFeCOOKX1i + β2educationX2i + εi

e)

logit(T2DM)i = αi + β1iFeCOOKX1i + β2BMIX2i + εi

f)

logit(T2DM)i = αi + β1iFeCOOKX1i + β2age at menarcheX2i + εi

g)

logit(T2DM)i = αi + β1iFeCOOKX1i + β2oral contraceptive useX2i + εi

h)

logit(T2DM)i = αi + β1iFeCOOKX1i + β2parityX2i + εi

i)

logit(T2DM)i = αi + β1iFeCOOKX1i + β2age at menopauseX2i + εi

j)

logit(T2DM)i = αi + β1iFeCOOKX1i + β2alcohol consumptionX2i + εi

k)

logit(T2DM)i = αi + β1iFeCOOKX1i + β2smoking historyX2i + εi

l)

logit(T2DM)i = αi + β1iFeCOOKX1i + β2physical activityX2i + εi

m)

logit(T2DM)i = αi + β1iFeCOOKX1i + β2C-reactive proteinX2i + εi

n)

logit(T2DM)i = αi + FeCOOK + age + ethnicity + BMI + alcohol consumption +

(Basic Model)

smoking history + physical activity level + eFe + iFe + C-reactive protein + εi,
where eFe = enhancers of iron absorption and iFe = inhibitors of iron absorption.
(Full Model)
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In terms of a conceptual model, the above associations and statistical models can be visualized as follows:
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Age (+)
Age at menarche (+)
Age at menopause (-)
Parity (-)
Oral contraceptive use (+)
Dietary Iron (+)
Supplemental Iron (+)
Alcohol consumption (+)
Smoking history (+)
Body composition (+)
Physical activity (-)
Education (+)
Ethnicity

Non-alcoholic fatty liver disease

FeCOOK

Insulin Resistance

Metabolic syndrome

Non-insulin dependent diabetes
mellitus

Dashed arrow indicates hypothesized mediation. Bolded arrows identify hypotheses tested in proposed statistical models.

CHAPTER 6: RESULTS

Data from 14,895 females aged 12 years and older during the years 2003-2010
were available for analysis in current study. After excluding females on the basis of
probable hemochromatosis (i.e., serum iron > 175 μg/dL, serum ferritin > 200 μg/L, and
transferrin saturation > 60%) (N = 304), who reported hepatitis C infection (N = 328) or
who reported being pregnant (N = 695), a total of 13,568 remained eligible for inclusion
from the initial pool of participants. Of these eligible females, 7,461 had complete data
that could be used for the calculation of iron repletion (i.e., FeCOOK) (Figure 1).
Demographics The mean age of females in this sample was 27.21 years (sd =
11.64, range: 12 – 49). White females comprised the largest proportion of the sample
population (42.65%, N = 3182), followed by Hispanic (32.30%, N = 2,432) and black
females (24.76%, N = 1,846) (Table 1). Roughly half of the sample population (52.97%)
reported having less than a high school education, 13.22% reported having a high school
diploma/GED equivalent, and 13.34% reported having a college or post-graduate degree.
Four females refused to provide information regarding education (Table 1). When
education was stratified by ethnicity, a greater percentage of white females reported
having a college or post-graduate degree compared to black or Hispanic females (68.1%
vs 17.6% and 14.3%, respectively).
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The average height in the sample population was 161.48 cm (sd = 7.03 cm, range:
132.9 – 194.2 cm). White females tended to be slightly taller than Hispanic and black
females (ẍ = 163.48 cm, sd = 6.68 cm vs 158.03 cm, sd = 6.37 cm and 162.60 cm, sd =
6.75 cm, respectively). The average weight for females in the current sample was 71.01
kg (sd = 20.97 kg: range 24.0-211.7 kg). Black females tended to weigh more than white
or Hispanic females (ẍ = 76.37 kg, sd = 24.19 kg vs 70.57 kg, sd = 20.42 kg and 67.53
kg, sd; = 18.05 kg, respectively). The average waist circumference for participants was
89.33 cm (sd = 16.85, range: 55.0 - 176.7 cm). Black females tended to have larger waist
circumferences than white or Hispanic females (ẍ = 90.74 cm, sd = 19.20 cm vs 88.67
cm, sd = 16.67 cm and 88.14 cm, sd = 15.05 cm, respectively. The mean BMI for females
in the sample population was 27.14 (sd = 7.47, range: 13.59 – 84.87). Most females had a
BMI between 18.5 and 24.9 (41.21%), followed by 29.45% having a BMI > 29.9,
23.88% having a BMI between 25.0 and 29.9 and 5.46% having a BMI < 18.5 (Table 1).
On average, white females had a lower BMI (ẍ = 26.34, sd = 7.20) than Hispanic females
(ẍ = 26.97, sd = 6.70) and black females (ẍ = 28.77, sd = 8.56). Moreover, when
collapsing the lowest two WHO BMI categories and collapsing the highest two WHO
BMI categories to create a dichotomous BMI variable (e.g., underweight to normal
weight vs. overweight to obese), a greater proportion of white females were categorized
in the former group compared to the latter (53.12% vs. 46.88%). This pattern reversed for
Hispanic females (44.02% vs. 55.98%) and was more pronounced for black females
(39.04% vs. 60.96%). When BMI was further stratified by ethnicity, more white females
had a BMI < 18.5 or between 18.5 and 24.9 than Hispanic or black females (47.64% vs.
29.53% and 22.83%; 48.67% vs. 30.96% and 20.37%, respectively). White and Hispanic
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females had similar proportions of BMIs between 25.0 and 29.9 (38.84% and 37.25%,
respectively), while the proportion of black females in this BMI range was smaller
(23.91%). More white females than Hispanic or black females had a BMI > 29.9 (36.42%
vs. 31.86% and 31.72%, respectively). As mentioned, however, white females tended to
have lower BMIs than Hispanic or black females.
Among females who reported drinking alcoholic beverages, the average number
of drinks consumed per day was 0.97 (sd = 1.75). The greatest proportion of females
(62.14%) reported that they did not drink alcoholic beverages, while 30.29% reporting
consuming between 1 to 3 drinks per day and 7.57% reported consuming greater than 3
alcoholic beverages a day (Table 1). When alcohol consumption was stratified by
ethnicity, a greater proportion of white and Hispanic than black females (35.47% and
36.07% vs. 28.46%), reported abstinence from drinking among those in this respondent
category. Among those who did report consuming alcohol, a greater proportion of white
females (54.46%) reported drinking than Hispanic (26.84%) or black females (18.70%).
When categorized further (i.e., 1 – 3 drinks/d vs > 3 drinks/d), a greater proportion of
white females (54.09%) than Hispanic (25.23%) or black females (20.67%) reported
alcohol consumption in this respondent category. Similar patterns were observed for
females reporting to drink greater than 3 alcoholic beverages a day, where a greater
proportion of white females than Hispanic or black females reported alcohol consumption
in this respondent category (55.93% vs 33.27% and 10.80%, respectively).
Among females who reported smoking cigarettes, the average number of
cigarettes smoked per day was 1.92 (sd = 5.87). Similar to the overall pattern observed
for alcohol consumption, however, 82.29% of the sample reported not smoking. The
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remaining 6.78% of females reported smoking 1 – 5 cigarettes per day and 10.93% of
females reported smoking > 5 cigarettes per day. When smoking was stratified by
ethnicity, a greater proportion of white and Hispanic than black females (38.51% and
35.39% vs. 26.10%), reported not smoking among respondents in this category. Among
those who smoked, a greater proportion of white females (61.92%) reported smoking
than Hispanic (19.53%) or black females (18.55%). When categorized further (i.e., 1 – 5
vs > 5 cigarettes/d), a greater proportion of white females reported smoking 1 – 5
cigarettes per day compared to Hispanic or black females (41.70% compared to 36.56%
and 21.74%, respectively). Similar patterns were observed for females in the highest
smoking category, where a greater proportion of white females (74.48%) reported
smoking > 5 cigarettes per day compared to Hispanic females (8.96%) and black females
(16.56%).
The average METS score in the current sample was 9.97 (sd = 9.24). On average,
white females were more active than black and Hispanic females: ẍ = 10.17 (sd = 9.15)
for white females, ẍ = 9.73 (sd = 8.48) for black females and ẍ = 9.29 (sd = 8.49) for
Hispanic females. When METS scores were grouped into tertiles, a greater proportion of
white females were in the highest tertile of METS scores compared to black and Hispanic
females (38.30%, compared to 30.40% and 26.69%, respectively, P < 0.0001).
Females in the current sample reported a mean dietary intake of 13.93 mg/day (sd
= 11.69 mg/day). When stratified by ethnicity, white females reported higher intakes of
dietary iron than Hispanic and black females: ẍ = 14.06 (sd = 10.35), ẍ = 13.88 (sd =
13.51) and ẍ = 13.28 (sd = 10.03), respectively), which was not statistically significant (P
= 0.35). A moderate proportion of females in the current sample reported using iron
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supplements (35.74% (95%CI: 32.23-39.25). When iron supplement use was stratified by
ethnicity, a greater proportion of black females compared to Hispanic and white females
reported using iron supplements (40.46% compared to 38.09% and 34.42%, P = 0.17). In
terms of dietary composition (i.e., USDA food groups), most of the total iron intake
among all females was obtained from grains and meats: 57.16% and 16.98%, respectively
for white females, 58.03% and 17.87% for Hispanic females and 52.66% and 22.98% for
black females. Taken together, black females obtained more of their total daily iron
intake from grains and meats compared to their white and Hispanic counterparts (Figure
2).
For convenience, dietary intakes, supplement intakes and dietary composition of
foodstuffs considered as covariates in the current work are summarized below in terms of
their effect on iron absorption (i.e., enhancers and inhibitors of iron absorption).
Promoters of iron absorption The average intake of saturated fats among
females in the current sample was 22.56 g/d (sd = 19.06 g/d). White females reported
higher intakes of saturated fats than black and Hispanic females: 23.09 g/d (sd = 16.06
g/d), 22.63 g/d (sd = 16.09 g/d) and 20.11 g/d (sd = 17.12 g/d), respectively, a small
fraction of which was obtained from supplements containing saturated fats. Only 3.04%
of white females reported taking supplements containing saturated fats, followed by
Hispanic females and black females (2.39% and 1.54%, respectively, P = 0.20). Overall,
most saturated fats were obtained from milk and milk products, meat, poultry and fish
and grains. The distribution across ethnicities, however, differed. For instance, among
white females, the dietary composition of saturated fats obtained from each of the
aforementioned USDA food groups was 27.84%, 21.46% and 28.58%. Among Hispanic
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females, the dietary composition of saturated fats obtained from each food group was
25.88%, 23.18% and 29.49%. Among black females, the dietary composition of saturated
fats obtained from each food group was 18.76%, 31.06% and 27.76%. Taken together,
black females obtained less saturated fats from milk and milk products and more
saturated fats from meats compared to their white and Hispanic counterparts (Figure 3).
The average intake of carbohydrates/sugars among females in the current sample
was 228.42 g/day (sd = 124.63). Overall, black females reported higher intakes of
carbohydrates/sugars than Hispanic and white females: 234.11 g/d (sd = 143.04 g/d),
229.99 g/d (sd = 154.44 g/d) and 227.01 g/d (sd = 106.70 g/d), respectively, a small
fraction of which was obtained from supplements containing carbohydrates/sugars.
Stratified by ethnicity, 16.67% of white females reported taking supplements containing
carbohydrates/sugars, followed by black females and Hispanic females (10.25% and
8.82%, respectively, P = 0.002). Overall, most carbohydrates/sugars were obtained from
grains and sugar/sweeteners/beverages. As with saturated fats, the dietary
composition/distribution of carbohydrates/sugar dietary differed across ethnicities. For
instance, among white females, the dietary composition of carbohydrates/sugars obtained
from each of the aforementioned USDA food groups was 42.94% and 24.78%. Among
Hispanic females, the dietary composition of carbohydrates/sugars obtained from each
food group was 44.14% and 24.20%. Among black females, the dietary composition of
carbohydrates/sugars obtained from each food group was 37.50% and 31.59%. Taken
together, black females obtained fewer carbohydrates/sugars from grains and more
carbohydrates/sugars from sugar/sweeteners/beverages compared to their white and
Hispanic counterparts (Figure 4).
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The average vitamin C intake among females in the current sample was 79.07
mg/day (sd = 126.84 mg/d). Hispanic females reported higher intakes of vitamin C than
black and white females: 95.99 mg/d (sd = 118.23 mg/d), 91.20 mg/d (sd = 124.62 mg/d)
and 73.07 mg/d (sd = 102.58 mg/d), respectively, a substantial fraction of which was
obtained from supplements containing vitamin C. When stratified by ethnicity, 48.43% of
Hispanic females reported taking supplements containing vitamin C, followed by black
and white females (46.17% and 44.42%, respectively, P = 0.39). Overall, most vitamin C
was obtained from fruits, vegetables and sugar/sweeteners/beverages. The
composition/distribution across ethnicities differed for vitamin C as well. For instance,
among white females, the dietary composition of vitamin C obtained from each of the
aforementioned USDA food groups was 39.82%, 26.06% and 15.95%. Among Hispanic
females, the dietary composition of saturated fats obtained from each food group was
45.80%, 19.11% and 19.96%. Among black females, the dietary composition of vitamin
C obtained from each food group was 43.23%, 15.36% and 32.43%. Taken together,
black females obtained more vitamin C from sugar/sweeteners/beverages than their white
and Hispanic counterparts and white females obtained less vitamin C from fruits and
more vitamin C from vegetables from their Hispanic and black counterparts (Figure 5).
Inhibitors of iron absorption The average intake of fiber among females in the
current sample was 14 g/d (sd = 13.74 g/d). Hispanic females reported higher intakes of
fiber than white and black females: 15.04 g/d (sd = 12.69 g/d), 14.18 g/d (sd = 13.09 g/d)
and 11.79 g/d (sd = 9.75 g/d), respectively, a small fraction of which was obtained from
supplements containing fiber. Only 3.09% of white females reported taking supplements
containing fiber, followed by black females and Hispanic females (2.37% and 1.84%,
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respectively, P = 0.45). Overall, most fiber was obtained from grains, fruits and
vegetables. The distribution across ethnicities, however, differed. For instance, among
white females, the dietary composition of fiber obtained from each of the aforementioned
USDA food groups was 46.28%, 11.45% and 20.92%. Among Hispanic females, the
dietary composition of fiber obtained from each food group was 46.81%, 15.18% and
15.96%. Among black females, the dietary composition of fiber obtained from each food
group was 43.95%, 10.76% and 23.75%. Taken together, black females obtained less
fiber from grains and more fiber from vegetables compared to their white and Hispanic
counterparts (Figure 6).
The average intake of calcium among females in the current sample was 860.46
mg/d (sd = 778.17 mg/d). White females reported higher intakes of calcium than
Hispanic and black females: 890.88 mg/d (sd = 675.16 mg/d), 832.74 mg/d (sd = 767.09
mg/d) and 729.08 mg/d (sd = 497.14 mg/d), respectively, a substantial fraction of which
was obtained from supplements containing calcium. When stratified by ethnicity, 57.04%
of Hispanic females reported taking supplements containing calcium, followed by white
females and black females (52.53% and 49.18%, respectively, P = 0.32). Overall, most
calcium was obtained from milk and milk products, grains, sugar/sweeteners/beverages,
meat and fruits. The composition/distribution of calcium differed across ethnicities as
well. For instance, among white females, the dietary composition of calcium obtained
from each of the aforementioned USDA food groups was 41.76%, 27.73%, 11.42%,
6.48% and 3.61%. Among Hispanic females, the dietary composition of calcium obtained
from each food group was 37.21%, 28.30%, 12.13%, 6.48% and 7.13%. Among black
females, the dietary composition of calcium obtained from each food group was 28.66%,
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30.65%, 12.81%, 10.84% and 7.07%. Taken together, black females obtained less
calcium from milk and milk products and more calcium from meats compared to their
white and Hispanic counterparts (Figure 7).
The average intake of magnesium among females in the current sample was
247.79 mg/d (sd = 216.12 mg/d). White females reported higher intakes of magnesium
than Hispanic and black females: 254.67 mg/d (sd = 203.46 mg/d), 246.08 mg/d (sd =
165.71 mg/d) and 212.61 mg/d (sd = 117.10 mg/d), respectively, a moderate fraction of
which was obtained from supplements containing magnesium. When stratified by
ethnicity, 38.92% of Hispanic females reported taking supplements containing
magnesium, followed by white and black females (37.35% and 34.37%, respectively, P =
0.71). Overall, most magnesium was obtained from grains, meats and milk/milk products.
The distribution across ethnicities, however, differed. For instance, among white females,
the dietary composition of magnesium obtained from each of the aforementioned USDA
food groups was 30.27%, 13.18% and 13.18%. Among Hispanic females, the dietary
composition of magnesium obtained from each food group was 34.35%, 15.15% and
10.57%. Among black females, the dietary composition of magnesium obtained from
each food group was 29.54%, 18.86% and 8.11%. Taken together, white females
obtained most of their magnesium from milk/milk products, Hispanic females obtained
most of their magnesium from grains and black females obtained most of their
magnesium from meat (Figure 8).
The average vitamin D intake among females in the current sample was 4.35 µg/d
(sd = 5.59 µg/d). White females reported higher intakes of vitamin D than Hispanic and
black females: 4.50 µg/d (sd = 5.11 µg/d), 4.47 µg/d (sd = 5.29 µg/d) and 3.44 µg/d (sd =

143

2.89 µg/d), respectively, a moderate fraction of which was obtained from supplements
containing vitamin D. When stratified by ethnicity, 48.92% of black females reported
taking supplements containing vitamin D, followed by Hispanic and white females
(48.13% and 43.18%, respectively, P = 0.09). Overall, most vitamin D was obtained from
milk/milk products, meat, grains and eggs. As with the above patterns, the
composition/distribution of vitamin D in the diet differed across ethnicities as well. For
instance, among white females, the dietary composition of vitamin D obtained from each
of the aforementioned USDA food groups was 51.52%, 17.98%, 14.18% and 6.16%.
Among Hispanic females, the dietary composition of vitamin D obtained from each food
group was 47.43%, 18.46%, 11.95% and 9.39%. Among black females, the dietary
composition of vitamin D obtained from each food group was 37.48%, 26.19%, 16.23%
and 8.31%. Taken together, white females obtained most of their vitamin D from
milk/milk products, Hispanic females obtained most of their vitamin D from eggs and
black females obtained most of their vitamin D from meat and grains (Figure 9).
The average vitamin E intake among females in the current sample was 6.51 mg/d
(sd = 8.96 mg/d). White females reported higher intakes of vitamin E than black and
Hispanic females: 6.74 mg/d (sd = 8.27 mg/d), 5.99 mg/d (sd = 4.05 mg/d) and 5.89 mg/d
(sd = 5.97 mg/d). Overall, most vitamin E was obtained from grains, vegetables, meat,
legumes/seeds and milk/milk products. The distribution across ethnicities, however,
differed. For instance, among white females, the dietary composition of vitamin E
obtained from each of the aforementioned USDA food groups was 32.67%, 15.97%,
11.97%, 12.82% and 6.19%. Among Hispanic females, the dietary composition of
vitamin E obtained from each food group was 34.10%, 15.81%, 14.45%, 8.85% and
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3.43%. Among black females, the dietary composition of vitamin E obtained from each
food group was 31.10%, 20.69%, 16.81%, 8.13% and 3.05%. Taken together, white
females obtained most of their vitamin E from milk/milk products, legumes, nuts and
seeds, Hispanic females obtained most of their vitamin E from grains and black females
obtained most of their vitamin E from meat and vegetables (Figure 10).
The average zinc intake among females in the current sample was 10.17 mg/d (sd
= 8.74 mg/d). White females reported higher intakes of zinc than Hispanic and black
females: 10.32 mg/d (sd = 6.17 mg/d), 9.96 mg/d (sd = 12.41 mg/d) and 9.62 mg/d (sd =
8.84 mg/d), respectively, a moderate fraction of which was obtained from supplements
containing zinc. When stratified by ethnicity, 40.12% of Hispanic and black females
reported taking supplements containing zinc, followed by white females (37.56%, P =
0.59). Overall, most zinc was obtained from meat, grains and milk/milk products. The
distribution/composition of zinc, however, differed across ethnicities. For instance,
among white females, the dietary composition of zinc obtained from each of the
aforementioned USDA food groups was 32.14%, 33.87%, and 15.90%. Among Hispanic
females, the dietary composition of zinc obtained from each food group was 36.14%,
33.75% and 13.07%. Among black females, the dietary composition of zinc obtained
from each food group was 43.53%, 29.16% and 8.81%. Taken together, white females
obtained most of their zinc from milk/milk products and grains compared to their
Hispanic and black counterparts who obtained most of their zinc from meat (Figure 11).
Reproductive Lifespan The mean age of menarche among the current sample
population was 12.36 years (sd = 1.61, range: 7 – 19) (Table 1). Menarche occurred
slightly earlier for Hispanic and black females (ẍ = 12.33) compared to white females (ẍ
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= 12.62). When age at menarche was categorized as < 12 years of age, 12 years old, or >
12 years of age, 27.75% of the sample population reported experiencing menarche at < 12
years of age, 28.33% reported experiencing menarche at age 12 and 43.92% reported
experiencing menarche > 12 years of age (Table 1). When stratified by ethnicity, 35.08%
of white females, 34.91% of Hispanic females and 30.01% of black females reported
experiencing menarche at < 12 years of age in this respondent category. Among those
who reported experiencing menarche at 12 years of age, a greater proportion of white
females (42.36%) than Hispanic or black females (33.17% and 24.47%, respectively)
reported experiencing menarche in this respondent category. Similar patterns were
observed among those reporting experiencing menarche > 12 years of age, where a
greater proportion of white females than Hispanic or black females (48.99% vs. 30.42%
and 20.59%, respectively) reported experiencing menarche in this group of respondents.
Roughly half of the sample population reported having ever used oral
contraceptives (53.11%) (Table 2) and the mean age of oral contraceptive users was
33.07 (sd = 9.94). When stratified by ethnicity, more white females than Hispanic or
black females reported ever having used oral contraceptive (53.50% vs. 25.14% and
21.36%, respectively). Most of the females in the current sample were nulliparous
(49.51%). Among those females reporting being pregnant at least one time, the average
number of pregnancies was 2.98 (sd = 1.93, range: 1 – 34). When the response was
categorized as 1 child, 2 to 3 children, or > 3 children, 10.02% of females reported having
a single child, 24.92% reported having between 2 to 3 children, and 15.55% reported
having > 3 children. When this variable was stratified by ethnicity, a greater proportion of
white females than Hispanic or black females reported having one child in this

146

respondent category (48.85% vs. 30.53% and 20.61%, respectively). Similarly, a greater
proportion of white females than Hispanic or black females reported having 2 to 3
children in this respondent category (47.05% vs. 31.51% and 21.44%, respectively). A
similar pattern was observed in the final respondent category, where a greater proportion
of white females reported having > 3 children than Hispanic or black females (39.67% vs.
34.94% and 25.39%, respectively). The mean age of menopause in the sample population
was 43.94 (sd = 4.80, range: 20 – 49) (Table 2). This variable was then categorized in
accordance with common definitions for premature menopause (i.e., < 40 years of age),
early menopause (i.e., between 40 and 45 years of age) and natural menopause (> 45
years of age) (Shuster et al.). Grouped in this manner, 16.99%, 35.38% and 47.63% of
females in the sample experienced premature menopause, early menopause and natural
menopause, respectively (Table 2). When stratified by ethnicity, a greater proportion of
white females than Hispanic or black females reported experiencing premature
menopause (68.85% compared to 16.39% and 14.75%, respectively). Similarly, a greater
proportion of white females than Hispanic or black females reported experiencing early
menopause (51.97% compared to 22.05 and 25.98%, respectively). The same pattern held
for natural menopause, where a greater proportion of white females reported experiencing
menopause naturally (53.80%), followed by black females (25.15%) and Hispanic
females (21.05%). The average length of the reproductive lifespan among females in this
sample was 27.55 years (sd=51.10). When stratified by ethnicity, black females had the
longest reproductive lifespan (36.94 years, sd = 10.17), followed by Hispanic females
(26.11 years, sd = 5.86) and white females (24.10 years, sd = 7.28) (Table 2).

147

Iron parameters Mean hemoglobin (Hb) concentration among the sample
population was 13.44 g/dL (sd = 2.96 g/dL) (Table 3). When stratified by ethnicity, white
females had the highest Hb concentration (ẍ = 13.64 g/dL, sd = 2.19 g/dL), followed by
Hispanic females (ẍ = 13.26 g/dL, sd = 1.90 g/dL) and black females (ẍ = 12.61 g/dL, sd
= 1.23 g/dL). Ethnicity explained ~ 10% of the variation in Hb concentration in the
current sample (r-squared = 0.09, P < 0.0001). Mean hematocrit (Hct) among the sample
population was 39.39% (sd = 9.09%) (Table 2). When stratified by ethnicity, white
females had the highest Hct (ẍ = 39.83%, sd = 7.36%), followed by Hispanic females (ẍ
= 38.89%, sd = 5.99%) and black females (ẍ = 37.62%, sd = 4.35%). Ethnicity explained
~ 6% of the variation in Hct concentration in the current sample (r-squared = 0.06, P <
0.0001). Mean serum iron concentration (μg/dL) among the sample population was 77.42
μg/dL (sd = 48.74 μg/dL) (Table 2). When stratified by ethnicity, white females had the
highest serum iron concentration (ẍ = 80.32 μg/dL, sd = 45.25 μg/dL), followed by
Hispanic females (ẍ = 73.58 μg/dL, sd = 42.65 μg/dL) and black females (ẍ = 66.61
μg/dL, sd = 25.65 μg/dL). Ethnicity explained ~ 2% of the variation in serum iron
concentration in the current sample (r-squared = 0.02, P < 0.0001). Mean total iron
binding capacity (TIBC) among the sample population was 365.02 μg/dL (sd = 102.28
μg/dL) (Table 2). When stratified by ethnicity, Hispanic females had the highest TIBC
concentration (ẍ = 371.13 μg/dL, sd = 76.10 μg/dL), followed by white females (ẍ =
364.26 μg/dL, sd = 83.02 μg/dL) and black females (ẍ = 362.60 μg/dL, sd = 58.86
μg/dL). Ethnicity explained < 1% of the variation in TIBC concentration in the current
sample (r-squared = 0.002, P = 0.52). Mean transferrin saturation (TSAT) among the
sample population was 21.84% (sd = 13.68%) (Table 2). When stratified by ethnicity,
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white females had the highest TSAT (ẍ = 22.64%, sd = 13.29%) followed by Hispanic
females (ẍ = 20.45%, sd = 13.63%) and black females (ẍ = 19.13%, sd = 8.73%).
Ethnicity explained ~ 1% of the variation in TSAT concentration in the current sample (rsquared = 0.01, P = 0.0007). Mean serum transferrin receptor (sTfR) concentration
(mg/L) among the sample population was 3.59 mg/L (sd = 2.47 mg/L) (Table 2). When
stratified by ethnicity, black females had the highest sTfR concentration (ẍ = 4.48 mg/L,
sd = 3.23 mg/L), followed by Hispanic females (ẍ = 3.63 mg/L, sd = 2.37 mg/L) and
white females (ẍ = 3.41 mg/L, sd = 1.97 mg/L). Ethnicity explained ~ 4% of the variation
in sTfR concentration in the current sample (r-squared = 0.04, P = 0.002). Mean ferritin
concentration (μg/L) among the sample population was 47.94 μg/L (sd = 47.47 μg/L)
(Table 2). When stratified by ethnicity, white females had the highest ferritin
concentration (ẍ = 49.22 μg/L, sd = 39.03 μg/L), followed by black females (ẍ = 46.95
μg/L, sd = 41.81 μg/L) and Hispanic females (ẍ = 43.07 μg/L, sd = 59.51 μg/L). Ethnicity
explained < 1% of the variation in serum ferritin concentration in the current sample (rsquared = 0.004, P = 0.08).
Total Body Iron and Demographics Mean iron stores via Cook’s iron repletion
index (i.e., FeCOOK) in the sample were 6.98 mg/kg (sd = 4.82 mg/kg) (Table 3). White
females were more iron replete (FeCOOK ẍ = 7.27 mg/kg, sd = 4.28 mg/kg), followed by
Hispanic females (FeCOOK ẍ = 6.52 mg/kg, sd = 6.81 mg/kg), and black females (FeCOOK
ẍ = 5.95 mg/kg, sd = 4.24 mg/kg) (P < 0.0001, Figure 12). Ethnicity explained ~ 2% of
the variation in FeCOOK concentration in the current sample (r-squared = 0.02, P <
0.0001). FeCOOK was linearly related to age, where FeCOOK increased 0.03 mg/kg with
each increasing year of age (P < 0.0001). The same trend was observed when stratified
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by ethnicity, where FeCOOK increased 0.03 mg/kg in white females (P < 0.0001), 0.02
mg/kg for Hispanic females (P = 0.03) and 0.02 mg/kg in black females (P = 0.06) with
each increasing year of age. Similar patterns were observed when age was treated as a
categorical variable, where FeCOOK increased across age categories. FeCOOK increased
from 6.32 mg/kg among those in the 12-21 year-old age group to 7.21 mg/kg among
those in the 22-31 year-old age group, decreased slightly among those in the 32-41 yearold age group to 7.10 mg/kg and increased again among those in the > 41 year-old age
group (FeCOOK ẍ = 7.32 mg/kg) (P < 0.0001, Figure 13). The same trend appeared when
stratified by ethnicity, where FeCOOK increased across the first two age categories (i.e.,
12-21y and 22-31y), decreased in the third age category (i.e., 32-41y) and increased again
in the highest age category (> 41 years of age) for white and Hispanic females and
increased monotonically across age groups in black females (Figure 14).
Mean FeCOOK increased with increasing education, where females in the highest
category of education had higher FeCOOK (ẍ = 6.48 among those with less than a high
school education, ẍ = 7.08 among those with a high school education/GED, ẍ = 7.21
among those with some college and ẍ = 7.38 among those with a college degree/postgraduate education) (P < 0.0001, Figure 15). This trend diverged slightly when stratifying
by ethnicity (Figure 16). FeCOOK increased across the lowest two categories of education,
decreased slightly in the third category of educational attainment and increased again in
the highest category for white females (ẍ = 6.73, ẍ = 7.48, ẍ = 7.43, ẍ = 7.57, P <
0.0001). For Hispanic females FeCOOK increased across the first three categories of
educational attainment and decreased in the highest category (ẍ = 6.23, ẍ = 6.72, ẍ =
6.96, ẍ = 6.76, P = 0.05). For black females, a saw-tooth pattern emerged where FeCOOK
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decreased from the lowest category of educational attainment to the second category,
increased significantly among females in the third category and decreased again among
females in the highest category of educational attainment (ẍ = 5.88, ẍ = 5.45, ẍ = 6.35, ẍ
= 5.86, P = 0.05).
FeCOOK was inversely associated with height (b1 = -0.03, t = -1.23, P = 0.22).
When stratified by ethnicity, this effect was more pronounced in white and black females
compared to Hispanic females (b1 = -0.06 mg/kg, t = -2.16, P = 0.03 for white females,
b1 = -0.05 mg/kg, t = -1.06, P = 0.29 for black females and b1 = -0.03, t = -0.86, P = 0.39
for Hispanic females). When height and FeCOOK were categorized according to tertiles,
the same pattern emerged where increasing height was associated with decreasing FeCOOK
(Ptrend = 0.01) and the trend persisted after stratifying by ethnicity, where taller females
within each ethnicity had lower FeCOOK than shorter females.
FeCOOK was linearly associated with weight and waist circumference, where
FeCOOK increased 0.009 mg/kg in with each increasing kilogram of weight (P < 0.0001)
and 0.01 mg/kg for each increasing centimeter of waist circumference (P < 0.0001).
FeCOOK was linearly related to BMI, where FeCOOK increased 0.01 mg/kg with each
increasing unit of BMI (P = 0.05). When BMI was categorized in accordance with the
risk-based strata developed by the WHO, a similar pattern was observed. However, the
linear trend was no longer statistically significant (P = 0.19, Figure 17).
FeCOOK was linearly related to alcohol consumption, where FeCOOK increased 0.23
mg/kg with each increasing unit of self-reported daily alcohol intake (P < 0.0001). The
same trend was observed after stratifying by ethnicity, though the magnitude of the
association was greater for white females compared to black and Hispanic females (b1 =
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0.23 mg/kg, P < 0.0001) vs 0.20 mg/kg (P = 0.01) and 0.13mg/kg (P = 0.02),
respectively, for each unit of increasing alcohol intake. When alcohol intake was
categorized into three groups (i.e., 0 drinks/d, 1-3 drinks/d or > 3 drinks/d), a similar
pattern emerged where FeCOOK increased 0.68 mg/kg with each increasing category (P <
0.0001, Figure 18). Again, the same trend was observed after stratifying by ethnicity,
where the magnitude of the association was greater for white females compared to black
and Hispanic females (b1 = 0.68 mg/kg, P < 0.0001) vs 0.37 mg/kg (P = 0.08) and 0.40
mg/kg (P = 0.01), respectively, for each increasing category of alcohol intake (Figure
19).
FeCOOK was positively associated with smoking, where FeCOOK increased 0.05
mg/kg with each increasing cigarette (P < 0.0001). The same trend was observed after
stratifying by ethnicity, though the magnitude of the association was greater for white
females compared to black and Hispanic females (b1 = 0.04 mg/kg, P < 0.0001) vs 0.01
mg/kg (P = 0.76) and 0.02 mg/kg (P = 0.63), respectively, for each cigarette smoked.
When cigarette smoking was categorized into two groups (i.e., non-smokers vs smokers),
a similar pattern emerged where FeCOOK was 0.86 mg/kg higher among smokers
compared to non-smokers (P < 0.0001, Figure 20). Again, the same trend was observed
after stratifying by ethnicity, where the magnitude of the association was greater for
white females compared to black and Hispanic females (b1 = 0.81 mg/kg, P < 0.0001) vs
0.79 mg/kg (P = 0.02) and 0.49 mg/kg (P = 0.13), respectively, comparing FeCOOK of
smokers to that of non-smokers (Figure 21). When cigarette smoking was categorized
into three groups (i.e., 0 cigarettes/d, 1-5 cigarettes/d or > 5 cigarettes/d), the same
pattern emerged where FeCOOK increased 0.53 mg/kg across each increasing category of
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smoking (P < 0.0001, Figure 22). Moreover, the same trend was observed after
stratifying by ethnicity, where the magnitude of the association was greater for white
females compared to black and Hispanic females (b1 = 0.50 mg/kg, P < 0.0001) vs 0.54
mg/kg (P = 0.008) and 0.42 mg/kg (P = 0.07), respectively, with each increasing category
of smoking (Figure 23).
FeCOOK was inversely associated with physical activity (i.e., METS score), though
the correlation was not statistically significant (r = -0.02, P = 0.11). The same pattern was
observed among white and black females when stratifying by ethnicity (b1 = -0.006
mg/kg for each increasing unit of METS, P = 0.71 for white females; b1 = -0.005 mg/kg
for each increasing unit of METS, P = 0.86 for black females). The pattern was opposite
for Hispanic females (b1 = 0.07 mg/kg for each increasing unit of METS, P = 0.05).
Though dietary iron was positively associated with FeCOOK, the correlation was
weak and not statistically significant (r = 0.01, P = 0.28). In addition, increasing amounts
of dietary iron did not have a substantial impact on FeCOOK (b1 = 0.007 mg/kg, P = 0.35).
Overall, the use of dietary supplements was inversely (but not significantly) associated
with FeCOOK (b1 = -0.03 mg/kg, P = 0.87), which was magnified when stratifying by
ethnicity. Compared to white females, FeCOOK was significantly inversely associated with
iron supplementation among both Hispanic and black females (b1 = -1.03 mg/kg, P =
0.04 and b1 = -1.79 mg/kg, P = 0.0004). Taken together, iron, whether obtained from
dietary or supplemental sources did not appear to be independently associated with iron
stores in the current sample of females.
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As above, the association between FeCOOK and dietary/supplement intakes from
foodstuffs considered as covariates in the current work are summarized below in terms of
their effect on iron absorption (i.e., enhancers and inhibitors of iron absorption).
Promoters of iron absorption Overall, increased intakes of total saturated fats (in
grams) obtained from the diet was positively associated with FeCOOK (b1 = 0.004 mg/kg,
P = 0.41). Given that the mean dietary intake of saturated fats was 22.56 grams per day,
this corresponds to an increase in FeCOOK of 0.09 mg/kg per day among those consuming
the average amount of saturated fats in the sample. Increased intakes of palmitic and
stearic saturated fatty acids were also positively associated with FeCOOK (b1 = 0.006, P =
0.56 and b1 = 0.009 mg/kg, P = 0.62, respectively). In addition, the use of dietary
supplements containing saturated fats was positively associated with FeCOOK (b1 = 0.28
mg/kg, P = 0.63). Increasing intakes of dietary carbohydrates and sugars were inversely
associated with FeCOOK (b1 = -0.0006 mg/kg, P = 0.09 and b1 = -0.002, P = 0.03,
respectively). In addition, use of supplements containing carbohydrates/sugars was
inversely associated with FeCOOK (b1 = -0.13, P = 0.71). Finally, increasing intakes of
vitamin C was inversely associated with FeCOOK (b1 = -0.0008 mg/kg, P = 0.25).
Conversely, use of supplements containing vitamin C was positively associated with
FeCOOK (b1 = 0.16 mg/kg, P = 0.51). Taken together, promoters of iron absorption did not
appear to be strongly associated with iron stores in this sample of females.
Inhibitors of iron absorption Intakes of dietary fiber were positively associated
with FeCOOK (b1 = 0.004 mg/kg, P = 0.51). Conversely, use of supplements containing
fiber was inversely associated with FeCOOK (b1 = -1.10 mg/kg, P = 0.01). Dietary and
supplemental calcium were positively associated with FeCOOK (b1 = 0.0002 mg/kg, P =
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0.07 and b1 = 0.31, P = 0.13, respectively). Magnesium from dietary sources and
supplements were both positively associated with FeCOOK (b1 = 0.001 mg/kg, P = 0.03
and b1 = 0.17 mg/kg, P = 0.47, respectively). Intakes of vitamin D from dietary and
supplemental sources were positively associated with FeCOOK (b1 = 0.04 mg/kg, P = 0.01
and b1 = 0.25 mg/kg, P = 0.28, respectively). Dietary vitamin E intake was positively
associated with FeCOOK (b1 = 0.003 mg/kg, P = 0.83). Dietary and supplemental zinc
intake was positively associated with FeCOOK (b1 = 0.02, P = 0.02 and b1 = 0.20 mg/kg, P
= 0.42). Taken together, the only inhibitor of iron absorption in the current sample of
females which was associated with decreased iron stores was fiber obtained from
supplements.
Total Body Iron and Reproductive Lifespan

Mean FeCOOK increased with self-

reported age at menarche (b1 = 0.009 mg/kg, P = 0.83). When age at menarche was
categorized as < 12 years of age, 12 years old or > 12 years of age, FeCOOK increased with
increasing age category: FeCOOK ẍ = 6.93 (sd = 5.63), ẍ = 6.94 (sd = 3.90) and ẍ = 7.03
(sd = 5.50), respectively, for each increasing age category (P = 0.76, Figure 24). A
similar pattern emerged when stratified by ethnicity (Figure 25). While FeCOOK increased
across increasing categories for each ethnicity, no differences in FeCOOK between
ethnicities were detected (P = 0.89).
FeCOOK increased with self-reported oral contraceptive use (FeCOOK ẍ = 7.29 (sd =
3.95) vs 6.32 (sd = 5.78), yes vs no) (P < 0.0001, Figure 26), decreased with increasing
parity: 1 child, FeCOOK ẍ = 7.59, (sd = 4.45); 2-3 children, FeCOOK ẍ = 7.04 (sd = 4.81); >
3 children, FeCOOK ẍ = 6.67, (sd = 4.74), P = 0.0009, Figure 27), and increased among
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post-menopausal females (FeCOOK ẍ = 9.98 (sd = 3.34) vs FeCOOK ẍ = 6.74 (sd = 4.87, P
< 0.0001, Figure 28).
Metabolic dysfunction When defined using the criteria developed by the WHO,
T2DM was present in 3.34% of the sample population (Table 3) and the mean age of
females affected with T2DM was 38.52 (sd = 9.45). When stratified by ethnicity, T2DM
was present in 2.64% of white, 3.79% of Hispanic and 3.95% of black females. When
females were grouped into categories according to menopausal status, T2DM was present
in 2.96% of premenopausal females and 10.58% of postmenopausal females (Table 3).
When defined using the criteria developed by ATP III, metabolic syndrome was present
in 15.71% of the sample (Table 3) and the mean age of those affected with metabolic
syndrome was 35.78 (sd = 10.36). When stratified by ethnicity, metabolic syndrome was
present in 13.83% of white, 14.82% of Hispanic and 14.08% of black females. When
females were grouped into categories according to menopausal status, metabolic
syndrome was present in 13.07% of premenopausal females and 34.01% of
postmenopausal females (Table 3). When defined by the U.S.-FLI, the prevalence of
NAFLD was 7.38% (Table 3) and the mean age of those affected with NAFLD was 31.49
(sd = 11.46). When stratified by ethnicity, the prevalence of NAFLD was 6.12% of white,
11.27% of Hispanic and 4.50% of black females. When females were grouped into
categories according to menopausal status, 7.06% of premenopausal females had NAFLD
and 11.58% of postmenopausal females had NAFLD (Table 3). When defined by
HOMA-IR, the distribution of insulin resistance in the sample population was 64.06% normal insulin resistance, 24.96% - moderate insulin resistance and 10.98% - severe
insulin resistance (Table 3). The mean age of those with moderate to severe insulin
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resistance was 27.74 (sd = 11.69). When stratified by ethnicity, the distribution of insulin
resistance for white females was 73.23% - normal insulin resistance, 18.72% - moderate
insulin resistance and 8.04% severe insulin resistance. For Hispanic females, the
distribution of insulin resistance was 57.49% - normal insulin resistance, 29.35% moderate insulin resistance and 13.16% - severe insulin resistance. The distribution of
insulin resistance among black females was similar to that of Hispanic females, where
57.52% of females experienced normal insulin resistance, 29.51% experienced moderate
insulin resistance and 12.96% experienced severe insulin resistance. When females were
grouped into categories according to menopausal status (i.e., pre- vs. post-menopausal),
64.98% of premenopausal females experienced normal insulin resistance, 24.64%
experienced moderate insulin resistance and 10.38% experienced severe insulin
resistance (Table 3). Approximately sixty-three percent (i.e., 63.37%) of postmenopausal
females experienced normal insulin resistance, 22.09% experienced moderate insulin
resistance and 14.53% experienced severe insulin resistance (Table 3). Taken together,
Hispanic and black females were disproportionately affected by T2DM, metabolic
syndrome and insulin resistance. In addition, the prevalence of NAFLD was nearly twofold higher in Hispanic females compared to their white counterparts and nearly threefold higher compared to black females. Regardless of ethnicity, metabolic dysfunction
was more prevalent among postmenopausal females compared to premenopausal females.
Total Body Iron and Metabolic Dysfunction

The odds of T2DM increased with

increasing FeCOOK (OR = 1.03, 95%CI: 0.99-1.08, P = 0.15 for each unit increase in
FeCOOK. The effect was slightly attenuated after adjusting for covariates. When
independently adjusting for 1) age, 2) ethnicity, 3) education, 4) BMI, 5) age at
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menarche, 6) OC use, 7) parity, 8) menopausal status, 9) alcohol consumption, 10)
smoking history, 11) physical activity and 12) C-reactive protein (CRP), the odds of
T2DM were 1) 1.01 (95%CI: 0.98-1.05, P = 0.43), 2) 1.05 (95%CI: 1.00-1.09, P = 0.05),
3) 1.03 (95%CI: 0.99-1.08, P = 0.16), 4) 1.03 (95%CI: 0.98-1.07, P = 0.24), 5) 1.03
(95%CI: 0.98-1.08, P = 0.25), 6) 1.02 (95%CI: 0.97-1.07, P = 0.40), 7) 1.03 (95%CI:
0.98-1.08, P = 0.21), 8) 1.00 (95%CI: 0.95-1.05, P = 0.94), 9) 1.04 (95%CI: 0.99-1.09,
P = 0.12), 10) 1.03 (95%CI: 0.99-1.08, P = 0.17), 11) 1.03 (95%CI: 0.99-1.08, P =
0.16) and 12) 1.02 (95%CI: 0.98-1.07, P = 0.37) (Table x), respectively. In a full model
which adjusted for all covariates, the odds of T2DM increased with increasing FeCOOK,
though the effect size was slightly attenuated (OR = 1.02, 95%CI: 0.97-1.06, P = 0.53)
(Table x). Given that ethnicity and menopausal status appeared to have the largest
impacts as covariates, separate models were built to examine the interaction of each on
the association between FeCOOK and odds of T2DM. Compared to white females, the odds
of T2DM among Hispanic and black females were 2.28 (95%CI: 1.65-3.14, P < 0.0001)
and 2.42 (95%CI: 1.77-3.30, P < 0.001), respectively, for each unit increase in FeCOOK.
Taken together, it appears that non-white ethnicity is an effect modifier of FeCOOK on the
risk of T2DM, since ethnicity is more strongly associated with the outcome rather than
the exposure. Compared to premenopausal females, the odds of T2DM among
postmenopausal females were nearly 3-fold higher (OR = 2.96, 95%CI: 1.78-4.94, P <
0.0001).
When FeCOOK was categorized according to tertiles, the odds of T2DM among
those in the highest tertile of FeCOOK compared to those in the lowest tertile were 1.30
(95%CI: 0.90-1.89, P = 0.17). A similar pattern was observed after stratifying by
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ethnicity. Among white females, the odds of T2DM among those in the highest tertile of
FeCOOK compared to those in the lowest tertile were 1.11 (95%CI: 0.57-2.19, P = 0.75).
The odds of T2DM were higher among Hispanic and black females in the highest tertile
of FeCOOK compared to those in the lowest tertile: OR = 1.52 (95%CI: 0.87-2.64, P =
0.14) and OR = 2.52 (95%CI: 1.39-4.57, P = 0.002. Finally, I examined the components
of T2DM (i.e., fasting glucose concentration and HbA1C). FeCOOK was linearly
associated with fasting glucose concentration. For each unit increase in glucose
concentration (md/dL), FeCOOK increased 0.01 mg/kg (P = 0.01). Similarly, for each unit
increase in FeCOOK, fasting glucose concentration increased 0.22 mg/dL (P = 0.01).
FeCOOK was inversely associated with HbA1C.For each unit (%) increase in HbA1C,
FeCOOK decreased 0.22 mg/kg (P = 0.02). Similarly, for each unit increase in FeCOOK,
HbA1C decreased 0.005% (P = 0.02).
The odds of metabolic syndrome increased with increasing FeCOOK (OR = 1.01,
95%CI: 0.99-1.04, P = 0.23 for each unit increase in FeCOOK. The effect was attenuated
after adjusting for individual covariates and inverted in the full model. For example,
when independently adjusting for 1) age, 2) ethnicity, 3) education, 4) BMI, 5) age at
menarche, 6) OC use, 7) parity, 8) menopausal status, 9) alcohol consumption, 10)
smoking history, 11) physical activity and 12) C-reactive protein (CRP), the odds of
metabolic syndrome were 1) 1.00 (95%CI: 0.98-1.02, P = 0.92), 2) 1.02 (95%CI: 1.001.04, P = 0.13), 3) 1.01 (95%CI: 0.99-1.03, P = 0.36), 4) 1.01 (95%CI: 0.99-1.03, P =
0.53), 5) 1.01 (95%CI: 0.98-1.03, P = 0.65), 6) 1.00 (95%CI: 0.97-1.02, P = 0.86), 7)
1.01 (95%CI: 0.98-1.03, P = 0.54), 8) 0.99 (95%CI: 0.96-1.01, P = 0.37), 9) 1.01
(95%CI: 0.99-1.03, P = 0.36), 10) 1.01 (95%CI: 0.99-1.04, P = 0.32), 11) 1.01 (95%CI:
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0.99-1.04, P = 0.25) and 12) 1.00 (95%CI: 0.98-1.02, P = 0.73) (Table x), respectively.
In a full model which adjusted for all covariates, the effect size inverted to mirror the
odds associated with FeCOOK and metabolic syndrome when menopausal status was
entered into the model (OR = 0.99, 95%CI: 0.96-1.01, P = 0.28) (Table x). Thus, a
separate model was built to examine the interaction of menopausal status on the
association between FeCOOK and odds of metabolic syndrome. Compared to
premenopausal females, the odds of metabolic syndrome among postmenopausal females
was 2.7-fold higher (OR = 2.65, 95%CI: 2.02-3.47, P < 0.0001). Thus, menopausal status
is an effect modifier of FeCOOK on the risk of metabolic syndrome, since menopausal
status is more strongly associated with the outcome rather than the exposure.
When FeCOOK was categorized according to tertiles, the odds of metabolic
syndrome among those in the highest tertile of FeCOOK compared to those in the lowest
tertile were 1.14 (95%CI: 0.94-1.39, P = 0.18). A similar pattern was observed after
stratifying by ethnicity. Among white females, the odds of metabolic syndrome among
those in the highest tertile of FeCOOK compared to those in the lowest tertile were 1.08
(95%CI: 0.82-1.41, P = 0.61). The odds of metabolic syndrome were higher among
Hispanic and black females in the highest tertile of FeCOOK compared to those in the
lowest tertile: OR = 1.28 (95%CI: 0.90-1.81, P = 0.16) and OR = 1.57 (95%CI: 1.152.16, P = 0.005). Finally, I examined the components of metabolic syndrome (i.e., fasting
glucose concentration, triglycerides, HDL cholesterol, waist circumference and blood
pressure). Among those with metabolic syndrome, FeCOOK was linearly associated with
fasting glucose concentration (b1 = 0.005 mg/kg, P = 0.39 for each mg/dL increase in
glucose concentration), triglycerides (b1 = 0.001 mg/kg, P = 0.0001 for each mg/dL
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increase in triglycerides), HDL cholesterol (b1 = 0.06 mg/kg, P = 0.52 for each mg/dL
increase in HDL cholesterol) and waist circumference (b1 = 0.009 mg/kg, P = 0.44 for
each cm increase in waist circumference). Among those with metabolic syndrome,
FeCOOK was inversely associated with systolic BP (b1 = -0.04 mg/kg, P = 0.002 for each
unit increase in systolic BP (mmHg) and diastolic BP (b1 = 0.01 mg/kg, P = 0.41 for
each unit increase in diastolic BP (mmHg).
FeCOOK was linearly associated with U.S.-FLI. For each unit increase in U.S.-FLI,
FeCOOK increased 0.02 mg/kg (P = 0.001). Similarly, for each unit increase in FeCOOK,
U.S.-FLI increased 0.34 units (P = 0.003). The odds of NAFLD increased with increasing
FeCOOK (OR = 1.04, 95%CI: 1.00-1.08, P = 0.04 for each unit increase in FeCOOK. The
effect was attenuated when adjusting for covariates and abrogated in the full model. For
instance, when independently adjusting for 1) age, 2) ethnicity, 3) education, 4) BMI, 5)
age at menarche, 6) OC use, 7) parity, 8) menopausal status, 9) alcohol consumption, 10)
smoking history, 11) physical activity and 12) C-reactive protein (CRP), the odds of
NAFLD were 1) 1.02 (95%CI: 0.99-1.06, P = 0.11), 2) 1.04 (95%CI: 1.00-1.08, P =
0.02), 3) 1.04 (95%CI: 1.00-1.08, P = 0.03), 4) 1.01 (95%CI: 0.98-1.05, P = 0.48), 5)
1.04 (95%CI: 0.99-1.08, P = 0.09), 6) 1.03 (95%CI: 0.99-1.08, P = 0.12), 7) 1.03
(95%CI: 0.99-1.08, P = 0.09), 8) 1.03 (95%CI: 0.99-1.07, P = 0.22), 9) 1.02 (95%CI:
0.98-1.06, P = 0.31), 10) 1.02 (95%CI: 0.98-1.06, P = 0.35), 11) 1.02 (95%CI: 0.981.06, P = 0.31) and 12) 1.02 (95%CI: 0.99-1.06, P = 0.22) (Table x), respectively. In a
full model which adjusted for all covariates, no increased odds of NAFLD as a function
of FeCOOK were observed (OR = 1.00, 95%CI: 0.96-1.04, P = 0.99) (Table x).
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When FeCOOK was categorized according to tertiles, the odds of NAFLD increased
across increasing tertiles (Ptrend = 0.04). Compared to those in the lowest tertile of FeCOOK
the odds of NAFLD were 1.05 (95%CI: 0.77-1.44, P = 0.74) for those in the middle
tertile of FeCOOK. Compared to those in the lowest tertile of FeCOOK, the odds of NAFLD
were 1.35 (95%CI: 1.00-1.81, P = 0.05). A similar pattern was observed after stratifying
by ethnicity. Among white females, the odds of NAFLD among those in the highest
tertile of FeCOOK compared to those in the lowest tertile were 1.52 (95%CI: 1.00-2.31, P =
0.05). The odds of NAFLD were higher among Hispanic females in the highest tertile of
FeCOOK compared to those in the lowest tertile: OR = 1.10 (95%CI: 0.69-1.75, P = 0.69).
Compared to their white and Hispanic counterparts, the odds of NAFLD were higher
among black females in the highest tertile of FeCOOK compared to those in the lowest
tertile: OR = 1.62 (95%CI: 0.88-3.01, P = 0.12). FeCOOK was also linearly associated with
liver fibrosis (i.e., NFS). For each unit increase in NFS, FeCOOK increased 0.42 mg/kg (P
< 0.0001). Similarly, for each unit increase in FeCOOK, NFS increased 0.05 units (P <
0.0001).
FeCOOK was linearly associated with insulin resistance. For each unit increase in
HOMA-IR, FeCOOK increased 0.02 mg/kg (P = 0.41). Similarly, for each unit increase in
FeCOOK, HOMA-IR increased 0.01 units (P = 0.43). The odds of insulin resistance
increased with increasing FeCOOK (OR = 1.04, 95%CI: 1.00-1.08, P = 0.05 for each unit
increase in FeCOOK. The effect was not attenuated after adjusting for covariates. When
independently adjusting for 1) age, 2) ethnicity, 3) education, 4) BMI, 5) age at
menarche, 6) OC use, 7) parity, 8) menopausal status, 9) alcohol consumption, 10)
smoking history, 11) physical activity and 12) C-reactive protein (CRP), the odds of
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insulin resistance were 1) 1.04 (95%CI: 1.00-1.08, P = 0.04), 2) 1.05 (95%CI: 1.01-1.09,
P = 0.01), 3) 1.04 (95%CI: 1.00-1.08, P = 0.02), 4) 1.03 (95%CI: 0.99-1.06, P = 0.20),
5) 1.04 (95%CI: 1.00-1.08, P = 0.04), 6) 1.04 (95%CI: 1.00-1.08, P = 0.03), 7) 1.04
(95%CI: 1.00-1.08, P = 0.04), 8) 1.04 (95%CI: 0.99-1.07, P = 0.07), 9) 1.03 (95%CI:
0.99-1.08, P = 0.12), 10) 1.03 (95%CI: 0.99-1.07, P = 0.17), 11) 1.03 (95%CI: 0.991.07, P = 0.22) and 12) 1.02 (95%CI: 0.98-1.06, P = 0.27) (Table x), respectively. In a
full model which adjusted for all covariates, the effect size persisted. However, the effect
was no longer statistically significant (OR = 1.04, 95%CI: 1.00-1.08, P = 0.07) (Table x).
When FeCOOK was categorized according to tertiles, the odds of insulin resistance
increased across increasing tertiles (Ptrend = 0.10). Compared to those in the lowest tertile
of FeCOOK the odds of insulin resistance were 1.23 (95%CI: 0.86-1.78, P = 0.26) for those
in the middle tertile of FeCOOK. Compared to those in the lowest tertile of FeCOOK, the odds
of insulin resistance were 1.46 (95%CI: 1.03-2.06, P = 0.03) among those in the highest
tertile of FeCOOK. A similar pattern was observed after stratifying by ethnicity, especially
among white females. Among white females, the odds of insulin resistance among those
in the highest tertile of FeCOOK compared to those in the lowest tertile were 2.59 (95%CI:
1.45-4.65, P = 0.005). The odds of insulin resistance were also higher among Hispanic
and black females in the highest tertile of FeCOOK compared to those in the lowest tertile:
OR = 1.04 (95%CI: 0.60-1.78, P = 0.58) and OR = 1.25 (95%CI: 0.80-1.96, P = 0.47),
respectively.
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CHAPTER 7: DISCUSSION, LIMITATIONS AND CONCLUSIONS

The aim of the current dissertation was to evaluate iron stores in a nationallyrepresentative, community-dwelling, non-institutionalized group of females participating
in continuous NHANES from 2003 to 2010 using an index of iron repletion developed by
JD Cook et al. in 1993 (i.e., FeCOOK) (50). I first sought to describe the relationships
between FeCOOK and age, ethnicity, education, BMI, physical activity, alcohol intake and
smoking status in the female cohort. I hypothesized that FeCOOK would be positively
associated with Hispanic and Non-Hispanic Caucasian ethnicity, education, BMI, alcohol
consumption, smoking and negatively associated with Non-Hispanic African American
ethnicity and physical activity. The results confirm that mean FeCOOK in all females in the
current sample was higher than the reference mean for the index (i.e., ẍ = 5.5 ± 3.4
mg/kg) (50), indicating that these females were iron-replete. This finding aligns with
several recent large prospective studies which indicate that most of the U.S. population is
iron-replete. In the current sample, Hispanic and white females had higher FeCOOK than
black females, with white females having higher body iron than other ethnicities.
Moreover, FeCOOK increased with increasing age, education, BMI, alcohol consumption
and smoking history among females in the sample and decreased with increasing physical
activity among white and black females. Therefore, it appears that FeCOOK as an index of
iron repletion demonstrates clinical utility in assessing the association between iron stores
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and demographic variables in the current sample of U.S. females. An unexpected finding
was that FeCOOK increased with increasing physical activity among Hispanic females.
Next, my aim was to examine the distribution of FeCOOK in the total sample after
stratifying participants on several variables related to the female reproductive lifespan.
Specifically, I hypothesized that FeCOOK would be positively associated with use of oral
contraceptives and decreasing age at menopause and negatively associated with age at
menarche and parity. The results confirm that FeCOOK increased with oral contraceptive
use, decreased with decreasing age at menarche and decreased with increasing parity,
highlighting again the practical use (i.e., clinical utility) of the index in assessing the
association between iron stores and reproductive parameters among U.S. females.
It should be noted, however, that the current results do not support the hypothesis
that FeCOOK increases with an earlier age at menopause. This could be due to several
factors, including the age distribution among females in the sample. As mentioned,
approximately 43% (i.e., 42.9%) of the sample were between the ages of 12 and 21
compared to 17% who were aged 42 years or older. Moreover, while the mean age of
females in the current sample was 27.21 years, the mode was 14 years of age. In addition,
NHANES did not collect data on the actual self-reported age at menopause among
females. Rather, the survey inquired as to what age each participant experienced her last
menstrual cycle. Given that this question was not age-restricted, nor was it associated
with any obvious any skip-pattern, one must infer that this question applied to all females
in the sample. In other words, the age at which a given participant experienced her ‘last’
menstrual cycle could have very well been the same age at which she was interviewed.
Thus, defining age at menopause based upon this NHANES variable would have
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obviously lead to biased results. Thus, menopausal status was ascertained in the current
sample by utilizing two additional survey questions (i.e., one which inquired as to
whether the participant had at least one period in the past twelve months and another
which inquired as to the reason why the participant had not had a period in the past
twelve months). When the age distribution of females who answered ‘no’ to the former
question and ‘menopause/hysterectomy’ to the latter question was examined, FeCOOK was
positively associated with age. This is not surprising, given that this particular finding
was derived from the self-reported age during the time of interview among females who
were subsequently scored as postmenopausal.
I then sought to estimate the prevalence of NAFLD among females in the current
sample using a validated algorithm developed by Ruhl et al. in 2015, the U.S. fatty liver
index (U.S.-FLI). Overall, the prevalence of NAFLD among females in the sample was
low (i.e., 7.38% in all females, 6.12% in white females, 11.27% in Hispanic females and
4.50% in black females). As mentioned, NAFLD is rarely observed in individuals
younger than 20 years (~1%), but increases with age (~18% in those aged 20-40 years to
39% among adults aged 60 and older) (442). Given the age distribution among females in
the current sample, these data are in agreement with the epidemiological literature.
Moreover, the prevalence of NAFLD observed across ethnicities in the current sample is
in accord with previous reports. For example, investigators from the Dallas Heart Study
have reported that the prevalence of NAFLD was higher in Hispanic Americans
compared to other ethnicities. Moreover, the same study demonstrated that African
Americans had the lowest prevalence of NAFLD (443). Taken together, these results are
in accord with the literature.

166

Next, my aim was to confirm and extend associations between iron stores, in
particular FeCOOK, and metabolic dysfunction reported in the epidemiological literature. I
hypothesized that FeCOOK would be positively associated with T2DM, metabolic
syndrome, NAFLD and insulin resistance after controlling for age, BMI, alcohol
consumption, smoking status, physical activity and micronutrient status. When metabolic
dysfunction was modeled as a function of continuously-scaled FeCOOK, the current work
confirms a positive association between FeCOOK and T2DM and insulin resistance but not
for metabolic syndrome or NAFLD after adjustment for covariates. All effect sizes were
small and not statistically significant. However, while the magnitude of associations
between continuously-scaled FeCOOK and metabolic dysfunction was small, the direction
of the observed associations supports previous work (395,396). It is worth noting that
T2DM, metabolic syndrome and NAFLD are all diseases which develop over several
decades. As mentioned, the prevalence of T2DM, metabolic syndrome and NAFLD
among individuals < 20 years of age is < 1%, ~7% and < 1%, respectively. Therefore, it
should be expected that the magnitude of association between continuously-scaled
FeCOOK and metabolic dysfunction in the current sample be small.
The current results also support previous work demonstrating independent
associations between ethnicity and menopausal status and risk of metabolic dysfunction.
In other words, when continuously-scaled FeCOOK was used to model metabolic
dysfunction, it appears that ethnicity and menopausal status modified the effect of FeCOOK
on the risk of T2DM and metabolic syndrome among females in this sample, indicating
that these two variables were significantly and independently associated with each
outcome.

167

Finally, and most importantly, the results between continuously-scaled FeCOOK and
metabolic dysfunction are not surprising based upon trends in reporting commonly found
in the literature, where nearly all associations between iron stores (i.e., serum ferritin,
TSAT) and metabolic dysfunction have modeled iron stores categorically (e.g., tertiles,
quartiles, quintiles). Thus, the current results align more closely with what has been
published when FeCOOK was also modeled categorically. For example, females in the
highest tertile of FeCOOK compared to those in the lowest tertile of FeCOOK had
significantly increased odds of T2DM, metabolic syndrome, NAFLD and insulin
resistance (OR = 1.30, 95%CI:0.90-1.89, Ptrend = 0.17 for T2DM, OR = 1.14, 95%CI:
0.94-1.39, Ptrend = 0.18 for metabolic syndrome, OR = 1.35, 95%CI: 1.00-1.81, Ptrend =
0.05 for NAFLD and OR = 1.46, 95%CI: 1.03-2.06, Ptrend = 0.03). Differential risk
patterns for each outcome emerged across ethnicities when categorizing FeCOOK in this
manner. Black females in the highest tertile of FeCOOK compared to those in the lowest
tertile of FeCOOK had significantly increased odds of T2DM compared to their Hispanic
and white counterparts. This does not align with prevalence estimates reported in the
literature, which indicate that Hispanic females have the highest risk of T2DM and
metabolic syndrome, followed by black females and white females. One might speculate
that the discordance between the current results and what has been reported in the
literature is due to Hispanic females in the current sample consuming 3.25 g/d more
dietary fiber (i.e., an inhibitor of iron absorption) than black females. Moreover, given
that all females were iron-replete, the decreased risk of T2DM, metabolic syndrome and
NAFLD among white females could have been moderated by increased physical activity
levels in this group. In addition, the increased risk of T2DM, metabolic syndrome and
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NAFLD among black females could have been moderated by increased intake of dietary
sugars and saturated fat in this group, where the former has been shown to increase iron
absorption and the latter increases siderophores.
A strength of the current work is that I used a large, ethnically-diverse and
nationally-representative sample of U.S. females. Therefore, the current findings should
be generalizable at the population level. Moreover, the standardized methodology
employed in the quantification of FeCOOK and outcomes of the study permits replication
of each finding, as NHANES data is available for public use. Another strength of the
study is that the clinical validity of the index developed by Cook et al. was highlighted
compared to TSAT when examining the associations between each index and metabolic
dysfunction (Appendix 2). While TSAT is widely used in the clinical setting to assess
iron stores, it was previously highlighted that it is unreliable due to diurnal variation in
serum iron concentrations (i.e., the numerator of TSAT). Moreover, only a small
percentage of total body iron is accounted for by TSAT (~1%, compared to 20% with
ferritin) (109,110). As also mentioned, inflammation and the use of oral contraceptives
decreases total iron binding capacity (i.e., the denominator of TSAT) which would
ultimately lead to lower TSAT among females who use them. To this end, most of the
females in the current sample reported using oral contraceptives (53.11%) and white
females had the highest self-reported usage of oral contraceptives compared to Hispanic
and black females (53.50% vs. 25.14% and 21.36%, respectively). It is important to
mention these proportions for several reasons. First, if one assumes that the use of oral
contraceptives influences TSAT, then it appears that the odds associated with each
outcome when TSAT was categorized according to tertiles track with these proportions
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(Table 13). Second, if one also considers the mean age of females in the sample with
T2DM (38.52, sd = 9.45), metabolic syndrome (35.78, sd = 10.36), NAFLD (31.49, sd =
11.46) and insulin resistance (27.74, sd = 11.69) with the mean age of oral contraceptive
users (i.e., 33.07 (sd = 9.94)), it is tempting to hypothesize that the reduced odds of each
outcome with increasing tertile of TSAT is also related to the use of oral contraceptives.
An alternative explanation is that increasing iron deficiency accounts for the increased
risk of metabolic dysfunction among those in the lowest tertile of TSAT. Otherwise,
females in the highest tertile of TSAT would not have had a decreased risk of metabolic
dysfunction compared to those in the lowest tertile of TSAT. Given the average TSAT
among females in the current sample was 21.84% and that a TSAT < 20% is typically the
threshold used in the clinical setting to distinguish iron deficiency, it doesn’t appear that
females in the current sample were iron deficient. Therefore, it doesn’t appear that
increasing iron deficiency was associated with an increased risk of metabolic
dysfunction, which is what the observed effect sizes indicate. A simpler explanation is
that TSAT among females in the current sample was adversely affected by the
aforementioned limitations of the index, particularly oral contraceptive use.
Theoretically, oral contraceptive use should increase iron stores (i.e., serum ferritin
concentrations) due to the cessation of menstruation. The results obtained in the current
work using the index developed by Cook et al supports this theory, where FeCOOK
increased with increasing OC use. Given that FeCOOK is unaffected by diurnal variation,
accounts for a larger fraction of body iron stores and is unaffected by inflammation or use
of oral contraceptives, it is reasonable to conclude that the clinical utility and clinical
validity of the index was highlighted in the current study.
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There are several limitations in the current work which must be noted. First, given
the cross-sectional study design of NHANES, one cannot infer causal relationships based
upon the current results. Second, a key variable used in the derivation of FeCOOK (i.e.,
serum transferrin receptor) was not collected among male participants or females aged
greater than 49 years of age. This is discouraging, as much of the current research
supporting an association between iron stores and metabolic dysfunction has been
obtained from studies using males and/or older (i.e., postmenopausal) females. As most
of the females in the sample were young (mode = 14), it is possible that no significant
associations between iron stores and metabolic dysfunction were observed due to regular
menstruation. Moreover, the development of each outcome can take decades to manifest.
In line with the latter association, I was able to detect a positive association between
increasing tertiles of FeCOOK and all outcomes among postmenopausal females when
FeCOOK was modeled in accordance with common reporting patterns in the current
literature (Table 14), though no comparison was statistically significant due to such a
small number of postmenopausal females in the current study.
Another limitation of the current work is that many females did not have complete
data for biochemical parameters required in the derivation of each outcome. Thus, the
sample size for each outcome differed from the number of females in the full sample and
it is therefore possible that 1) the low prevalence of metabolic dysfunction might have
been an artefact of missing data and 2) the original power calculations were
overestimates. The latter is a limitation, as post hoc power analyses were not conducted
in the current work. Moreover, the reduced and variable sample sizes for each outcome
may have been affected by the PROC SURVEY procedures employed to obtain results
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that could generalize to the population. It would have been interesting to model the data
using standard SAS procedures. While one could not generalize to the population,
different patterns may have been observed among females in the current sample.
In conclusion, the current results highlight the clinical utility of FeCOOK in assessing
the iron status in females of reproductive age. I did not observe a statistically significant
association between metabolic dysfunction and continuously-scaled FeCOOK. However,
when FeCOOK was modeled in accordance with common reporting patterns (i.e., where
iron stores are modeled categorically), significant, positive associations between
increasing FeCOOK and metabolic dysfunction were observed among all females, and this
pattern persisted after stratification by ethnicity and menopausal status. Further research
is warranted to examine the clinical utility of FeCOOK among other cohorts. Moreover,
additional research using FeCOOK is recommended in order to replicate these findings
among a larger sample comprised of both males and older females.
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Figure 1: Flowchart of sample N’s.

Females aged 12 and older in NHANES from 2003-2010
N = 14,895

Females with probable hemochromatosis
N = 304

Females with self-reported Hepatitis C infection
N = 328

Females who self-reported being pregnant at the time of interview
N = 695

Females missing data for serum ferritin or serum transferrin receptor
N = 6,107

Final N for analysis = 7,461
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Table 1: Demographics of female participants: continuous NHANES 2003-2010
(N = 7,461)
Variable
Value
N (%)
Age
(yr)

Ethnicity

Education

Waist circumference

Body mass index

12-21

3,200 (42.89)

22-31

1,490 (19.97)

32-41

1,504 (20.16)

42-49

1,267 (16.98)

White

3,182 (42.65)

Black

1,846 (24.76)

Hispanic

2,432 (32.30)

< High school diploma

3,952 (52.97)

High school diploma / GED

986 (13.22)

Some college

1,542 (20.43)

College degree / post graduate degree

995 (13.34)

Mean (sd)

89.33 (16.85)

< 18.5

403 (5.46)

18.5 – 24.9

3,039 (41.21)

25.0 – 29.9
1,761 (23.88)
> 29.9
2,172 (29.45)
0 drinks/d
4,635 (62.14)
Alcohol
1-3 drinks/d
2,259 (30.29)
Consumption
> 3 drinks/d
565 (7.57)
0 cigarettes/d
6,138 (82.29)
Smoking Status
1-5 cigarettes/d
506 (6.78)
> 5 cigarettes/d
815 (10.93)
* N’s do not sum to 7,461 due to missing values for given variable
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Table 2: Variables associated with reproductive lifespan of female
participants: continuous NHANES 2003-2010 (N = 7,461)
Variable
Value
N (%)
Mean (sd)
12.36 (1.61)
Age at menarche
1,813 (27.75)
< 12 y
Age at menarche
1,851 (28.33)
12 y
category*
2,870 (43.92)
> 12 y
Oral Contraceptive
Use*

Parity*

Age at menopause
Age at menopause
category*

No
Yes
0
1
2-3
>3
Mean (sd)
< 40 y

3,063 (46.89)
3,469 (53.11)
3,235 (49.51)
655 (10.02)
1,628 (24.92)
1,016 (15.55)
43.94 (4.80)
61 (16.99)

40-45 y

127 (35.28)

171 (47.63)
> 45 y
* N’s do not sum to 7,461 due to missing values for given variable

236

Table 3: Biochemical parameters of female participants: continuous NHANES 2003-2010
Variable
All females, mean
Premenopausal females,
Postmenopausal
(sd)
mean (sd)
females, mean (sd)
Hemoglobin
13.44 (2.96)
13.42 (2.64)
13.88 (1.10)
(g/dL)
Hematrocrit (%)
39.39 (9.09)
39.30 (8.02)
40.64 (3.75)
Serum Iron
77.42 (48.74)
77.72 (47.89)
79.61 (39.34)
(μg/dL)
TIBC (μg/dL)
365.02 (102.28)
366.06 (104.61)
340.57 (43.57)
TSAT (%)
21.84 (13.68)
21.80 (12.86)
23.33 (11.57)
sTfR (mg/L)
3.59 (2.47)
3.60 (2.43)
3.27 (1.56)
Ferritin (μg/L)
47.94 (47.47)
44.73 (45.93)
86.28 (50.75)
Serum Insulin
11.67 (13.61)
11.46 (13.44)
11.12 (5.66)
(uIU/mL)
Serum Glucose
5.27 (1.41)
5.25 (1.40)
5.52 (0.96)
(mmol/L)
GGT (U/L)
18.92 (29.63)
18.01 (26.45)
28.88 (40.07)
Platelets (1000
284.75 (118.27)
283.07 (117.33)
287.15 (86.42)
cells/uL)
Albumin (g/dL)
4.21 (0.62)
4.21 (0.62)
4.20 (0.43)
Triglycerides
106.87 (138.58)
104.82 (146.83)
139.63 (55.40)
(mg/dL)
HDL cholesterol
57.62 (36.17)
57.53 (34.33)
57.82 (17.69)
(mg/dL)
HbA1c (%)
5.28 (0.78)
5.25 (0.80)
5.53 (0.84)
C-reactive protein
0.39 (0.96)
0.38 (0.98)
0.51 (0.54)
(mg/dL)

Table 4: Predictor and Outcome Variables
All females, mean
Variable
(sd) or
tertile/category
cutoff %
FeCOOK mean (SD)
White
FeCOOK
Hispanic
Black
<3
HOMA-IR
3-5
>5
< 30
U.S.-FLI
≥ 30
NFS
≤ 0.676
> 0.676
Metabolic
Absent
Syndrome
Present
T2DM
Absent
Present

6.98 (4.82)
7.27 (4.28)
6.51 (6.81)
5.95 (4.24)
64.06%
24.96%
10.98%
92.62%
7.38%
99.63%
0.37%
84.29%
15.71%
96.66%
3.34%

237

Premenopausal
females, mean (sd)
or tertile/category
cutoff %

Postmenopausal
females, mean (sd) or
tertile/category cutoff
%

6.74 (4.87)
7.02 (4.21)
6.31 (6.25)
5.70 (5.33)
65.14%
24.25%
10.61%
92.94%
7.06%
99.70%
0.30%
85.31%
14.69%
97.08%
2.92%

9.98 (3.34)
10.03 (2.36)
10.33 (1.68)
9.46 (2.49)
62.05%
22.56%
15.38%
88.42%
11.58%
97.87%
2.13%
69.52%
30.48%
91.78%
8.22%

Table 5: Common iron parameters with reference ranges

Iron Parameter

Lab Test / Calculation

Hemoglobin (Hb)

Colorimeter

Typical Range of Values /
Reference Range

Males: 14 - 18 g/dL
Females: 12 - 16 g /dL

Hematocrit (Hct)

Hepcidin

Automated cell counter: (Red Cell
Number/MCV) or

Range: 0 - 100%
Males: 40 - 54%

Indirect: (packed red cells/1000 ml of
whole blood)

Females: 36 - 48%

Immunoassay

Males: 0.6 – 23.3 nM
Females: 0.5 – 23.2 nM

Mean corpuscular volume
(MCV)

(Volume of packed red cells/1000 mL
of whole blood) / (red cell count in
millions/mL)

80 – 100 fL

Mean corpuscular hemoglobin
(MCH)

(Hb (g) / 1000 mL whole blood) / (red
cell count in millions/mL)

26 – 34 pg/cell

Mean corpuscular hemoglobin
concentration (MCHC)

(Hb (g) / 1000 mL whole blood) /
(Volume of packed red cells/1000 mL
of whole blood)

31 -37 g/dL

RDW

Whole Blood

11.5 – 14.5%

Whole Blood

4 – 6%

Whole Blood

40 – 180 mcg/dL

Glycosylated Hb

Serum Iron (μg/dL)
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Table 5 (continued): Common iron parameters with reference ranges
Whole Blood

170 – 370 mg/dL

TIBC (μg/dL)

Whole Blood

250 – 450 mcg/dL

TSAT (%)

Serum Iron*(100)/TIBC

Range: 0-100%

Transferrin

25 – 35%

sTfR (mg/L)

Immunoassay

5.6 ± 0.3 mcg/L

Ferritin (μg/L)

Immunoassay

Males: 20 – 300 ng/mL
Females: 15 – 200 ng/mL

FeCOOK (mg/kg)

sTfR:Ferritin Index

Range: -20 – 20

(−[log10(𝑅 ∗ 1000/𝐹)
− 2.8229])
/0.1207

Mean = 5.5 ± 3.4 mg/kg

sTfR/log(F)

Range: 1 – 10
Mean = 4.1 ± 1.7

Log(sTfR)/Ferritin ratio

log(sTfR)/F

Range: 1 – 10
Mean = 2.3 ± 0.3
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Table 6a: Iron-loading conditions (primary iron overload)
Primary iron overload
Iron loading
Genetic
Locus
Mode of
Mechanism
disorder
Mutation
Inheritance
HFE-related
hemochromatosis

HFE

6p21

Autosomal
recessive

Low hepcidin

TFR2-related
hemochromatosis

TFR2

7q22

Autosomal
recessive

Low hepcidin

FPN-related
hemochromatosis

SLC40A1
(FPN1)

2q32

Autosomal
dominant

Reduced iron
export from
macrophages,
hepcidin
resistance

Juvenile
hemochromatosis
2a

HJV

1q21

Autosomal
recessive

Reduced
HAMP
activation
leading to
low hepcidin

Juvenile
hemochromatosis
2b

HAMP

19q13

Autosomal
recessive

Low to
absent
hepcidin

Adapted from 178-181
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Affected
Iron
Parameters
High
serum
iron,
TSAT,
ferritin
Low
TIBC,
StfR

Disease
association/clinical
features
Parenchymal iron
overload, liver
disease,
hepatocellular
carcinoma,
endocrinopathy,
diabetes,
arthropathy

High
TSAT,
ferritin
High
ferritin
Low to
normal
TSAT
High
TSAT,
ferritin

Parenchymal iron
overload, liver
disease
Parenchymal and
reticuloendothelial
iron overload

High
TSAT,
ferritin

Severe
parenchymal iron
overload,
cardiovascular
disease, liver
disease,
endocrinopathy,
diabetes,
arthropathy
Severe
parenchymal iron
overload,
cardiovascular
disease, liver
disease, endocrine
failure diabetes,
arthropathy

Table 6b: Iron-loading conditions (ineffective erythropoiesis)
Secondary iron overload: ineffective erythropoiesis
Iron loading
disorder

Genetic
Mutation

Beta
thalassemia

Locus

Mode of
Inheritance

Mechanism

Affected Iron
Parameters

Disease
association/clinical
features
Parenchymal and
reticuloendothelial
iron overload

HBB

Low to
normal
hepcidin

High serum
iron, TSAT,
ferritin, StfR
Low TIBC

Sickle cell
anemia

HBB

Low to
normal
hepcidin

High serum
iron, TSAT,
ferritin
Low TIBC

Parenchymal and
reticuloendothelial
iron overload

X-linked
sideroblastic
anemia

ALAS2

Low
hepcidin

High serum
iron, TSAT,
ferritin
Low TIBC

Parenchymal and
reticuloendothelial
iron overload

Adapted from 178-181

Table 6c: Iron-loading conditions (chronic hemolytic anemias)
Secondary iron overload: Chronic hemolytic anemias
Iron loading
disorder

Genetic
Mutation

Locus

Mode of
Inheritance

Pyruvatekinase
deficiency

PKLR

Low
hepcidin

Hereditary
spherocytosis

Heterogeneous

Low
hepcidin

Adapted from 178-181
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Mechanism

Affected
Iron
Parameters
High
serum
iron,
TSAT,
ferritin
Low TIBC

Disease
association/clinical
features
Parenchymal iron
overload, anemia

High
serum
iron,
TSAT,
ferritin
Low TIBC

Parenchymal
anemia, jaundice,
splenomegaly

Table 6d: Iron-loading conditions (hypoplastic anemias)
Secondary iron overload: hypoplastic anemias
Iron
loading
disorder
Fanconi
anemia
DiamondBlackfan
anemia
Chronic
renal
failure

Genetic
Mutation

Locus

Mode of
Inheritance

Mechanism

FANC group

Low
hepcidin

Heterogeneous

Low
hepcidin

Affected
Iron
Parameters

High
hepcidin

Disease
association/clinical
features
Pancytopenia,
myelodysplastic
syndromes
Red cell aplasia,
predisposition to
leukemia
Iron loading,
anemia due to
ineffective
erythropoiesis

Adapted from 178-181

Table 6e: Iron-loading conditions (other iron loading conditions)
Other iron-loading disorders
Iron loading
disorder

Genetic
Mutation

Friedreich ataxia

FXN

Locus

Mode of
Inheritance

Mechanism

Unknown

Affected
Iron
Parameters
High
serum
iron,
TSAT,
ferritin
Low TIBC

Disease
association/clinical
features
Mitochondrial iron
overload,
Neurological
disease,
cardiovascular
disease

Hereditary
atransferrinemia

TF

3q21

Autosomal
recessive

Low
hepcidin

High
TSAT,
ferritin
Low
serum iron

Liver disease,
cardiovascular
disease

Hereditary
aceruloplasminemia

CP

3q23q24

Autosomal
recessive

Low
hepcidin

High
ferritin
Low
serum
iron,
TSAT

Neurological
disease, retinal
degeneration,
diabetes

Adapted from 178-181
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Table 7: Comparison of non-invasive measure for hepatic steatosis
NALFD estimate

Individual Components

Sensitivity

Specificity

AUC

Biopsy

Liver sample

ref

ref

ref

Abdominal Ultrasound
(AUS)

Ultrasound of Liver

49.1%

75%

N/A

Hepatorenal Ultrasound
Index (HRI)

Ratio between median
brightness level of the liver
and cortex of the right
kidney

Cutoff ≥ 1.5
(representing 5%
fatty liver), 100%
(vs biopsy)
(Webb)

Cutoff ≥ 1.5
(representing 5%
fatty liver), 91%
(vs biopsy)
(Webb)

0.99

AST-to-platelet ratio index
(APRI)

Aspartate aminotransferase
/ platelet count

89% (Adler)

75% (Adler)

0.82 (Adler)

AST-to-ALT ratio

Aspartate
aminotransferase, alanine
aminotransferase ratio

53%

100%

N/A

Original European Liver
Fibrosis panel (OELF) /
Enhanced Liver Panel (ELF)

Age, hyaluronic acid, nterminal propeptide of type
III collagen, tissue
inhibitors of matrix
metalloproteinase-1

Cutoff > 0.375,
89% (Rosenberg)

Cutoff > 0.375,
96%
(Rosenberg)

0.87 (Rosenberg)

90% (Nobili)
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41% (Nobili)

0.80 (Nobili)

Table 7 (con’t): Comparison of non-invasive measure for hepatic steatosis
NALFD estimate

Individual Components

Sensitivity

Specificity

AUC

Fatty Liver Index (FLI)

triglycerides, body mass
index, gamma glutamyl
transferase

Cutoff > 20, 62%
vs LAP (yang)

Cutoff > 20,
86% vs LAP
(yang);

Females, 0.83
(0.82-0.83)
(yang)

Cutoff ≥ 60, 87%
(Bedogni)

Cutoff ≥ 60,
86% (Bedogni)

0.84 (Bedogni)

Cutoff > 30, 80%
Huang

Cutoff > 30,
72% (Huang)

Cutoff = 60, 62%
(Koehler)

Cutoff = 60,
81% (Koehler)

Cutoff = 1.3, 85%
(McPherson)

Cutoff = 1.3,
65%
(McPherson)

FIB-4 index

Platelet count, aspartate
aminotransferase, alanine
aminotransferase, age

70% (Shah)

83 (Huang)
81% (Koehler)

0.86
(McPherson)
0.80 (Shah)

74% (Shah)

FibroIndex

Platelet count, aspartate
aminotransferase, gamma
glutamyl transferase

78%

74%

N/A

FibroMeter

Platelet count, gamma-2
macroglobulin, aspartate
aminotransferase, age,
prothrombin index,
hyaluronic acid, blood urea
nitrogen

Cutoff = 0.61,
79% (Cales)

Cutoff = 0.61,
96% (Cales)

0.94 (Cales)

Fibrospect II

Hyaluronic acid, tissue
inhibitors of matrix
metalloproteinase-1, alpha2 macroglobulin

83.5%

66.7%

N/A

FibroTest

gamma-2 macroglobulin,
apolipoprotein A1, gamma
glutamyl transferase, total
bilirubin

Fibrosis cutoff
score ≥ 2, 77%
(Ratziu)

Fibrosis cutoff
score ≥ 2, 98%
(Ratziu)

0.86 (Ratziu)

Forns

Age, platelet count, gamma
glutamyl transferase,
cholesterol level

94% (Adler)

51% (Adler)

0.86 (Adler)
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Table 7 (con’t): Comparison of non-invasive measure for hepatic steatosis
NALFD estimate

Individual Components

Sensitivity

Specificity

AUC

Hepascore

Age, gender, bilirubin,
gamma glutamyl
transferase, hyaluronic
acid, gamma-2
macroglobulin

63%

89%

N/A

Lipid Accumulation
Products (LAP)

Waist circumference,
Triglycerides

Cutoff = 31.6,
66% (Chiang)

Cutoff = 31.6,
93% (Chiang)

0.87 (Chiang)
Females, 0.794
(0.786-0.802)
(yang)

PGA index

Prothrombin index, gamma
glutamyl transferase,
apolipoprotein A1

91%

81%

N/A

SHASTA index

Hyaluronic acid, aspartate
aminotransferase, albumin

100%

52%

N/A

SimpleTest

Age, hyperglycemia, body
mass index, platelet count,
albumin, AST/ALT ratio

78%

58%

N/A

SteatoTest

FibroTest + alanine
aminotransferase, body
mass index, glucose,
triglycerides, cholesterol,
gender, age, sex

Cutoff = 0.30,
90% (vs biopsy)

Cutoff = 0.30,
54%, (vs biopsy)

0.79

Cutoff = 0.30,
90% (Poynard)

Cutoff = 0.30,
70% (Poynard)
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0.79 (Poynard)

Table 8: The association between iron stores and type 2 diabetes mellitus
Author(s)
Year
Country /
Study design
Case selection /
Ethnicity
Source
population
Abou2006
Egypt
Case-control
NA
Shousha

Control selection

N
Cases / Controls

Age
Mean (sd)

Sex
(% female)

Iron Indices

Comparison

Effect size

Normal healthy
volunteers

20 /10

48.5 (10.6)

Female only

Serum ferritin,
sTfR

Mean difference in
ferritin concentration
(cases vs controls)

Cases: 54 (SE:
0.45) Controls:
52.6
(SE: 0.45)
T2DM w/
retinopathy: 58 (3);
T2DM w/o
retinopathy: 63
(10); controls: 63
(14)
Cases: 52.5 (7.8);
controls: 51.1 (6.5)

Serum ferritin

Mean difference in
ferritin concentration
(cases vs controls)

184.47
(5.86363.08)
ng/mL
35.52 (6.8964.15)
ng/mL

Serum ferritin,
transferrin

Mean difference in
ferritin concentration
(cases vs controls)

26.10 (6.50-58.70)
ng/mL

Matching:
1,2,40

CSerum ferritin

Mean difference in
ferritin concentration
(cases vs controls)

-73.00 (5.54-100.94)
ng/mL

Matching:
1,2

Non-DM: 49.1
(SE:0.7); Newly
dx DM: 52.7
(SE: 4.6);
previously dx
DM: 43.7 (SE:
3.1)

Serum ferritin,
TSAT

RR (serum ferritin)

Males: 8.96
(4.6217.40);
Females:
5.83 (2.6113.01)

Sex
stratified
means; RR
estimates
adjusted for
1,5,6,10,22,
31,32

Age
Mean (sd)

Sex
(% female)

Iron Indices

Comparison

Effect size

Cases: 43.6 (9.5);
controls: 41.8 (6.7)

Cases: 73.2;
controls 60

Ferritin,
transferrin,
TSAT

Mean difference in
ferritin concentration
(cases vs controls)

36.19 (5.9866.40) ng/mL

Matching /
adjustment
variables
Matching: 1,2

Males: 50.00
(20.4779.53);
Females:
51.00 (18.3083.70)
54.00 (29.7578.25) ng/mL

Ashourpo
ur

2010

Tehran, Iran

Crosssectional

Members of the
Iranian diabetes
society in Tehran

Normal healthy
volunteers

54 / 53

Elis

2004

Israel

Case-control

Patients free from
T2DM and
retiopathy

51 / 40

Elsammak

2005

Egypt

Case- control

T2DM patients
w/ severe
diabetic
retinopathy and
DM patients w/o
retinopathy
T2DM patients

NA

22 / 18

Ford

1999

U.S.A

Crosssectional

NHANES III

NHANES III w/o
T2DM

924 / 7,861

Control selection

N
Cases /
Controls
30 / 30

Non-DM: 42.1
(SE:0.4); IFG: 56.6
(SE:0.9); Newly dx
DM: 59.4 (SE:
1.0); previously dx
DM: 58.9 (SE: 0.8)

T2DM w/
retinopathy:
55.5; T2DM
w/o retinopathy:
58.6; controls:
60
ases:
41.0;
Controls:
44.4

Matching /
adjustment
variables
Matching:
1,2,3,4

Matching:
1,2

Adapted from 395, 396
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Table 8 (con’t): The association between iron stores and type 2 diabetes mellitus
Author(s)
Year
Country /
Study design
Case selection /
Ethnicity
Source
population
Ganesh
2012
India
Case-control
Attendees of the
Endocrine Clinic
at the M.S. Majah
Hospitals
Hughes
1998
Singapore
CrossRandom sample
(Chinese,
sectional
of individuals
Malay, Indian)
aged 40-69 yrs
from Singapore
gen pop
Kim

2008

U.S.A

Crosssectional

Kim

2011

South Korea

Crosssectional

Lee

2011

South Korea

Crosssectional

Normal healthy
volunteers

Those free from
T2DM in same
sample
population

126 / 530

Range: 40-69

51.2

Serum ferritin

Mean difference in
ferritin concentration
(cases vs controls)

Non-pregnant
females in
NHANES III w/
T2DM
Voluntary health
check-up
participants

Non-pregnant
females in
NHANES III w/o
T2DM
Voluntary health
check-up
participants

244 / 6,015

T2DM: 46 nonT2DM: 36

Females only

Serum ferritin

Mean difference in
ferritin concentration
(cases vs controls)

1,054 / 11,036

47.3

Serum ferritin

RR

1.30 (0.891.89)

Adjustment:
1,6,9,10,12,1
3,16,20,21,31

KNHANES 2008

KNHANES 2008
participants w/o/
T2DM

Males: NFG: 50.4
(9.5); IFG: 52.2
(8.3); T2DM: 55.3
(8.6)
Females: NFG:
49.5 (8.9); IFG:
53.3 (8.8); T2DM:
58.1 (8.2)
Males: 43.3 (SE:
0.45)
Premenopausal
Females: 36.9 (SE:
0.33)
Postmenopausal
Females: 62.6 (SE:
0.37)

57.5
(premenopausal:
33.6;
postmenopausal:
23.9)

Serum ferritin

RR

Males: 1.80
(1.09-2.97)
Premenopaus
al Females:
3.57 (1.389.21)
Postmenopau
sal Females:
1.54 (0.902.65)

Adjustment:
1,6,9,10,22,2
3,24

313 / 5,998

Sex stratified
means;
Adjustment:
1,5

Adjustment:
1,5,7,9,10,18,
19

Table 8 (con’t): The association between iron stores and type 2 diabetes mellitus
Author(s)
Year
Country /
Study design
Case selection /
Ethnicity
Source
population
Luan
2008
China
CrossCHANES
sectional
Shi

2006

China

Crosssectional

CHANES

Skomro

2001

Canada

Case-control

T2DM patients
attending hospital
outpatient clinic

Smotra

2008

India

Case-control

Sun

2008

China

Crosssectional

Waheed

2009

Pakistan

Case-control

Obese patients w/
T2DM randomly
selected from
tertiary care
hospital
Nutrition &
Health of Aging
Population in
China Study
participants w/
T2DM
Patients w/
T2DM randomly
selected from
diabetes clinics

Control selection

CHANES

N
Cases /
Controls
147 / 2,850

Age
Mean (sd)

Sex
(% female)

Iron Indices

Comparison

Effect size

Matching /
adjustment
variables
Adjustment:
1,2,7,9,10,11,1
6,20,25,39
Adjustment:
1,2,5,6,8,9,10

Males: 47.2
(14.6); Females:
46.8 (14.4)
Males: 47.2
(14.6); Females:
46.8 (14.4)
Cases: 57.2
(14.5); controls:
53.1 (15.2)

54.0

Serum ferritin

RR

2.96 (1.535.72)

54.1

Serum ferritin

RR

1.83 (1.003.36)

Cases: 50
Controls: 44.4

Serum ferritin

Mean difference in
ferritin
concentration
(cases vs controls)
Mean difference in
ferritin
concentration
(cases vs controls)

47.70 (-5.54100.94) ng/mL

Matching: 1,2

52.70 (31.4673.94) ng/mL

Matching:
1,2,6

CHANES
participants w/o
T2DM
Non-T2DM
patients attending
hospital
outpatient clinic
Non-T2DM
patients from
same hospital

100 / 2,722

50 / 50

Cases: 39.1
(2.88); controls:
39 (3.10)

56

Serum ferritin

Nutrition &
Health of Aging
Population in
China Study
participants w/o
T2DM
Healthy
volunteers with
FPG < 6 mmol/L

440 / 2,725

Range: 50-70

56.2

Serum ferritin

RR

3.06 (2.204.27)

Adjustment:
1,2,6,7,8,9,10,1
1,17,22,29,30

30 / 30

NA

NA

Serum ferritin

Mean difference in
ferritin
concentration
(cases vs controls)

181.23 (124.89237.57) ng/mL

Matching: 1,2

58 / 48

Adapted from 395, 396
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Table 8 (con’t): The association between iron stores and type 2 diabetes mellitus
Author(s)
Year
Country /
Study
Case selection /
Ethnicity
design
Source
population
Forouhi
2007
UK
Nested
EPIC-Norfolk
CaseStudy
control

Jehn

2007

U.S.A

Jiang

2004

U.S.A

Le

2008

U.S.A

Rajpathak

2009

U.S.A

Salmoaa

2010

Finland

Nested
Case-cohort
(Follow-up
time: mean
7.9 yrs)
Nested
case-control
(Follow-up
time: 10
yrs)
Cohort
(Follow-up
time: mean:
4.5 yrs)
Nested
case-control
(Follow-up
time: 2.8
yrs)
Cohort
(Follow-up
time: Md: 7
yrs)

Control selection

EPIC-Norfolk
Study

N
Cases /
Controls
360 / 758

Age
Mean (sd)

Sex
(% female)

Iron Indices

Comparison

Effect size

Cases: 62.4 (8.3)

42

Serum ferritin

Mean difference
in ferritin
concentration
(cases vs
controls)

Males: 56.67
(28.74-84.60)
ng/mL
Females: 39.22
(13.75-64.69)
ng/mL
0.83 (0.521.30)

Matching /
adjustment
variables
Sex stratified
means; Matching:
1,6,41,42

ARIC Study

ARIC Study

599 / 690

Cases: 53.3 SE:
0.24)

Cases: 57.7

Serum ferritin

RR

Adjustment:
1,2,5,6,9,10,12,13,
16,20,21,31,33,34,
35,37,38

Nurses’ Health
Study

Nurses’ Health
Study

698 / 716

Cases: 56.5 (6.9);
controls: 56.4 (6.9)

Females only

Serum ferritin

RR

2.45 (1.663.60)

Adjustment:
1,5,6,7,8,9,10,11,1
3,14,36

ACLS
participants
enrolled
between 1995
& 2001
Placebo arm of
Diabetes
Prevention
Program

ACLS
participants
enrolled between
1995 & 2001

220 / 5,292

Males: 48.1 (9.2);
Females: 48.6 (9.2)

32

Serum ferritin

RR

1.79 (1.132.82)

Adjustment:
1,2,5,6,12,20,26

Placebo arm of
Diabetes
Prevention
Program

280 / 280

Cases: 50.4 (SE:
0.6); controls: 50.2
(SE: 0.6)

63.6

Serum ferritin

12.10 (-6.3630.56)

Adjustment:
1,5,7,9,10,18

Health 2000
study
participants

Health 2000
study participants

179 / 4,798

Males: 52.1 (9.7)
Females: 53.7
(10.5)

45.7

Serum ferritin

Mean difference
in ferritin
concentration
(cases vs
controls)
RR

1.52 (1.042.23)

Adjustment:
1,2,6,9,12,15,20,2
1,27,28,31

Table 9: The association between iron stores and metabolic syndrome
Author(s)
Year
Country /
Study design
Case
Ethnicity
selection /
Source
population
Lee
2014
Korea
Cross-sectional

Control selection

N
Cases / Controls

Age
Mean (sd)

Sex
(% female)

248

Iron Indices

Comparison

Effect size

51 / 1,299

Serum ferritin

Mean difference in
ferritin
concentration (SD)
(cases vs controls)
Mean difference in
ferritin
concentration (SD)
(cases vs controls)
Mean difference in
ferritin
concentration (SD)
(cases vs controls)
Mean difference in
ferritin
concentration (SD)
(cases vs controls)
Mean difference in
ferritin
concentration (SD)
(cases vs controls)
Mean difference in
ferritin
concentration (SD)
(cases vs controls)
Mean difference in
ferritin
concentration (SD)
(cases vs controls)

41.49 (17.82)
ng/mL vs.
36.67 (19.58)
ng/mL
50.4 (0.6)
ng/mL vs 50.2
(0.6) ng/mL

Rajpathak

2009

U.S.A

Case-control

280 / 280

Serum ferritin

Lin

2010

China

Cross-sectional

166 / 1,479

Serum ferritin

Gabrielso
n

2012

U.S.A

Cohort

38 / 87

Serum ferritin

Tang

2007

China

Case-control

60 / 63

Serum ferritin

Li

2006

China

Case-control

60 / 60

Serum ferritin

Xiao

2011

China

Case-control

87 / 102

Serum ferritin

Adapted from 11, 440

102.4 (65.95)
ng/mL vs. 82
(59.20) ng/mL
260 (23)
ng/mL vs. 185
(21) ng/mL
199.5 (60.23)
ng/mL vs.
112.45 (45.89)
ng/mL
196.35 (72.15)
µg/mL vs.
110.28 (68.32)
µg/mL
243.4 (65.3)
ng/mL vs.
156.5 (47.3)
ng/mL

Matching /
adjustment
variables

Table 9 (con’t): The association between iron stores and metabolic syndrome
Study design
Case selection /
Author(s)
Year
Country /
Source population
Ethnicity

Control selection

N
Cases / Controls

Age
Mean (sd)
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Iwanaga

2014

Japan

Cohort

Jehn

2004

U.S.A

Cross-sectional

NHANES III

NHANES III

5,949

48

Bozzini

2005

Italy

Cross-sectional

479

2005

Korea

Cross-sectional

Verona Heart
Project
Welfare Centers of
Seoul Metropolitan

Verona Heart Project

Choi

Welfare Centers of
Seoul Metropolitan

959

Soto
Gonzalez

2006

Spain

Cross-sectional

Vari

2007

France

Cohort

Patients of the
Endocrinology &
Nutrition Service of
Hospital
DESIR sohort

Patients of the
Endocrinology &
Nutrition Service of
Hospital
DESIR sohort

Shi

2008

China

Cross-sectional

CHANES 2002

Sun

2008

China

Cross-sectional

Ryu

2008

Korea

Cross-sectional

Kim

2011

Korea

Park

2012

Kang

Sex
(% female)

47 / 638

Iron Indices

Comparison

Effect size

Serum ferritin

Mean difference in
ferritin concentration
(SD) (cases vs
controls)
Quartiles (Q1 vs Q4)
OR

204.7 (140.9) ng/mL
vs. 96.4 (91.9) ng/mL

52

Serum ferritin

58

27

Serum ferritin

OR

72

Females only

Serum ferritin

OR

598

38

66

Serum ferritin

OR

944

47

51

Serum ferritin

OR

CHANES 2002

2,816

Range: 40-49

54

Serum ferritin

Quartiles (Q1 vs Q4)
OR

Nutrition & Health
of Aging Population
in China Study
participants w/
MetS
Korean Rural
GENOMIC Cohort

Nutrition & Health of
Aging Population in
China Study
participants w/ MetS

3,165

58

56

Serum ferritin

Quartiles (Q1 vs Q4)
OR

Korean Rural
GENOMIC Cohort

1,444

58

62

Serum ferritin

Quartiles (Q1 vs Q4)

Cross-sectional

Healthy volunteers

Healthy volunteers

7,253

51

47

Serum ferritin

OR

Korea

Cohort

44

0

Serum ferritin

OR

Korea

Cross-sectional

Check-up of men in
Health Promotion
Center
KNHANES IV

13,084

2012

Check-up of men in
Health Promotion
Center
KNHANES IV

7,346

48

56

Serum ferritin

Quartiles (Q1 vs Q4)

Hamalainen

2012

Finland

Case-control

Citizens invited to
health check-up 2004

766

52

55

Serum ferritin

OR

Leiva

2013

Chile

Cross-sectional

57

69

Serum ferritin

OR

2013

Taiwan

Cross-sectional

Research program of
Risk Factors for
Cardiovascular
Disease of Talca
NAHSIT 2005-2008

155

Chang

2,654

55

57

Serum ferritin

OR

1.72 (1.21-2.45)

Li

2013

China

Cross-sectional

Citizens invited to
health check-up
2004
Research program
of Risk Factors for
Cardiovascular
Disease of Talca
NAHSIT 20052008
CHANES

CHANES

8,441

51

53

Serum ferritin

Quartiles (Q1 vs Q4)

Males: 4.05 (3.195.14); Females: 2.34
(1.84-2.97)

Adapted from 11, 440

Men: 1.60 (0.92-2.77);
Premenopausal
Females: 2.40 (1.105.22); Postmenopausal
Females: 2.70 (1.744.19)
1.53 (1.27-1.84)
Postmenopausal
Females: 1.40 (1.231.59)
2.03 (1.69-2.44)

Premenopausal
Females: 1.66 (1.032.68); Postmenopausal
Females: 1.62 (1.082.43)
Males: 1.16 (0.731.84); Females: 1.66
(1.15-2.39)
1.95 (1.48-2.57)

Males: 1.41 (0.742.68); Females: 1.61
(1.03-2.51)
Males: 1.58 (1.062.36); Females: 1.07
(0.71-1.62)
1.66 (1.38-2.00)

Males: 1.46 (1.081.98); Females: 1.22
(0.91-1.64)
Males: 1.59 (1.291.95); Females: 1.71
(1.40-2.09)
3.36 (1.75-6.45)

Matching /
adjustment
variables

Table 10: The association between iron stores and non-alcoholic fatty liver disease
Author(s)
Year
Country /
Study design
Case selection /
Follow-up
Ethnicity
Source
Period
population
(months)
Valenti
2007
Italy
Non3 liver units in
12
randomized
northern Italy
controlled

3 Italian centers
across an 18
month period

N
Cases / Controls

Age
Mean (sd)

Sex
(% female)

64 / 64

Phlebotomy group:
Controls:

17

6-8

79 / 119

Phlebotomy group:
Controls:

16.7
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Definition of
Phlebotomy &
Iron Indices
Removing
350cc of blood
every 10-15
days according
to baseline Hb
until ferritin
concentration
was < 80ng/mL
in the presence
of low TSAT
Weekly or
fortnightly
removal of
350cc of blood
according to
baseline Hb
concentration
until ferritin
concentration
was < 80ng/mL
in the presence
of low TSAT
Removing
350cc of blood
every 10-15
days according
to baseline Hb
until ferritin
concentration
was < 30ng/mL
or TSAT <
25%
Removing 200300mL of
blood every 2-3
weeks
according to
baseline Hb
until ferritin
concentration
was < 45ng/mL
Any ironloading HFE
mutation

Valenti

2011

Italy

Nonrandomized
controlled

Valenti

2014

Italy

Randomized
controlled

24

21 / 17

Phlebotomy group:
Controls:

10.5

Adams

2016

Australia

Randomized
controlled

6

33 / 41

Phlebotomy group:
Controls:

40.5

PerezAguilar

2004

Spain

Genetic
association

Histologically
confirmed
NAFLD

Healthy
volunteers

22 / 21

Lin

2005

Taiwan

Genetic
association

Histologically
confirmed
NAFLD

Healthy
volunteers

33 / 125

Any ironloading HFE
mutation

Simsek

2006

Turkey

Genetic
association

Histologically
confirmed
NAFLD

Healthy
volunteers

30 / 2,677

Any ironloading HFE
mutation

Lee

2010

Korea

Genetic
association

Histologically
confirmed
NAFLD

Healthy
volunteers

125 / 221

Any ironloading HFE
mutation

Floreani

2007

Italy

Genetic
association

Histologically
confirmed
NAFLD

Healthy
volunteers

171 / 205

Any ironloading HFE
mutation

Aigner

2008

Austria

Genetic
association

Histologically
confirmed
NAFLD

Liver biopsies
with
unexplained
pathology

61 / 20

Any ironloading HFE
mutation

Adapted from 468. Any HFE mutation defined as: C282Y/C282Y; C282Y/H63D; C282Y/WT; H63D/H63D; H63D/WT

Comparison

Effect size

HOMA-IR Mean
Difference between
groups after
phlebotomy

1.73 (1.27-2.19)

HOMA-IR Mean
Difference between
groups after
phlebotomy

1.14 (0.57-1.71)

HOMA-IR Mean
Difference between
groups after
phlebotomy

0.30 (-0.45-1.05)

HOMA-IR Mean
Difference between
groups after
phlebotomy

0.20 (0.02-0.38)

Odds (OR) of any
HFE mutation in
NAFLD patients
vs. controls
Odds (OR) of any
HFE mutation in
NAFLD patients
vs. controls
Odds (OR) of any
HFE mutation in
NAFLD patients
vs. controls
Odds (OR) of any
HFE mutation in
NAFLD patients
vs. controls
Odds (OR) of any
HFE mutation in
NAFLD patients
vs. controls
Odds (OR) of any
HFE mutation in
NAFLD patients
vs. controls

0.67 (0.39-1.16)

Matching /
adjustment
variables

0.96 (0.16-5.67)

2.29 (1.12-4.70)

*

1.54 (1.09-2.20)

*

1.03 (0.82-1.31)

0.95 (0.80-1.12)

Table 10: The association between iron stores and non-alcoholic fatty liver disease
Author(s)
Year
Country /
Study
Case selection /
Control selection
Ethnicity
design
Source
population
Venat
2003
France
Genetic
Histologically
Healthy
association
confirmed
volunteers
NAFLD

N
Cases / Controls

Age
Mean (sd)

Sex
(% female)

Iron Indices

Comparison

Effect size

12 / 9

Any iron-loading
HFE mutation

Odds (OR) of any
HFE mutation in
NAFLD patients vs.
controls
Odds (OR) of any
HFE mutation in
NAFLD patients vs.
controls
Odds (OR) of any
HFE mutation in
NAFLD patients vs.
controls
Odds (OR) of any
HFE mutation in
NAFLD patients vs.
controls

1.43 (0.71-2.88)

Pucelikova

2004

Czech
Republic

Genetic
association

Histologically
confirmed
NAFLD

Healthy
volunteers

41 / 257

Any iron-loading
HFE mutation

Begianesi

2004

Italy

Genetic
association

Histologically
confirmed
NAFLD

Blood donors

210 / 204

Any iron-loading
HFE mutation

Mendler

1999

France

Genetic
association

Histologically
confirmed
NAFLD

Healthy
volunteers

86 / 75

Any iron-loading
HFE mutation

Matching /
adjustment
variables

1.52 (0.81-2.84)

1.09 (0.89-1.34)

0.72 (0.54-0.95)

*

Adapted from 468. Any HFE mutation defined as: C282Y/C282Y; C282Y/H63D; C282Y/WT; H63D/H63D; H63D/WT
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Table 10: The association between iron stores and non-alcoholic steatohepatitis
Author(s)
Year
Country
Study design
Case selection /
/
Source population
Ethnicity
George
1998
Australia
Genetic
Histologically
association
confirmed NASH

Control
selection

N
Cases / Controls

Healthy
volunteers

Age
Mean (sd)

Sex
(% female)

Iron Indices

Comparison

Effect size

51 / 2465

Any iron-loading
HFE mutation

Odds (OR) of any HFE
mutation in NASH
patients vs. controls
Odds (OR) of any HFE
mutation in NASH
patients vs. controls
Odds (OR) of any HFE
mutation in NASH
patients vs. controls
Odds (OR) of any HFE
mutation in NASH
patients vs. controls
Odds (OR) of any HFE
mutation in NASH
patients vs. controls
Odds (OR) of any HFE
mutation in NASH
patients vs. controls

1.54 (0.892.65)

Bonkovsky

2000

U.S.A

Genetic
association

Histologically
confirmed NASH

Historic
controls

57 / 348

Any iron-loading
HFE mutation

Chitturi

2002

Australia

Genetic
association

Histologically
confirmed NASH

Blood
donors

42 / 127

Any iron-loading
HFE mutation

Valenti

2009

Italy

Genetic
association

Histologically
confirmed NASH

Blood
donors

594 / 184

Any iron-loading
HFE mutation

Zamin

2006

Brazil

Genetic
association

Histologically
confirmed NASH

Healthy
volunteers

29 / 20

Any iron-loading
HFE mutation

Neri

2007

Italy

Genetic
association

Histologically
confirmed NASH

Blood
donors

272 / 430

Any iron-loading
HFE mutation

Adapted from 468. Any HFE mutation defined as: C282Y/C282Y; C282Y/H63D; C282Y/WT; H63D/H63D; H63D/WT

2.36 (1.423.92)

Matching /
adjustment
variables

*

1.09 (0.641.87)
1.00 (0.921.09)
1.28 (0.802.05)
0.71 (0.570.89)

*
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Table 11: Matching indices for study summaries
Index
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
Adapted from 395

Variable
Age
Sex
Height
Weight
Ethnicity
BMI
Family history of diabetes
Physical activity
Smoking
Alcohol consumption
Dietary factors
Cholesterol
Menopausal status
Fasting status
Blood glucose
Waist circumference/central obesity
Leg length
Parity
SES
Hypertension
Triglycerides
Education
AST
ALT
Sedentary time
Obesity
Medication used to treat hypertension
History of cardiovascular disease
Geographic location
Use of iron supplements
Inflammatory factors (e.g., CRP)
Examination session attended
Fasting insulin concentration
Study center
Fasting glucose concentration
Glycemic load
Glycated hemoglobin
sTfR
Abnormal blood lipids
Hemoglobin concentration
General practice
Recruitment date

Table 12: Odds of metabolic dysfunction (continuously-scaled predictors)
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Outcome

Type of Model & Covariates

T2DM

Basic Model
Age
Ethnicity
Education
BMI
Age at menarche
OC use
Parity
Menopausal Status
Alcohol Consumption
Smoking History
Physical Activity
C-reactive protein
Full model
Basic Model
Age
Ethnicity
Education
BMI
Age at menarche
OC use
Parity
Menopausal Status
Alcohol Consumption
Smoking History
Physical Activity
C-reactive protein
Full model

Metabolic
Syndrome

Unadjusted
OR
1.03
1.01
-

Unadjusted
P-value
0.15
0.23
-

FeCOOK
Adjusted OR
1.01
1.05
1.03
1.03
1.03
1.02
1.03
1.00
1.04
1.03
1.03
1.02
1.02
1.00
1.01
1.01
1.01
1.01
1.00
1.01
0.99
1.01
1.01
1.01
1.00
0.99

Adjusted Pvalue
0.43
0.05
0.16
0.24
0.25
0.40
0.21
0.94
0.12
0.17
0.16
0.37
0.53
0.92
0.13
0.35
0.53
0.64
0.86
0.54
0.36
0.36
0.31
0.24
0.73
0.28

Unadjusted
OR
0.97

0.97

Unadjusted
P-value
0.08

TSAT
Adjusted OR

Adjusted Pvalue

0.97
0.97
0.98
0.97
0.97
0.97
0.97
0.97
0.97
0.97
0.97
0.99
1.00

0.08
0.17
0.08
0.84
0.09
0.09
0.13
0.08
0.09
0.07
0.08
0.43
0.91

0.96
0.96
0.96
0.99
0.96
0.96
0.97
0.96
0.96
0.96
0.96
0.97
0.98

<0.0001
<0.0001
<0.0001
0.21
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
0.0003
0.14

<0.0001
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Table 12 (continued): Odds of metabolic dysfunction (continuously-scaled predictors)
FeCOOK
Outcome
Type of Model & Covariates
Unadjusted
Unadjusted
Adjusted OR
OR
P-value
NALFD
Basic Model
1.04
0.04
Age
1.02
Ethnicity
1.04
Education
1.04
BMI
1.01
Age at menarche
1.04
OC use
1.03
Parity
1.03
Menopausal Status
1.03
Alcohol Consumption
1.02
Smoking History
1.02
Physical Activity
1.02
C-reactive protein
1.02
Full model
1.00
Insulin
Basic Model
1.04
0.05
Resistance
Age
1.04
Ethnicity
1.05
Education
1.04
BMI
1.03
Age at menarche
1.04
OC use
1.04
Parity
1.04
Menopausal Status
1.04
Alcohol Consumption
1.03
Smoking History
1.03
Physical Activity
1.03
C-reactive protein
1.02
Full model
1.04

Adjusted Pvalue
0.11
0.02
0.04
0.48
0.09
0.11
0.09
0.21
0.31
0.35
0.31
0.22
0.99
0.04
0.01
0.02
0.20
0.04
0.03
0.04
0.07
0.12
0.17
0.22
0.27
0.07

Unadjusted
OR
0.96

0.97

Unadjusted
P-value
<0.0001

TSAT
Adjusted OR

Adjusted Pvalue

0.96
0.96
0.96
0.98
0.96
0.96
0.96
0.96
0.95
0.95
0.95
0.97
0.99

<0.0001
<0.0001
<0.0001
0.13
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
0.001
0.26

0.98
0.98
0.98
0.99
0.98
0.97
0.97
0.97
0.97
0.97
0.96
0.98
1.00

0.03
0.06
0.02
0.51
0.06
0.05
0.03
0.04
0.01
0.01
0.002
0.16
0.93

0.01

Table 13: Odds of metabolic dysfunction: highest tertile versus lowest tertile
Outcome
T2DM

Metabolic
Syndrome

NAFLD

Insulin
Resistance
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Categorization
All females
White
Hispanic
Black
All females
White
Hispanic
Black
All females
White
Hispanic
Black
All females
White
Hispanic
Black

OR
1.30
1.01
1.52
2.52
1.14
1.08
1.28
1.57
1.35
1.52
1.10
1.62
1.46
2.59
1.04
1.25

FeCOOK
95%CI
0.90-1.89
0.57-2.19
0.87-2.64
1.39-4.57
0.94-1.39
0.82-1.41
0.90-1.81
1.15-2.16
1.00-1.81
1.00-2.31
0.69-1.75
0.88-3.01
1.03-2.06
1.45-4.65
0.60-1.78
0.80-1.96

Ptrend
0.17
0.75
0.14
0.002
0.18
0.61
0.005
0.02
0.05
0.05
0.69
0.12
0.03
0.005
0.58
0.47

OR
0.48
0.41
0.70
0.74
0.47
0.44
0.54
0.50
0.41
0.39
0.40
0.69
0.50
0.56
0.48
0.74

TSAT
95%CI
0.26-0.86
0.17-1.04
0.30-1.66
0.23-2.40
0.31-0.71
0.25-0.77
0.25-1.15
0.22-1.11
0.28-0.61
0.22-0.69
0.17-0.90
0.29-1.64
0.28-0.90
0.23-1.40
0.17-1.34
0.30-1.83

Table 14: Association between highest vs. lowest FeCOOK tertile, postmenopausal status and metabolic dysfunction
Outcome
OR
95%CI
Ptrend
T2DM
1.12
0.15-8.62
0.91
Metabolic Syndrome
1.10
0.46-2.62
0.83
NAFLD
1.76
0.41-7.46
0.44
Insulin Resistance
2.24
0.30-16.58
0.43

Table 15: Association between highest vs. lowest TSAT tertile, postmenopausal status and metabolic dysfunction
Outcome
OR
95%CI
Ptrend
T2DM
1.00
0.16-6.31
0.99
Metabolic Syndrome
0.97
0.37-2.48
0.94
NAFLD
2.93
0.39-22.12
0.30
Insulin Resistance
1.64
0.18-15.39
0.66

Ptrend
0.01
0.06
0.42
0.61
0.0003
0.004
0.11
0.09
<0.0001
0.001
0.02
0.40
0.02
0.28
0.19
0.77
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Appendix 1:
Mechanics of FeCOOK So that the reader develops a more complete understanding
of the mechanics of FeCOOK, the following section details how the index changes when
1) serum transferrin receptor concentrations increase, holding serum ferritin
concentrations constant, 2) serum transferrin receptor decrease, holding serum ferritin
concentrations constant, 3) serum ferritin concentrations increase, holding serum
transferrin receptor concentrations constant, 4) serum ferritin concentrations decrease,
holding serum transferrin receptor concentrations constant, 5) serum transferrin receptor
concentrations increase and serum ferritin concentrations decrease, 6) serum transferrin
concentrations decrease and serum ferritin concentrations increase, 7) both increase and
8) both decrease. For convenience, the index is given below:
FeCOOK (mg/kg) =

−[log 10(

𝑅∗1000
)−2.8229]
𝐹

0.1207

,

where R = serum transferrin receptor (mg/L) and F = serum ferritin (µg/L). As
mentioned, serum transferrin receptor is primarily derived from developing red blood
cells, reflects the magnitude of erythropoiesis and the body’s demand for iron and is
relatively unaffected by inflammation. Ferritin is an intracellular protein whose primary
function is iron storage.
As one can see from the simulations below, the index increases substantially
when serum transferrin receptor concentrations decrease and serum ferritin
concentrations are held constant or increase (simulations 2 and 6, respectively).
Simulation 2 represents a scenario where there is a decreased requirement for iron in the
presence of stable iron stores. Therefore, if serum ferritin concentrations do not change
in the presence of decreasing serum transferrin receptor concentrations, the index
283

increases. Simulation 6 represents a scenario where there is a decreased requirement for
iron coupled with an increase in iron stores, indicative of increased iron absorption with
a concomitant increase in FeCOOK. The index increases more slowly when both analytes
increase (simulation 7) and this represents a scenario of both an increased requirement
for iron with an increase in iron storage. The opposite is true when serum transferrin
receptor concentrations increase and serum ferritin concentrations are held constant or
decrease (simulations 1 and 5, respectively). Simulation 1 represents a scenario of
increasing iron deficiency with stable serum ferritin concentrations. Therefore, if serum
ferritin concentrations do not change in the presence of increasing serum transferrin
receptor concentrations, the index decreases. Simulation 5 represents a scenario of
increasing iron deficiency coupled with decreased iron storage. This scenario might be
best visualized within the context of continual blood donation. The index decreases
more slowly when both analytes decrease (simulation 8), represented by a scenario
where there is a decreased requirement for iron coupled with a decrease in iron stores.
When serum transferrin receptor concentrations are held constant, the index increases
with increasing serum ferritin concentrations (simulation 3) and decreases with
decreasing serum ferritin concentrations (simulation 4). Given that serum transferrin
receptor concentrations are only affected by the rate of erythropoiesis and cellular iron
content and are unaffected by inflammation, simulation 3 represents a scenario where
the behavior of the index can be examined under such conditions (i.e., increases in
serum ferritin concentrations due to inflammation). As is evident, the index increases but
does so more slowly compared to other simulations.
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Simulation

1

Simulation

2

Simulation

3

Simulation

4

sTfR (mg/L)
1
1.5
2
2.5
3
3.5
4
4.5
5

ferritin (μg/L)
50
50
50
50
50
50
50
50
50

FeCOOK
12.60870
11.14978
10.11466
9.31176
8.65575
8.10109
7.62063
7.19683
6.81773

sTfR (mg/L)
5
4.5
4
3.5
3
2.5
2
1.5
1

ferritin (μg/L)
50
50
50
50
50
50
50
50
50

FeCOOK
6.81773
7.19683
7.62063
8.10109
8.65575
9.31176
10.11466
11.14978
12.60870

sTfR (mg/L)
3
3
3
3
3
3
3
3
3

ferritin (μg/L)
50
55
60
65
70
75
80
85
90

FeCOOK
8.65575
8.99869
9.31176
9.59977
9.86642
10.11466
10.34688
10.56502
10.77068

sTfR (mg/L)
3
3
3
3
3
3
3
3
3

ferritin (μg/L)
90
85
80
75
70
65
60
55
50

FeCOOK
10.77068
10.56502
10.34688
10.11466
9.86642
9.59977
9.31176
8.99869
8.65575
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Simulation

5

Simulation

6

Simulation

7

Simulation

8

sTfR (mg/L)
2.7
2.8
2.9
3.0
3.1
3.2
3.3
3.4
3.5

ferritin (μg/L)
90
85
80
75
70
65
60
55
50

FeCOOK
11.14978
10.81326
10.46886
10.11466
9.74844
9.36755
8.96883
8.54833
8.10109

sTfR (mg/L)
2.5
2.4
2.3
2.2
2.1
2.0
1.9
1.8
1.7

ferritin (μg/L)
50
55
60
65
70
75
80
85
90

FeCOOK
9.31176
9.80159
10.26780
10.71575
11.14978
11.57358
11.99036
12.40304
12.81436

sTfR (mg/L)
2.7
2.8
2.9
3.0
3.1
3.2
3.3
3.4
3.5

ferritin (μg/L)
50
55
60
65
70
75
80
85
90

FeCOOK
9.03485
9.24693
9.43375
9.59977
9.74844
9.88245
10.00394
10.11466
10.21603

sTfR (mg/L)
2.5
2.4
2.3
2.2
2.1
2.0
1.9
1.8
1.7

ferritin (μg/L)
90
85
80
75
70
65
60
55
50

FeCOOK
11.42670
11.36792
11.30292
11.23064
11.14978
11.05869
10.95524
10.83670
10.69943
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Appendix 2:
Transferrin saturation (TSAT) and Metabolic Dysfunction

The odds of T2DM

decreased with increasing TSAT (OR = 0.97 95%CI: 0.95-1.00, P = 0.07 for each unit
increase in TSAT. The effect was slightly amplified after adjusting for covariates. When
independently adjusting for 1) age, 2) ethnicity, 3) education, 4) BMI, 5) age at
menarche, 6) OC use, 7) parity, 8) menopausal status, 9) alcohol consumption, 10)
smoking history, 11) physical activity and 12) C-reactive protein (CRP), the odds of
T2DM were 1) 0.97 (95%CI: 0.95-1.00, P = 0.08), 2) 0.98 (95%CI: 0.95-1.01, P = 0.17),
3) 0.97 (95%CI: 0.95-1.00, P = 0.08), 4) 0.97 (95%CI: 0.96-1.03, P = 0.84), 5) 0.97
(95%CI: 0.94-1.01, P = 0.09), 6) 0.97 (95%CI: 0.94-1.01, P = 0.09), 7) 0.97 (95%CI:
0.94-1.01, P = 0.13), 8) 0.97 (95%CI: 0.93-1.00, P = 0.08), 9) 0.97 (95%CI: 0.95-1.00,
P = 0.09), 10) 0.97 (95%CI: 0.95-1.00, P = 0.07), 11) 0.97 (95%CI: 0.94-1.02, P =
0.08) and 12) 0.99 (95%CI: 0.96-1.05, P = 0.43) (Table x), respectively. In a full model
which adjusted for all covariates, the odds of T2DM did not increase with increasing
TSAT (OR = 1.00, 95%CI: 0.96-1.05, P = 0.91) (Table 12).
When TSAT was categorized according to tertiles, the odds of T2DM among
those in the highest tertile of TSAT compared to those in the lowest tertile were 0.48
(95%CI: 0.26-0.86, P = 0.01). A similar pattern was observed after stratifying by
ethnicity. Among white females, the odds of T2DM among those in the highest tertile of
TSAT compared to those in the lowest tertile were 0.41 (95%CI: 0.17-1.04, P = 0.06).
The odds of T2DM were higher among Hispanic and black females in the highest tertile
of TSAT compared to those in the lowest tertile: OR = 0.70 (95%CI: 0.30-1.66, P = 0.42)
and OR = 0.74 (95%CI: 0.23-2.40, P = 0.61).
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The odds of metabolic syndrome decreased with increasing TSAT (OR = 0.97
95%CI: 0.95-0.98, P < 0.0001 for each unit increase in TSAT. The effect was slightly
amplified after adjusting for individual covariates in the full model. When independently
adjusting for 1) age, 2) ethnicity, 3) education, 4) BMI, 5) age at menarche, 6) OC use, 7)
parity, 8) menopausal status, 9) alcohol consumption, 10) smoking history, 11) physical
activity and 12) C-reactive protein (CRP), the odds of metabolic syndrome were 1) 0.96
(95%CI: 0.95-0.98, P < 0.0001), 2) 0.96 (95%CI: 0.95-0.98, P < 0.0001), 3) 0.96
(95%CI: 0.95-0.98, P < 0.0001), 4) 0.99 (95%CI: 0.97-1.01, P = 0.21), 5) 0.96 (95%CI:
0.95-0.98, P < 0.0001), 6) 0.96 (95%CI: 0.95-0.98, P < 0.0001), 7) 0.97 (95%CI: 0.950.98, P < 0.0001), 8) 0.96 (95%CI: 0.94-0.98, P < 0.0001), 9) 0.96 (95%CI: 0.95-0.98, P
< 0.0001), 10) 0.96 (95%CI: 0.95-0.98, P < 0.0001), 11) 0.96 (95%CI: 0.95-0.98, P <
0.0001) and 12) 0.97 (95%CI: 0.98-0.99, P = 0.0003) (Table 12), respectively. In a full
model which adjusted for all covariates, the odds of metabolic syndrome slightly
increased to 0.98 (95%CI: 0.96-1.01), which was no longer statistically significant (P =
0.14) (Table 12).
When TSAT was categorized according to tertiles, the odds of metabolic
syndrome among those in the highest tertile of TSAT compared to those in the lowest
tertile were 0.46 (95%CI: 0.30-0.70, P = 0.0003). A similar pattern was observed after
stratifying by ethnicity. Among white females, the odds of metabolic syndrome among
those in the highest tertile of TSAT compared to those in the lowest tertile were 0.43
(95%CI: 0.25-0.76, P = 0.004). The odds of metabolic syndrome were higher among
Hispanic and black females in the highest tertile of TSAT compared to those in the lowest

288

tertile: OR = 0.53 (95%CI: 0.25-1.13, P = 0.10) and OR = 0.49 (95%CI: 0.22-1.09, P =
0.08), respectively.
TSAT was inversely associated with U.S.-FLI. For each unit increase in U.S.-FLI,
TSAT decreased 0.15% (P < 0.0001). Similarly, for each unit increase in TSAT, U.S.-FLI
decreased 0.31 units (P < 0.0001). The odds of NAFLD decreased with increasing TSAT
(OR = 0.96, 95%CI: 0.94-0.97, P < 0.0001 for each unit increase in TSAT. The effect was
slightly amplified in the full model after adjusting for covariates. When independently
adjusting for 1) age, 2) ethnicity, 3) education, 4) BMI, 5) age at menarche, 6) OC use, 7)
parity, 8) menopausal status, 9) alcohol consumption, 10) smoking history, 11) physical
activity and 12) C-reactive protein (CRP), the odds of NAFLD were 1) 0.96 (95%CI:
0.94-0.98, P < 0.0001), 2) 0.96 (95%CI: 0.94-0.98, P < 0.0001), 3) 0.96 (95%CI: 0.940.98, P < 0.0001), 4) 0.98 (95%CI: 0.96-1.01, P = 0.13), 5) 0.96 (95%CI: 0.94-0.98, P <
0.0001), 6) 0.96 (95%CI: 0.94-0.98, P < 0.0001), 7) 0.96 (95%CI: 0.94-0.98, P <
0.0001), 8) 0.96 (95%CI: 0.94-0.98, P < 0.0001), 9) 0.95 (95%CI: 0.93-0.97, P <
0.0001), 10) 0.95 (95%CI: 0.93-0.97, P < 0.0001), 11) 0.95 (95%CI: 0.93-0.97, P <
0.0001) and 12) 0.97 (95%CI: 0.96-0.99, P = 0.001) (Table x), respectively. In a full
model which adjusted for all covariates, no increased odds of NAFLD as a function of
TSAT were observed (OR = 0.99, 95%CI: 0.96-1.01, P = 0.26) (Table 12).
When TSAT was categorized according to tertiles, the odds of NAFLD decreased
across increasing tertiles (Ptrend < 0.0001). Compared to those in the lowest tertile of
TSAT the odds of NAFLD were 0.62 (95%CI: 0.39-0.97, P = 0.04) for those in the
middle tertile of TSAT. Compared to those in the lowest tertile of TSAT, the odds of
NAFLD were 0.41 (95%CI: 0.28-0.61, P < 0.0001) among those in the highest tertile. A
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similar pattern was observed after stratifying by ethnicity. Among white females, the
odds of NAFLD among those in the highest tertile of TSAT compared to those in the
lowest tertile were 0.39 (95%CI: 0.22-0.69, P = 0.001). The odds of NAFLD were higher
among Hispanic females in the highest tertile of TSAT compared to those in the lowest
tertile: OR = 0.40 (95%CI: 0.17-0.90, P = 0.02). Compared to their white and Hispanic
counterparts, the odds of NAFLD were higher among black females in the highest tertile
of TSAT compared to those in the lowest tertile: OR = 0.69 (95%CI: 0.29-1.64, P =
0.40). TSAT was also inversely associated with liver fibrosis (i.e., NFS). For each unit
increase in NFS, TSAT decreased 0.56% (P = 0.01). Similarly, for each unit increase in
TSAT, NFS decreased 0.01 units (P = 0.02).
TSAT was inversely associated with insulin resistance. For each unit increase in
HOMA-IR, TSAT decreased 0.60% (P = 0.002). Similarly, for each unit increase in
TSAT, HOMA-IR decreased 0.04 units (P < 0.0001). The odds of insulin resistance
decreased with increasing TSAT (OR = 0.97, 95%CI: 0.95-0.99, P = 0.01) for each unit
increase in TSAT. The effect was slightly amplified after adjusting for covariates. When
independently adjusting for 1) age, 2) ethnicity, 3) education, 4) BMI, 5) age at
menarche, 6) OC use, 7) parity, 8) menopausal status, 9) alcohol consumption, 10)
smoking history, 11) physical activity and 12) C-reactive protein (CRP), the odds of
insulin resistance were 1) 0.97 (95%CI: 0.95-0.99, P = 0.01), 2) 0.98 (95%CI: 0.97-0.99,
P = 0.03), 3) 0.98 (95%CI: 0.96-1.00, P = 0.06), 4) 0.98 (95%CI: 0.95-0.99, P = 0.02),
5) 0.99 (95%CI: 0.96-1.02, P = 0.51), 6) 0.98 (95%CI: 0.95-1.00, P = 0.06), 7) 0.97
(95%CI: 0.95-1.00, P = 0.05), 8) 0.97 (95%CI: 0.94-0.99, P = 0.03), 9) 0.97 (95%CI:
0.95-0.99, P = 0.04), 10) 0.97 (95%CI: 0.94-0.99, P = 0.01), 11) 0.96 (95%CI: 0.94-
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0.99, P = 0.002) and 12) 0.98 (95%CI: 0.96-1.01, P = 0.16) (Table x), respectively. In a
full model which adjusted for all covariates, the odds of insulin resistance did not
increase with increasing TSAT (OR = 1.00 95%CI: 0.97-1.04, P = 0.93) (Table 12).
When TSAT was categorized according to tertiles, the odds of insulin resistance
decreased across increasing tertiles (Ptrend = 0.06). Compared to those in the lowest tertile
of TSAT the odds of insulin resistance were 0.75 (95%CI: 0.44-1.28, P = 0.29) for those
in the middle tertile of TSAT. Compared to those in the lowest tertile of TSAT, the odds
of insulin resistance were 0.50 (95%CI: 0.28-0.90, P = 0.02) among those in the highest
tertile of TSAT. A similar pattern was observed after stratifying by ethnicity, especially
among white females. Among white females, the odds of insulin resistance among those
in the highest tertile of TSAT compared to those in the lowest tertile were 0.56 (95%CI:
0.23-1.40, P = 0.28). The odds of insulin resistance were also higher among Hispanic and
black females in the highest tertile of TSAT compared to those in the lowest tertile: OR =
0.48 (95%CI: 0.17-1.34, P = 0.19) and OR = 0.74 (95%CI: 0.30-1.83, P = 0.77),
respectively.
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Appendix 3: Power Calculations
Insulin Resistance:
proc power;
twosamplefreq test=pchi
relativerisk = 1.2 1.3 1.4 1.5
refproportion = 0.35
ntotal = 3149
sides = 2
alpha = 0.0125
power = . ;
run;
Non-alcoholic fatty liver disease:
proc power;
twosamplefreq test=pchi
relativerisk = 1.2 1.3 1.4 1.5
refproportion = 0.291
ntotal = 3057
sides = 2
alpha = 0.0125
power = . ;
run;
Metabolic Syndrome:
proc power;
twosamplefreq test=pchi
relativerisk = 1.2 1.3 1.4 1.5
refproportion = 0.234
ntotal = 6511
sides = 2
alpha = 0.0125
power = . ;
run;
Type 2 diabetes mellitus:
proc power;
twosamplefreq test=pchi
relativerisk = 1.2 1.3 1.4 1.5
refproportion = 0.11
ntotal = 6841
sides = 2
alpha = 0.0125
power = . ;
run;
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Table 16: Power and sample size calculations: T2DM

Outcome of
interest

Population
prevalence (i.e.,
reference
proportion) in
females
11.2%

Year of NHANES
survey

Relative
Risk

2468

1.2

0.40

11.2%

2468

1.3

0.70

11.2%

2468

1.4

0.90

2468

1.5

0.98

2682

1.2

0.42

11.2%

2682

1.3

0.74

11.2%

2682

1.4

0.93

11.2%

2682

1.5

0.99

2003-2004

11.2%
11.2%

Type 2 diabetes
mellitus

Computed
Power**

Total sample
size*

11.2%

2005-2006

2109

1.2

0.35

11.2%

2007-2008

2109

1.3

0.63

11.2%

2109

1.4

0.86

2109

1.5

0.96

2512

1.2

0.40

11.2%

2512

1.3

0.71

11.2%

2512

1.4

0.91

11.2%

2512

1.5

0.98

2003-2010

9771

1.2

0.92

(pooled)

9771

1.3

0.99

11.2%

9771

1.4

> 0.99

11.2%

9771

1.5

> 0.99

11.2%
11.2%

11.2%
11.2%

2009-2010

*Total sample size refers to the number of females during each year who have complete
data for the calculation for TotFe and Non-alcoholic fatty liver disease.
**See appendix for SAS code used to calculate power.
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Table 17: Power and sample size calculations: Metabolic syndrome

Outcome of
interest

Outcome of
interest

Outcome of
interest

Outcome of
interest

Outcome of
interest

Outcome of
interest

11.2%

2468

1.3

0.70

11.2%

2468

1.4

0.90

11.2%

2468

1.5

0.98

11.2%

2005-2006

2682

1.2

0.42

Metabolic

11.2%
Metabolic

Metabolic

2682
Metabolic

1.3
Metabolic

0.74
Metabolic

syndrome

11.2%
syndrome
11.2%

syndrome

2682
syndrome
2682

1.4
syndrome
1.5

0.93
syndrome
0.99

11.2%

2007-2008

2109

1.2

0.35

11.2%

2109

1.3

0.63

11.2%

2109

1.4

0.86

2109

1.5

0.96

2512

1.2

0.40

11.2%

2512

1.3

0.71

11.2%

2512

1.4

0.91

11.2%

2512

1.5

0.98

2003-2010

9771

1.2

0.92

(pooled)

9771

1.3

0.99

11.2%

9771

1.4

> 0.99

11.2%

9771

1.5

> 0.99

11.2%
11.2%

11.2%
11.2%

2009-2010

*Total sample size refers to the number of females during each year who have complete
data for the calculation for TotFe and Non-alcoholic fatty liver disease.
**See appendix for SAS code used to calculate power.
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Table 18: Power and sample size calculations: Non-alcoholic fatty liver disease

Outcome of
interest

Outcome of
interest

Outcome of
interest

Outcome of
interest

Outcome of
interest

Outcome of
interest

11.2%

2468

1.3

0.70

11.2%

2468

1.4

0.90

Non-alcoholic

11.2%
Non-alcoholic
11.2%

Non-alcoholic
2005-2006

2468
Non-alcoholic
2682

1.5
Non1.2

0.98
Non0.42

fatty liver

11.2%
fatty
liver

fatty liver disease

2682
fatty
liver

1.3
alcoholic

0.74
alcoholic

2682
disease
2682
(y = U.S.-FLI)
2109

1.4
fatty liver
1.5
disease
1.2

0.93
fatty liver
0.99
disease
0.35

11.2%

2109

(y =1.3
U.S.-

(y =
U.S.0.63

11.2%

2109
2109

1.4
FLI)
1.5

0.86
FLI)
0.96

2512

1.2

0.40

11.2%

2512

1.3

0.71

11.2%

2512

1.4

0.91

11.2%

2512

1.5

0.98

9771

1.2

0.92

9771

1.3

0.99

11.2%

9771

1.4

> 0.99

11.2%

9771

1.5

> 0.99

disease
(y = U.S.-FLI)

11.2%
disease
11.2%
(y = U.S.-FLI)
11.2%

(y = U.S.-FLI)
2007-2008

11.2%
11.2%

11.2%
11.2%

2009-2010

2003-2010
(pooled)

*Total sample size refers to the number of females during each year who have complete
data for the calculation for TotFe and Non-alcoholic fatty liver disease.
**See appendix for SAS code used to calculate power.
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Table 19: Power and sample size calculations: insulin resistance

Outcome of
interest

Outcome of
interest

Outcome of
interest

Outcome of
interest

Outcome of
interest

Outcome of
interest

11.2%

2468

1.3

0.70

11.2%

2468

1.4

0.90

Insulin

11.2%
Insulin
11.2%

Insulin
resistance
2005-2006

2468
Insulin
2682

1.5
Insulin
1.2

0.98
Insulin
0.42

resistance

11.2%
resistance

(y = HOMA-IR)

2682
resistance

1.3
resistance

0.74
resistance

(y = HOMA-IR)

11.2%
(y = HOMA-IR)
11.2%
2007-2008

2682
(y = HOMA2682
IR)
2109

1.4
(y =
1.5
HOMA-IR)
1.2

0.93
(y =
0.99
HOMA-IR)
0.35

11.2%

2109

1.3

0.63

11.2%

2109

1.4

0.86

2109

1.5

0.96

2512

1.2

0.40

11.2%

2512

1.3

0.71

11.2%

2512

1.4

0.91

11.2%

2512

1.5

0.98

9771

1.2

0.92

9771

1.3

0.99

11.2%

9771

1.4

> 0.99

11.2%

9771

1.5

> 0.99

11.2%

11.2%
11.2%

11.2%
11.2%

2009-2010

2003-2010
(pooled)

*Total sample size refers to the number of females during each year who have complete
data for the calculation for TotFe and Non-alcoholic fatty liver disease.
**See appendix for SAS code used to calculate power.
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Research and Clinical Interests
Psychiatric Pharmacogenomics, Cancer Epidemiology, Genetic Epidemiology, Aging
Immunology, Tumor Immunology, Childhood Cancer, Maternal & Child Health.

Professional Employment Experience
2016-present

Analytics Consultant

Humana, Inc.

Work with team to maintain current version of a dynamic claims-based provider attribution
algorithm which incorporates member and provider attributes such as geographical distance,
provider specialty and a variety of proprietary business rules in order to establish value-based
member-provider (PCP) assignments.
Developed and implemented a method to examine the financial impact (i.e., claims spend,
premiums spend, MER) of a provider attribution algorithm among members whose PCP was
determined by self-selection, Humana assignment (i.e., proprietary business rules), claimsbased assignment.
Worked with team to complete a Six-Sigma Green Belt project which examined root causes of
inaccurate member-provider assignments. Deliverable to leadership included recommending
people, processes and technology to improve member/provider experience with business
impacts being accurate panel lists and related STARS quality data & rewards and improved
relationships/trust with participating PCPs.
Developed and maintain a fuzzy matching algorithm using SAS functions SPEDIS,
SOUNDEX, CONTAINS, COMPARE, COMPGED, PRXPARSE, PRXMATCH to evaluate
the concordance between member-PCP relationships across two databases. Automated said
project with Microsoft Access.
Developing a prescriber attribution model which quantifies the effect of incorporating
pharmacy claims into provider attribution models which do not utilize said data. Developed
conditional logic which allows members to be attributed to a prescribing provider when no
other claims (e.g., AWV, E&M) are available.
Developed a novel metric for use in the calculation of continuity of care among memberprovider networks. The equation takes into account within-provider prescribing behavior that
can lead to drug-drug interactions as well as between-provider prescribing behavior that can
lead to additional drug-drug interactions.
Developed an annotated training manual for future Attribution Analytics associates.
Developing a PCP Treating model using graph theory and social network analysis and an
advanced personalized member model.
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2012–2016
Inc.

Biostatistician

Assurex Health,

Using a priori biological knowledge and preselected SNPs within a finite set of xenobiotic
metabolizing and transport genes, assist in the development of clinical decision support
algorithms which classify and predict pharmacokinetic and pharmacodynamic response to a
panel of commonly prescribed psychotropic and analgesic medications by reducing the
dimensionality inherent to permutations and combinations of drug-drug, drug-gene, and genegene interactions.
Conduct cross-validation analyses of results obtained from previous in-house clinical trials.
Head of using a systematic and methodological approach to data imputation in order to
account for the differential effect of subject (i.e., treated vs control) attrition in the above
mentioned clinical trials.
Following testing for clinical, methodological, and statistical heterogeneity, merge data from
in-house clinical trials of similar design to derive pooled effect sizes, which in turn are used to
inform sample size calculation for future trials.
Conducted a current (as of Dec 2012) meta-analysis of the published literature reporting upon
the effect of the -759C/T HTR2C transition on antipsychotic-induced weight-gain (AIWG),
stratified by drug-experienced versus drug-naive subjects. Random-effects models were
employed to account for heterogeneity among study designs. Publication bias was examined
via funnel plots and Egger’s regression.
Lead biostatistician of a recently launched large-scale (projected N = 1350), treatmentresistant depression (TRD), randomized, controlled trial examining the clinical utility and
clinical validity of a multigenic combinatorial phenotype method for selecting geneticallyconcordant antidepressant medications.
Executed sensitivity analyses for TRD RCT solving for sample size, alpha, and power in order
to provide study sponsor with information to guide strategic decision making with respect to
overall study recruitment.
Using the CRF implemented in the above TRD RCT as guidance, created a data schema to
standardize and accommodate all previous/ongoing clinical trial data. Developed a clinical
database/data warehouse thereafter using MySQL to store standardized data.
Co-developed a novel data reduction method which facilitates pairwise comparisons across
single enzyme phenotypes and a composite (5 enzyme) phenotype.
Head of creation and management of clinical trials dossier.
Co-developed a methodology to evaluate the performance of several versions of the same
clinical decision support algorithm via simulation. Head of automation and statistical analyses
of simulations using SAS & R.
Co-developed the methodology to calculate company-wide sales metrics based upon physician
ordering patterns. Independently created a SAS program to automate monthly and quarterly
calculations.
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Co-developed the methodology to calculate 13 KPIs for the Medical Affairs/Clinical
Development department within the company. Independently created a SAS program to
automate monthly and quarterly calculations.

2010-present
Technical College
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Jefferson Community &

Full-time professor of three psychology courses at the Carrollton, KY extension campus.
Courses taught: PSY110 (General Psychology), PSY223 (Developmental Psychology),
PSY230 (Psychological Aspects of Aging, Dying, Death, & Bereavement.
Direct undergraduate students in the stepwise process of curating academic literature from
various databases in order to construct annotated bibliographies, which in turn are employed in
the development of a term paper of publishable quality; assist students in the interpretation of
academic literature; develop and deploy psychology courses on Blackboard; deliver fifteen
lectures per course per semester.

Research Experience
2014: Project Manager, School of Public Health and Information Sciences, Department of
Epidemiology and Population Health, University of Louisville.
Supervisor: Frank D. Groves, M.D., M.P.H.

Conducted a secondary analysis of a multistage, nationally-representative probabilistic
sample of NHANES I/NHEFS linked databases examining the role of hematological
parameters on subsequent development of cardiovascular disease and cancer. KaplanMeier curves were constructed to estimate differential survival among sample
population, stratified by each hematological parameter. Cox proportional hazards
regression analyses were employed derive hazard ratios associated with each
parameter, stratified by gender and ethnicity.

2013: Project Manager, School of Public Health and Information Sciences, Department of
Epidemiology and Population Health, University of Louisville.
Supervisor: Kira Taylor, Ph.D., M.S.

Completed and submitted manuscript proposal for a candidate gene study examining
genetic variation in the PI3k/Akt/mTOR pathway and subsequent development of
pathological left ventricular hypertrophy in Jackson Heart Study population. Bayesian
network analysis (BNA) was employed using R software to curate a concise set of
genes within the signaling pathway. Validity and robustness of BNA was ascertained
using likelihood ratio tests and bootstrapping for cross-validation. Multi-factor
dimensionality reduction (MDR) was employed to finalize a set of tagging SNPs from
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selected genes for statistical modeling to reduce the effect of multiple testing. Principal
components analysis was employed to reduce multicollinearity among covariates in
final logistic regression model.

2013: Project Manager, School of Public Health and Information Sciences, Department of
Epidemiology and Population Health, University of Louisville.
Supervisor: Elizabeth O’Brien, Ph.D.

Conducted an exploratory simulation to model the dependency of genetic expression
on genetic variants within PI3K/Akt/mTOR signaling pathway to augment the above
candidate gene study. Using a priori biological knowledge, dynamic Bayesian network
analysis was employed using R and Markov chain Monte Carlo and Python software
to account for time-varying probabilistic modeling of RNA expression. Normalized
mutual information (MI) between genetic variants and gene expression was calculated
to derive statistical models with greatest maximum likelihood. Chi-square tests were
then applied to test statistical significance of the final set of MIs.
2012: Project Collaborator, School of Public Health and Information Sciences, Department of
Epidemiology and Population Health, University of Louisville.
Supervisor: Rudolph Parrish, Ph.D.
Collaborated on secondary data analysis to explore age-period and site-related effects of air
pollution and passive smoking on the development of wheezing in two cohorts of children. Ttests were employed to quantify differential demographic characteristics with continuous
outcomes and chi-squared tests were employed to examine differential demographic
characteristics with categorical outcomes. Generalized estimating equations were employed to
model categorical time-dependent repeated measures and to test for the effect of site on
symptom development. QIC criterion was used to evaluate model selection.

2012: Project Manager, School of Public Health and Information Sciences, Department of
Epidemiology and Population Health, University of Louisville.
Supervisor: Frank D. Groves, M.D., M.P.H.
Employed MedlineR (a library of literature mining alogorithms in R), PubMatrix, and Bitola
to mine academic databases to curate a comprehensive literature on tumor immunology.
Methodological algorithms were developed and articles were scored and sorted by scientific
strength using SAS Enterprise Miner. A formal literature review was produced to update the
field on emerging concepts and techniques.
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2011: Project Collaborator, School of Public Health and Information Sciences, Department of
Epidemiology and Population Health, University of Louisville.
Supervisor: John Myers, Ph.D.
Evaluated the performance of two novel bioassays for the detection of bovine paratuberculosis
by employing ROC/AUC analysis. Sensitivity and specificity for each test were calculated,
followed by the statistical comparison of each AUC. Estimates and standard errors from each
test were utilized to derive a difference score. Difference scores and standard error of the
combined tests were then used to calculate z-scores for each respective test. Z-scores were
used to obtain p-values to test the null hypothesis that the tests exhibited similar performance.

2011: Project Manager, School of Public Health and Information Sciences, Department of
Epidemiology and Population Health, University of Louisville.
Supervisor: Frank D. Groves, M.D., M.P.H.,
Employed MedlineR, PubMatrix, Bitola, and CoPub to mine academic databases to curate a
comprehensive literature focused on the association between iron deficiency/iron overload and
subsequent development of cancer. Using Python, natural language processing was further
applied to published abstracts to extract novel associations between the explanatory variables
and outcome. Methodological algorithms were developed and articles were scored and sorted
by scientific strength using SAS Enterprise Miner. A formal literature review was then
produced to update the field on emerging concepts and techniques.

2011: Project Manager, School of Public Health and Information Sciences, Department of
Epidemiology and Population Health, University of Louisville.
Supervisor: Susan Muldoon, Ph.D.
Following a comprehensive Medline literature review, designed and conducted a metaanalysis using SAS software to examine the association between dietary iron excess and
subsequent development of Alzheimer’s Disease. A weighting variable was created to account
for strength of study methodology and statistical analysis. Studies were scored and sorted by
employing SAS Enterprise Miner. Effect estimates were derived by applying additivity of chisquared statistics, creating a composite chi-squared test statistic for all studies using study as
the effect. Covariates were then added to the model.
2010-2011: Project Manager, School of Public Health and Information Sciences, Department
of Epidemiology and Population Health, University of Louisville.
Supervisor: Carlton Hornung, Ph.D.
Following a comprehensive Medline literature review, designed and conducted a metaanalysis using SAS examining the association between maternal NIDDM and congenital heart
defects in neonates. A weighting variable was created to account for strength of study
methodology and statistical analysis. Studies were scored and sorted by employing SAS
Enterprise Miner. Effect estimates were derived by applying additivity of chi-squared
statistics, creating a composite chi-squared test statistic for all studies using study as the effect.
Covariates were then added to the model and forest plots were constructed to visually depict
study effect.
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2009-2010: Project Manager, Health Behavior Change Research Program, Department of
Psychological and Brain Sciences, University of Louisville.
Supervisor: Barbara A. Stetson, Ph.D.
Secondary data analysis of 65 adults with Type 1 diabetes examining personal history of
hypoglycemia and hypoglycemia-associated cognitions and their associations with physical
activity. ANOVA tests were employed to examine the association between participant
questionnaire responses and outcome. Self-reported scores on the Exercise Benefits/Barriers
Scale (EBBS) were associated with the Stanford Usual Activity Questionnaire (SUAQ) [R2 =
0.87, F = 3.99, df = 1,42 p = 0.042]. Entry of a 2nd block with the item “disliking sensations of
physical activity” yielded no significant change in R2. Entry of a 2nd block item “difficulty
distinguishing sensations of physical activity from low blood glucose” significantly increased
R2 for SUAQ vigorous activity (p=0.049) and marginally increased R2 for SUAQ moderate
activity (p=0.052). Noteworthy in this study was that less than 1/3 of all participants reported
receiving physical activity instructions from their health care provider.

2009-2010: Research Coordinator and Project Manager for multi-site study examining
psychological predictors for exercise initiation among adults with Type 2 diabetes following a
diabetes self-management education program.
Supervisor: Jason Bonner, Ph.D.
General Role: In-field data collection of survey data, participant recruitment, database and
supplies management, participant tracking, collaboration on statistical analyses, and expediting
data summaries to lead investigator.
Statistical role: employing ANCOVA to determine if the means of each of the outcome
variables in the study were equal across levels of salient predictor variables, controlling for
other covariates. Employing hierarchical cluster analysis to the Health Action Process
Approach model to examine the effects of germane covariates).

Statistical Consultation
2012

Statistical consultant

Assisted in an exploratory factor analysis of a 26-item quality of life survey for a population of
adults with type 2 diabetes. Factors were extracted using principal components analysis with
varimax rotation and a scree plot was developed. KMO test was employed to verify sampling
adequacy (KMO = .93). Three questionnaire components emerged which had eigenvalues
above Kaiser’s criterion of 1 and in combination explained 55.46% of the variance.
Client: Theresa Jackson, Ph.D. in Nursing, Marshall University
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2011

Statistical consultant

Co-developed project methodology and headed statistical testing of a secondary data analysis
examining the association between genetic variation in BRCA1/BRCA2 and response to
letrozole in cohort of patients with ovarian cancer. This gene-drug interaction project tested
the hypothesis that early-stage ovarian cancer patients with BRCA1/BRCA2 mutations would
be more responsive to therapy. T-tests were employed to quantify differential demographic
characteristics with continuous outcomes and chi-squared tests were employed to examine
differential demographic characteristics with categorical outcomes. MANOVA was employed
to model differences in treatment response and stage of ovarian cancer as a function of
BRCA1/BRCA2 carrier status (i.e., homozygous, carrier, null). MANOVA was followed with
discriminant function analysis to obtain the relative contribution of genetic variation to
treatment response and stage of cancer.
Client: R. Brad Baker, D.O. OB-GYN, University of Kentucky

Publications
2015: Altar CA, Carhart JM, Allen JD, Hall-Flavin D, Winner JG, Dechairo BM. Clinical
Utility of combinatorial pharmacogenomics-guided antidepressant therapy: evidence from
three clinical studies. Mol Neuropsychiat, 2015
2015: Winner JG, Carhart JM, Altar CA, Goldfarb S Lavezzari G, Parsons KK, Marshak
AG, Garavaglia A, Dechario BM. Combinatorial pharmacogenomic guidance for psychiatric
medications reduces overall pharmacy costs in a 1 year prospective evaluation. Curr Med Res
Opin,
2015: Altar CA, Carhart JM, Allen JD, Hall-Flavin DK, DeChairo BM, Winner JG. Clinical
validity: combinatorial pharmacogenomics predicts antidepressant responses and healthcare
utilizations better than single gene phenotypes. The Pharmacogenomics Journal, 2015.

2013: Hall-Flavin DK, Winner JG, Allen JD, Carhart JM, Proctor B, Snyder KA, Drews MS,
Eisterhold LL, Geske J, Mrazek DA. Utility of integrated pharmacogenomics testing to
support the treatment of major depressive disorder in a psychiatric outpatient setting.
Pharmacogenetics & Genomics, 2013;23(10): 535-548.
2013: Winner JG, Carhart JM, Altar CA, Allen JD, Dechairo BM. A prospective,
randomized, double-blind study assessing the clinical impact of integrated pharmacogenomics
testing for major depressive disorder. Discovery Medicine, 2013;16(89): 219-227.
2011: Stetson, B., Bonner, J. Carhart, J. (2011). Psychological predictors of self-reported
physical activity initiation in type 2 diabetes patients following diabetes self-management
education. Annals of Behavioral Medicine, 41, S243.
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Poster Presentations
2013: Winner, J., Carhart, JM., Allen, J., Dechario, B. Psychiatric pharmacogenomic
decision support: metal analysis of prospective studies shows improved antidepressant
efficacy and predicted outcomes. CINP: Pharmacogenomics and Personalized Medicine in
Psychiatry.
2013: Mrazek, D., Altar, CA., Allen, J., Carhart, JM. Combinatorial pharmacogenomics
testing improves prediction of antidepressant responses and health utilizations compared to
single gene testing. American Psychiatric Association.
2013: Hall-Flavin, D., Winner, J., Allen, J., Carhart, JM. Translational pharmacogenomics:
physician use and satisfaction with an integrated, multi-gene psychiatric pharmacogenomics
test and interpretive report. American Psychiatric Assocation.
2011: Carhart, J., Stetson, B., Mokshagundam S. (April, 2011). Hypoglycemia Experience
and Barrier Associations with Physical Activity in Type 1 Diabetes. Rapid Communication
Presentation at the 32nd Annual Meeting of the Society of the Behavioral Medicine,
Washington DC.

Professional Recognition
2012

Nominated as JCTC faculty for Kentuckiana Metroversity Adult Learner
Award.

Volunteer and Community Service Experiences
2016

Little Loomhouse’s Friendly Fenley Cemetery Cleanup
Cleaned above cemetery of detritus with fellow members of
Humana’s Clinical Analytics Attribution team

2011-present

Carroll County School System
Volunteer/Worker
Designed and conducted physics demonstrations for grades K-3 for
outdoor classroom

2007-2009

American Cancer Society
Volunteer/Worker
Co-organized relay for life fundraiser within a rural community
setting

2008-2009

American Diabetes Association
Volunteer/Worker
Co-organized fund raising bicycle ride within a rural community
setting

2008

Kentucky Humane Society
Volunteer/Worker
Conducted measures to curb feral cat population expansion

2005

Habitat for Humanity
Volunteer/Worker
Participated in a home rebuild post-flooding within a rural
community
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